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ABSTRACT 
Experimental evidence suggests that growth of the exocrine pancreas is stimulated by 
many hormones including cholecystokinin and gastrin. The important role of these 
growth factors in cancer is now being recognised and their analogues or their 
antagonists are being analysed as possible therapeutic agents for neoplastic diseases. 
Pancreatic cancer by virtue of its resistance to radiation and chemotherapy, is an 
appropriate neoplasm in which to explore the applicability of cholecystokinin/gastrin 
receptor (CCK-R) antagonists in the management of this malignant disease. This thesis 
entails molecular, cellular and in vivo studies in order to determine the role of 
cholecystokinin/gastrin receptors in the growth of human pancreatic cancer. 
The molecular studies show the 7 human pancreatic cancer cell lines examined 
expressed both CCK-A (CCK-AR) and CCK-B receptors (CCK-BR) but at very low 
levels. This was in contrast to high levels of expression found in the human gall 
bladder (CCK-A), human gastric mucosa (CCK-B) and the mouse fibroblast cell line 
NlH3T3 transfected with the human CCK-BR (NIH3T3CCK-BR). Furthermore, cell 
culture studies on 2 human pancreatic cancer cell lines (BxPc-3 and Mia PaCa-2), 
showed a lack of growth response to CCK-R agonists, gastrin (nsG-17) and 
cholecystokinin (sCCK-8) while NIH3T3CCK-BR showed growth stimulation. 
Radioligand binding assays showed that the NIH3T3CCK-BR cells had approximately 
12.5 fold more CCK-BR than the Mia PaCa-2 cells. Molecular studies using semi- 
quantitative RT-PCR showed no difference in CCK receptor expression in 4 cancers 
compared with their matched normal pancreas. 
In vivo studies on xenografted Mia PaCa-2 cells in nude mice indicate that treatment 
with nsG-17 or sCCK-8 have no significant effect on tumour mass, DNA or protein 
content compared with the control group. Moreover treatment with the CCK-R 
antagonists tested were unsuccessful in reducing tumour growth. 
The discovery of a novel serine/threonine kinase isolated from two human pancreatic 
cancers which is over-expressed in pancreatic cancers, normal pancreas and in human 
pancreatic cancer cell lines may prove to be important in the development of this disease 
and a potential target for the diagnosis and/or treatment of pancreatic cancer. 
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Cholecystoldnin (CCK) is among the most well characterised of the peptides, that were 
initially discovered in the gut (Ivy & Oldberg, 1928) and subsequently localised in the 
central nervous system (Beinfeld et al., 198 1, Beinfeld & Palkovits, 1982). CCK 
extracted from porcine intestine, was originally identified as a 33 amino acid peptide 
(Jorpes & Mutt, 1966; Mutt & Jorpes, 1968). 
1.1.1 Molecular characterisation 
The chemical structure of CCK is complicated by the natural occurrence of multiple 
molecular forms that range from 4 to 58 amino acids (CCK-4 to CCK-58) of which 
sulphated CCK-8 (sCCK-8) is probably the dominant form (Anderson & Dockray, 
1988). Species-specific molecular variants of the CCK amino acid sequences have 
been identified which are identical at the pentapeptide carboxyl terminus in all species 
studied. This terminus is also present in the gastrointestinal hormone gastrin (Mutt, 
1980). The pentapeptide appears to be the minimum sequence required for biological 
activity (Crawley et al., 1984; Mutt, 1980, see Figure 1.1). The 33 amino acid 
sequence of CCK-33 and its 8 amino acid C-terminal have been demonstrated in pig, 
rat, chicken, dog and man (Eysselein etal., 1984; Fan etal., 1987; Maton etal., 1982; 
Rehfeld, 1978a). A prominent feature of the structure of CCK-33 is the presence of a 
sulphated tyrosine at position 27. The sulphated C-terminal octapeptide (sCCK-8) 
possesses a high degree of biological activity (Ondetti et al., 1970; Williams, 1982), 
and is approximately 1500 times more potent than its non-sulphated counterpart 
(nsCCK-8, Patel & Spraggs, 1992) in contracting the longitudinal muscle of the 
guinea-pig ileum. The activity of sCCK-8 in stimulating pancreatic growth is thought 
to be equipotent to that of sCCK-33 (Williams, 1982; Anderson & Dockray, 1988). 
The tetrapeptide (CCK-4) is approximately 22,000 times less potent than sCCK-8 
overall (Williams, 1982; Patel & Spraggs, 1992). Neither the C-terminal tripeptide nor 










Figure 1.1 Structure of CCK-58. The C-terminal pentapeptide sequence is 
important for the biological activity of the peptide (indicated are the sequences for 
CCK-8 and CCK-33). 
1.1.2 Post translational processing of procholecystokinin 
1.1.2.1 Intestinal procholecystokinin (proCCK) 
Although the majority of CCK is synthesised in the central nervous system, an essential 
portion is synthesised in the endocrine cells of the intestinal mucosa (Rehfeld, 1978a). 
Moreover, the majority of the CCK in plasma originates from the endocrine I cells of 
the small intestine, named according to Wiesbaden classification of gut endocrine cells 
(Solcia et al., 1973). 1 cells have not been shown to contain other gut hormones. 
ProCCK-denved peptides of different chain lengths (varying from 4-95 amino acids) 
have been identified from extracts of both the small intestine and brain (Mutt & Jorpes, 
196 8,197 1; Mutt, 1976). 
Cholecystoldnin is translated from its mRNA to preprocholecystokinin (preproCCK) in 
the rough endoplasmic reticulum (RER). In human and rat preproCCK is a 115 amino 
acid polypeptide that undergoes specific enzymatic cleavage to fon-n the biologically 
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active hormone. Following translation, the N-terminal pre- (or signal peptide) is 
removed from preproCCK and the remaining intact proCCK (95 amino acids) is 
transported to the Golgi apparatus. In the Golgi apparatus proCCK is completely 
tyrosyl-0-sulphated at three positions (Tyr-77,92 and 95) and cleaved at multiple 
processing sites. The endoproteolytic activity continues in small vesicles which carry 
the processing intermediates to the basal part of the I cells, where the processing 
continues in the secretory granules (see Figure 1.2). The final step in the synthesis of 
bioactive CCK peptides occurs during storage and maturation in the secretory granules 
that contain the precursor for the two enzymes necessary for amidation, which removes 
glyoxylate from the immediate precursors (the glycine extended CCKs), to complete the 
synthesis of bioactive a-carboxyamidated peptides. 
As a result of the biosynthetic pathway, the intestinal I cells release a heterogeneous 
mixture of proCCK products from the mature secretory granules. A small percentage 
are non-amidated precursors. The amidated CCKs constitute a mixture of the longest 
possible bioactive product of proCCK, i. e., CCK-83 (Eberlein etaL, 1992), as well as 
the intermediate sized CCK-58, -39, -33, and -22 (Eng etal., 1984; Mutt and Jorpes, 
1968; Mutt, 1976; Rehfeld, 1978b) and the short CCK-8 and CCK-5 (Dockray etal., 
1978; Rehfeld & Hansen, 1986; Shively etal., 1987). The distribution and release 
patterns vary widely among species (Cantor & Rehfeld, 1989; Eberlein et al., 198 8). 
1.1.2.2 Extra-intestinal procholecystokinin 
Neurones in all regions of the brain synthesise CCK peptides (as in the I cells), though 
cerebellar neurones do so only in the foetal stage (Larsson and Rehfeld, 1979a; 
Rehfeld, 1992). In addition, cholecystokinin coexists within the same neurone as other 
neurotransmitters at many sites such as dopamine and substance P (Hokfelt et al., 
1980; Skirboll et al., 1982). CCK peptides are widely expressed in peripheral 
neurones, primarily in the gastrointestinal tract but also in the genitourinary tract 
(Larsson and Rehfeld, 1979a). Low levels of expression have been found in pituitary 
corticotrophs (Rehfeld, 1986), in thyroid C cells (Rehfeld etal., 1990), in the adrenal 
medulla (Bardram et al., 1989), in the bronchial mucosa (Ghatei et A, 1982) and in 
spermatogenic cells of certain species (Persson etal., 1989). 
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Figure 1.2 A model showing the organelles and some ofthe biochernical reactions 
responsible for the synthesis, processing and targeting for secretion of' GI peptide 
hormones. 
1.1.3 Biological Actions 
1.1.3.1 Gall bladder contraction 
CCK was originally discovered because of its ability to stimulate gallbladder 
contraction. Convincing evidence that endogenous CCK is critical for gallbladder 
contraction has recently been provided by the use of specific CCK receptor antagonists. 
Sufficient doses of antagonist have consistently demonstrated complete blockade of 
either food or CCK-stimulated gallbladder contraction (Liddle et al., 1989; Niederau et 
(1., 1989). Physiological levels of CCK in blood that occur after a meal are sufficient 
to account for postprandial gallbladder contraction (Liddle et al., 1985). In addition to 
effects on the gallbladder, CCK stimulates hepatic secretion ofbicarbonate into bile 
(Shaw & Jones, 1978) and induces relaxation of the sphincter of Oddi (Lin, 1975). 
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Thus, after a meal CCK co-ordinates many aspects of bile delivery to the duodenum. 
1.1.3.2 Lower oesophageal sphincter 
Several gastrointestinal hormones including CCK have been shown to relax the lower 
oesophageal sphincter (Resin et al., 1973). CCK appears to decrease lower 
oesophageal sphincter pressure through a nonadrenergic noncholinergic, neuronal 
mechanism (Dodds et al., 198 1). 
1.1.3.3 Gastric emptying 
In most species studied, CCK slows the rate at which food empties from the stomach. 
(Debas et al., 1975). "Mis delay occurs by CCK-induced relaxation of the proximal 
part of the stomach and constriction of the pyloric sphincter (Anuras et al., 1974; Chey 
etal., 1970). The ability of CCK to delay gastric emptying has been shown to occur 
with even low levels of circulating hormone (Liddle etal., 1986a; Debas etal., 1975). 
The identification of CCK receptors on the pyloric sphincter provide strong evidence 
that CCK directly effects the gastric musculature (Smith, etal., 1984). 
1.1.3.4 Intestinal motility 
In the intestine, CCK has been shown to stimulate motor activity and decrease intestinal 
transit time (B ertaccini & Agosti 197 1; Levant et al., 1974). CC K appears to affect 
bowel motility by two routes. First, it has been shown to release acetylcholine from 
parasympathetic postganglionic neurones (Vizi etal., 1973) and second, to act directly 
on smooth muscle of the small bowel to stimulate contraction (Yamagishi & Debas, 
1978). 
1.1.3.5 Gastric acid secretion 
CCK peptides are weak stimulants of basal acid secretion in most species but inhibit 
stimulated acid secretion. In the cat, CCK stimulates acid secretion to the same 
maximum achieved by gastrin and has no inhibitory action (Way, 197 1). Observations 
that injection of high amounts of CCK reduced gastric acid led to the hypothesis that 
CCK may function as an enterogastrone in humans and dogs. Enterogastrones are 
hormonal substances released by fat in the upper small intestine that cause inhibition of 
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gastric acid secretion. The CCK-AR antagonist, devazepide, was found to potently 
reverse CCK-induced inhibition of meal-stimulated gastric acid secretion in dogs and 
significantly reverse acid inhibition produced by intestinal perfusion with fat (Lloyd et 
d., 1992). 
1.1.3.6 Pancreatic effects 
CCK has been shown to stimulate growth of the pancreas when administered to 
animals (Brants & Morisset, 1976). This effect appears to be a physiological action of 
CCK, since feeding trypsin inhibitors stimulated pancreatic growth while treatment of 
animals with CCK receptor antagonists produced pancreatic atrophy (Niederau et al., 
1987). 
71be administration of glucose or amino acids into the intestine results in greater insulin 
secretion than the same amount of nutrient given intravenously (Hampton etal., 1986). 
CCK receptors have been identified on P cells of rat pancreatic islets (Sakamoto et al., 
1985) indicating that islet p cells have CCK receptors that are linked to the stimulation 
of insulin release. In humans, although exogenous CCK has been shown to potentiate 
amino acid-stimulated insulin release (Rushakoff et al., 1987), CCK alone does not 
significantly modify insulin secretion since CCK receptor (CCK-R) blockade with 
specific CCK-A receptor antagonists did not affect insulin levels. In addition to 
insulin; CCK also potentiated the release of other islet cell hormones, including 
glucagon and pancreatic polypeptide (Schmid et al., 1989). The precise role of CCK in 
the regulation of insulin and glucagon secretion remains unclear. 
Preparations of isolated pancreatic acini in vitro have provided an excellent model for 
studying pancreatic secretion on a cellular level. Extremely low concentrations of CCK 
are needed to stimulate secretion of most pancreatic enzymes (Kerstens et al., 1985). 
Although amylase is the most abundant pancreatic enzyme secreted, many other 
pancreatic enzymes are also secreted in parallel but in comparison CCK has little effect 
on their release (Nakajima et al., 1973). This differential effect of CCK on enzyme 
secretion is referred to as nonparallel secretion. In addition to stimulating pancreatic 
enzyme secretion, CCK has direct effects on enzyme biosynthesis. In particular, CCK 
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has been shown to increase the pancreatic content of serine proteases relative to amylase 
(Leroy et al., 197 1). CCK is also a weak stimulant of bicarbonate secretion (You et al. 
1983). 
1.1.3.7 Satiety 
The discovery by Gibbs et al. (1973) that CCK decreases food intake in rats led to 
intensive investigations into the mechanisms by which CCK induces satiety. In rats, 
CCK induces the typical behavioural pattern of satiety such as grooming and 
exploration as well as a reduction in food intake (Antin et al., 1975). The ability of 
peripherally administered CCK to produce satiety, appeared to be mediated by the 
vagus nerve since CCK had no effect on satiety when given to vagotomised animals 
(Smith et al., 198 1). Investigations on rhesus monkeys indicated that the satiety effect 
of peripherally administered CCK was due to its ability to inhibit gastric emptying 
(McHugh & Moran, 1986). However, studies in baboons suggested that effects on 
gastric emptying could not account for all the satiety effects of CCK (Stein et al., 
1986). Thus, the exact mechanism(s) by which vagal afferents signal satiety within the 
brain are unknown. Research determining whether the levels of CCK in the blood are 
sufficiently high to produce satiety have been inconclusive. In dogs, the amount of 
CCK required to cause satiety was greater than that necessary to stimulate gall bladder 
contraction (Pappas et al., 1985). Later studies in pigs immunised against CCK had 
increased food intake and accelerated weight gain compared to non-immunised animals 
(Pekas & Trout, 1990; Pekas, 1991). Studies with CCK-AR specific antagonists 
showed that CCK-AR blockade increased food intake in pigs (Ebenezer et al., 1990) 
and decreased satiety in humans (Wolkowitz et al., 1990) and CCK-BR antagonists had 
no effect. These studies with CCK-R antagonists provide evidence that endogenous 
CCK plays a role in regulating satiety. 
1.1.4 Release 
CCK is released into the blood from the duodenum during ingestion of a meal. The 
CCK levels gradually increase to a maximum at 10-45 minutes following the start of a 
meal and then gradually decline, but remain elevated upto 3 to 5 hours after eating. 
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Food components including protein digestatcs and fat are stimulants of CCK secretion 
(Meyer & Jones, 1974; Liddle et al., 1985). The amino acids tryptophan and 
phenylalanine appear to be the most potent stimulants of intestinal CCK (Go et al., 
1970; Konturek et al., 1973) and carbohydrate in the form of glucose is also a weak 
stimulant of CCK (Liddle etal., 1985). However, there are clear species differences in 
the CCK responses to different food components (Liddle etal., 1986b). The exact 
mechanisms by which food stimulates CCK secretion have yet to be elucidated. 
Recently, two naturally occurring trypsin-sensitive peptides have been shown to act 
within the lumen of the intestine to stimulate CCK release (Iwai et al., 1987; Miyasaka 
etal., 1989). Monitor peptide, a 61 amino acid protein is produced by the pancreas and 
secreted into pancreatic juice. Upon reaching the intestine, monitor peptide stimulates 
CCK release. In contrast, another "CCK releasing factoe' has been partially 
characterised from the intestine (Lu etal., 1989; Miyasaka etal., 1989). This factor is 
secreted by the intestine into the gut lumen under basal conditions. 
At present it is not known which of these factors is the most important for controlling 
CCK secretion but it is known that multiple mechanisms exist to ensure proper 
regulation of CCK release such as bombesin and vagal stimulation (Walsh, 1987). 
Stimulants responsible for the release of CCK from the brain and the male reproductive 
system are yet unknown. 
1.1.5 Metabolism 
Peptides shorter than CCK-8 are broken down much faster than the larger forms. 
Plasma CCK is mainly degraded by aminopeptidase (Deschodt-Lanckman etal., 1981, 
1983). CCK peptides with sulphated tyrosine are degraded more slowly than their 
non-sulphated counterparts. Several types of enzymatic activity in tissue are able to 
degrade CCK-8 including membrane bound aminopeptidases (Deschodt-Lanckman, 
1982). It is well known from studies with gastrin fragments that the pentapeptide and 
tetrapeptide common to gastrin and CCK are almost removed from the portal blood 
during a single pass through the liver (Doyle etal., 1984). 
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1.2 GASTRIN 
Gastrin is a gastrointestinal peptide honnone which was first extracted by Edkins in 
1905 and the protein sequence was independently determined later in 1964 (Anderson 
et al., 1964; Gregory& Tracy, 1964). 
1.2.1 Molecular characterisation 
There are a number of gastrin peptides which range from 5 to 34 amino acids in 
sequence (Walsh & Grossman, 1975) arising from a larger parent polypeptide (Walsh, 
1987). The most abundant form in the duodenum is the 34-amino acid (G-34), 
whereas the heptadecapeptide G-17 is more abundant in the antrum. About half of G- 
17 and G-34 molecules in the antrum and duodenum have a sulphated tyrosine residue 
which is located in the sixth position proximal to Phe-NH2 (Walsh, 1987). Sulphated 
forms of gastrin are also known as gastrin 111. The most abundant form of gastrin in the 
blood corresponds to G-34. About two-thirds of circulating gastrin in the basal state 









Figure 1.3 Structure of G-34. The C-terminal pentapeptide sequence is important 
for the biological activity of the peptide (the sequence of G-17 is indicated). 
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The remainder is G-17 and small amounts of G-14, which is a smaller fragment of 
gastrin also known as minigastrin (Gregory et al., 1979). The hexapeptide G-6 is the 
smallest gastrin fragment isolated from the stomach (Gregory et al., 1983). Larger 
forms of gastrin have not yet been characterised structurally. Species differences have 
been found in gastrins from different mammals (Reeve et al., 198 1; Bonato et al., 
1986; Jiang etal., 1988). 
1.2.2 Post-translational processing of progastrin 
1.2.2.1 Antral progastrin 
The majority of gastrin is synthesised and secreted by endocrine cells in the antral 
mucosa of the stomach (Larsson, 1980; Rehfeld, 1981). These cells are known as G 
cells. These G cells can be distinguished from CCK-containing cells by specific 
patterns of antibody reactivity and by ultrastructural appearance. Some gastrin cells are 
found in the adult duodenal mucosa (Buchan et al., 1979). However, gastrin 
biosynthesis studies have so far focused on antral tissue (Brand et al., 1984; Hilsted & 
Rehfeld, 1987). 
Gastrin is translated from its mRNA to preprogastrin in the rough endoplasmic 
reticulum (RER). Following translation the N-terminal signal peptide is removed from 
preprogastrin and the remaining intact progastrin (95 amino acids) is transported to the 
Golgi apparatus. In the Golgi apparatus progastrin is tyrosyl-0-sulphated (66) and 
cleaved at multiple processing sites. From the Golgi apparatus, network vesicles carry 
the intermediates of progastrin towards the basal part of the G cells, where the peptides 
are stored in characteristic secretory granules (Hakanson et al., 1982; Larsson & 
Rehfeld, 1979b). It is thought that the endoproteolytic trypsin-like and exoproteolytic 
carboxypeptidase E-like processings (as well as the subsequent glutamyl cyclisation, 
corresponding to the N-termini of G-34 and G-17) continue during the transport from 
the Golgi to the early secretory granules. Ile final processing step in the synthesis of 
gastrin occurs during storage and maturation in the secretory granules. The amidation 
enzymes in the granules remove glyoxylate from the immediate precursors (the glycine- 
extended gastrins), to complete the synthesis of bioactive a-carboxyamidated peptides. 
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Amidation is a crucial all-or-none activation process which is carefully controlled 
(Hilsted etal., 1986,1988). 
The results of this biosynthetic pathway release a heterogeneous mixture of progastrin 
products from the secretory granules (G71,34,17,15,14,7 and 4). A small 
percentage are non-amidated precursors, mainly glycine-extended gastrins. In humans 
>95% dre a-amidated bioactive gastrins, of which the longest molecular form is G-7 1. 
Thus of the amidated gastrins 90% are G-17,5% are G-34 and the rest a mixture of G- 
7 1, G- 15, G- 14 and short C-terminal hepta- or tetrapeptide amide fragments (Gregory 
etal., 1983; Hilsted & Hansen, 1988; Rehfeld & Larsson, 1979; Yalow & Berson, 
1970). Approximately half of the amidated gastrins are tyrosyl-sulphated (Hilsted & 
Rehfeld, 1987). 
Due to gross differences in metabolic clearance rates, the distribution of gastrins in 
peripheral plasma changes so that larger gastrins with their long half-lives predominate 
over G-17 and shorter gastrins (Jensen, etal., 1989). 
1.2.2.2 Extra-antral progastrin 
The gastrin gene is expressed at the peptide level in several cell types other than the G 
cells. Quantitatively, the gastrin contribution in plasma from other cells is very small. 
This is mainly because the secretion seems to serve local purposes rather than a general 
endocrine function and also because the biosynthetic processing is cell specific. 
Expression of progastrin and its products has been detected in the distal small intestine 
(Buchan et al., 1979), colon, (Luttichau et al., 1993), in endocrine cells in the foetal 
and neonatal pancreas (Bardram etal., 1990), in spermatogenic cells (Schalling etal., 
1990), in a few cerebellar and vagal neurones (Rehfeld, 1991; Uvnas-Wallensten et al., 
1977) and in the bronchial mucosa (Rehfeld et al., 1989). The concentrations and 
synthesis of gastrin in the extra-antral tissues are far below those of the antrurn and the 
precise function of gastrin synthesised outside the antroduodenal mucosa is largely 
unknown. However, one important function is in the paracrine or autocrine regulation 
of malignant growth (Hoosein etal., 1988). 
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Although it is possible that extra-antral synthesis of gastrin is without function in the 
adult organism, recognition of the phenomenon has considerable clinical relevance. 
Hence, tumours originating from tissues and cells that normally express the gastrin 
gene even at low level may produce gastrin in lethal amounts. 
1.2.3 Biological Actions 
1.2.3.4 Acid secretory effects 
Gastrin has a wide range of actions on epithelial and smooth muscle targets in the 
gastrointestinal tract. Gastrin plays an important role in the regulation of meal- 
stimulated gastric acid secretion (McGuigan et al., 197 1; Walsh & Grossman, 1975). 
Large fragments of gastrin that contain the C-terminal tetrapeptide amide sequence, 
including G-34, G- 17, and G- 14 have similar acid-stimulating potency (Carter et al., 
1979; Eysselein etal., 1984). Both sulphated and non-sulphated forms of G-17 and of 
G-14 have similar acid stimulating potency. The primary target of circulating gastrin 
may be the histamine-containing gastric enterochromaffin-like cell, the parietal. cell or 
both (Soll et al., 1984; Chuang et al., 1992; Sandvik & Waldum, 199 1; Ruiz 
&Michelangeli, 1986). 
1.2.3.2 Trophic effects 
A potentially important role of gastrin is the regulation of mucosal growth, especially of 
the acid-secreting mucosa of the stomach (Johnson, 1976). Most cell division occurs 
in the area of the mucous neck cells. From here cells migrate to the surface of the gland 
where they become parietal cells. The origin of the chief and enterochromaffin-like 
cells is currently unknown. When gastrin is released it passes into the circulation to the 
oxyntic mucosa where it stimulates DNA synthesis (Enochs & Johnson, 1977) and 
proliferation of the oxyntic mucosal cells (Crean etal., 1969), particularly the parietal 
cells and the ECL cells. Resection of the antrum (the site of gastrin secretion) results in 
atrophy of the gastric mucosa (Johnson, 1988). This atrophy can be reversed by the 
administration of gastrin. CCK in high doses appears to be a competitive inhibitor of 
the trophic effects of gastrin in the stomach (Johnson, 1977). Trophic effects of gastrin 
have also been found in the colon mucosa (Dembinski & Johnson, 1979). 
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1.2.4 Release 
Food components, namely glucose and fats, are weak stimulants of gastrin release 
(Walsh, 1987; Walsh, 1992). Gastrin is mainly released in response to peptides, amino 
acids (phenylalanine and tryptophan) and calcium in the gastric lumen, by the activation 
of nervous reflexes, and by catecholamines and bombesin circulating in blood (Walsh 
& Grossman, 1975). Food components, especially small peptides and amino acid 
fragments resulting from the digestion of protein also cause gastrin release (Taylor et 
d., 1982). Gastrin is also released by vagal stimulation mediated by cholinergic 
mechanisms that may be induced by the sight, smell and taste of food (Nilsson et al., 
1972). Gastrin release is inhibited by a low pH in the stomach, by several peptides 
including somatostatin and by certain prostaglandins (Walsh, 1987; Walsh, 1988). 
1.2.5 Metabolism 
The rates at which various form s of gastrin disappear from the circulation and the sites 
of removal have been studied more thoroughly than the mechanisms for inactivation. 
The liver does not appear to play an important role in clearance of larger gastrins 
present in the circulation, but it removes short gastrin fragments such as the tetrapeptide 
and pentagastrin (Strunz, etal., 1978). The kidney may play a major role in clearance 
of G-34 (Loly et al., 1982). The kidney tubule contains enzyme activity that cleaves 
the C-terminal dipeptide from G-4 (Walsh & Laster, 1973), however it is still unclear if 
this enzyme acts on the larger gastrin molecules. 
1.2.6 Mode of cellular release of CCK and Gastrin 
Different types of cells release CCK and gastrin in different manners. CCK and gastrin 
are now known to be released by five different routes. i) Classical endocrine secretion, 
where secretory granules of the endocrine I and G cells in the gastrointestinal mucosa 
empty their peptides into surrounding capillaries after appropriate stimulation. ii) 
Peptides in neurones are released from synaptosomal vesicles in the nerve terminals to 
the receptors of adjacent target cells i. e. neurotransmitter or neurocrine release. iii) It 
has been shown that there are gastrin-producing paracrine cells in the small intestinal 
mucosa (Larsson, 1980). These cells carry gastrin granules through cytoplasmic 
extensions to specific target cells in the neighbourhood. iv) Autocrine secretion 
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whereby the trophic peptides bind to their specific receptors in the membranes of cells 
in which they are synthesised. The growth of colon cancer in vitro (Hoosein et at., 
1988,1990) and pancreatic cancer cells (Blackmore & Hirst, 1992; Seva et al., 1990a) 
has been shown to be stimulated by autocrine secretion. v) In spermatozoa, the CCK 
or gastrin peptides are carboxyamidated and are concentrated in the acrosome. The 
peptides are released from the spermatozoon by contact with the jelly coat of the egg 
and are subsequently bound to the receptors in the egg membrane. 
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1.3 CHOLECYSTOKININ AND GASTRIN RECEPTORS 
The cholecystokinin and gastrin families of peptides act as hormones and neuropeptides 
on central and peripheral CCK receptors to mediate their physiological responses. 
CCK and its receptors am widely distributed in the central nervous system (CNS) and 
contribute to the regulation of satiety, anxiety, analgesia and dopamine-mediated 
behaviour. Although the wide distribution, myriad functions and reported 
pharmacological heterogeneity of CCK receptors (CCK-R) might suggest a large 
number of subtypes, application of modem molecular biological techniques has so far 
identified only two CCK receptors. These are the CCK-A and CCK-B receptors that 
mediate the actions of CCK and gastrin. Gastrin receptors have been found to be 
identical to the CCK-B receptor (Kopin et al., 1994). 
Receptors for CCK have been pharmacologically classified on the basis of their affinity 
for the peptide agonists, CCK and gastrin and by recently developed subtype specific 
antagonists (Presti & Gardner, 1993). 
1.3.1 Discovery 
The CCK-A receptor (CCK-AR) was first characterised on pancreatic acinar cells 
(Sankaran et al., 1980) and in the same year a second receptor with a different 
pharmacology was discovered in the brain (Innis & Snyder, 1980) and termed the 
CCK-B receptor (CCK-BR). 
The characterisation of CCK binding sites was conducted using agonists, and 
antagonists. The differences in binding affinities of the various forms of CCK resulted 
in the elucidation of two subtypes of CCK-R. The CCK-AR is highly selective for 
sulphated analogues (500- to 1000-fold higher affinity) and the antagonist L-364,718 
(Chang & Lotti, 1986). CCK-BR have similarly high affinity for both the sulphated 
and non-sulphated peptide analogues of CCK and gastrin (only a 3- to 10-fold higher 
afrinity for sulphated peptide analogues) and the antagonist L-365,260 (Lotti & Chang, 
1989). The receptors were termed the peripheral or alimentary CCK-A receptor 
subtype and the central or brain CCK-B/gastrin receptor subtypes, respectively. 
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1.3.2 Distribution and function 
1.3.2.1 Cholecystokinin-A receptors (CCK-AR) 
The CCK-AR has been described on pancreatic acinar cells (Sankaran et d, 1980), gall 
bladder smooth muscle (Bitar & Makhlouf, 1982), chief and D cells of gastric mucosa 
(Soll et al., 1984), selected areas of the central and peripheral nervous systems (Moran 
et al., 1986) and turnour cell lines such as the rat pancreatic turnour cell line, AR42J, 
(Logsdon, 1986) and the human neuroblastoma cell line CHP 212 (Klucppelberg et al., 
1990) where they mediate growth. 
CCK-AR stimulation with physiological concentrations of CCK causes pancreatic 
exocrine enzyme secretion (Sankaran et al., 1980), growth (Zucker et al., 1989), 
endocrine islet cell secretion of insulin (Rosseti etal., 1987) and pancreatic polypeptide 
(Liddle et al., 1990). CCK-AR in the stomach mediates secretion of pepsin from 
gastric chief cells and release of somatostatin from D cells of the gastric mucosa, 
resulting in inhibition of acid secretion (Lloyd et al., 1992). CCK-AR on smooth 
muscle cells cause gall bladder emptying (Bitar & Makhlouf, 1982), increased pyloric 
sphincter tone with delayed gastric emptying and within the intestine decreased small 
bowel and increased colonic transit time (Meyer et al., 1989). CCK-AR is also present 
in the sphincter of Oddi (Behar & Bianchini, 1980) and on inhibitory postganglionic 
neurones in the lower oesophageal sphincter causing relaxation (Rattan & Goyal, 
1986). 
Although the CCK-AR has been traditionally classified as a peripheral receptor, it is 
present in selective areas of the central nervous system and peripheral nervous system 
(vagus nerve), where it mediates the satiety effect of CCK. CCK-AR in the nucleus 
accumbens regulates dopamine release that has potential implications in human 
neuropsychiatric diseases such as schizophrenia (Crawley, 1991). The CCK-AR 
present in the dorsal hom of the spinal cord in primates antagonise opioid analgesia 
tolerance (Baber et aL, 1989) and in the anterior pituitary corticotrophs CCK-AR 
mediates the release of adrenocorticotrophic hormone and p-en'dorphin (Kamilaris etal., 
1992). 
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1.3.2.2 Cholecystokinin-B receptorS (CCK-BR) 
The CCK-BR is found on cells throughout the central nervous system (Innis & Snyder 
1980), immune cells such as monocytes and T lymphocytes (Lignon et al., 1991) and 
tumour cell lines such as the AR42J cell line (Lambert et al., 1991) and human 
leiomyosarcoma cells (Pearson etal., 1989). 
CCK acting on the CCK-BR in the anterior nucleus accumbens, unlike the CCK-AR in 
the posterior nucleus accumbens, has an inhibitory effect on dopamine release. The 
CCK-BR is also involved in the regulation of anxiety by peripheral and central CCK 
(Harro et al., 1993). The function of CCK-B receptors on monocytes and T 
lymphocytes is yet unknown. The CCK-BR present on turnours and tumour derived 
cell lines stimulates growth. The CCK-BR mediates acid secretion from parietal cells in 
the stomach (Soll etal., 1984), release of histamine from enterochrornaffin-like cells 
(Nakata et al., 1992) and contraction of smooth muscle cells (Grider & Makhlouf, 
1990). CCK-BR is also present on pancreatic acinar ceUs in dog and guinea pig where 
it mediates growth but not enzyme secretion (Founny et al., 1984; Yu et al., 1990). 
The so called "gastrin receptoe, which was first characterised on canine parietal cells 
(Soll et al., 1984) has equally high affinity for sulphated CCK and gastrin and an 
intermediate affinity for non-sulphated CCK and CCK-4 compared with the CCK-B 
receptor (Chang et al., 1986; Soll et al., 1984). The basis for suspecting that the 
gastrin receptor in the stomach and CCK-BR in the brain were distinct types of CCK 
receptors was due to their different relative affinities for CCK and gastrin-like peptides 
(Menozzi et al., 1989). However, researchers have subsequently shown that this 
receptor is the CCK-B receptor: when the canine parietal cell gastrin receptor was 
expressed in COS cells it had the same affinity for CCK and gastrin displayed by the 
native CCK-BR in human and guinea-pig (Kopin etal., 1994). Furthermore, high 
stringency Northern blot analysis utilising a fragment of the gastrin receptor as a probe, 
showed receptor messenger RNA in the canine gastric parietal cells, pancreas and 
cerebral cortex. The idea that the gastrin receptor was different from the CCK-BR was 
also supported by the affinities for the benzodiazepine derived CCK-BR antagonist, L- 
365,260 and CCK-AR antagonist, L-364,718. The canine parietal cells showed a 
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greater affinity for the L-364,718 compound, whereas the CCK-BR in the brain of 
other species showed a higher affinity for L-365,260 (Lotti & Chang, 1989). The 
reversal in canine gastrin-receptor affinity for the antagonists has been ascribed to a 
species specific change of a single nucleotide, resulting in a single amino acid 
substitution (valine in the rat and human and leucine in the dog) in the sixth 
transmembrane domain (Beinborn et al., 1993). 
1.3.3 CCK receptor structure 
CCK receptor structure has been studied primarily by mdioligand affinity cross-linking, 
followed by receptor purification and most recently by the cloning of the receptor 
cDNA and deduction of the primary amino acid sequence. 
1.3.3.1 CCK-A receptors 
The size and number of covalently cross-linked protein bands vary with the ligand, 
cross-linking reagent, species and the tissue expressing the CCK receptor (Miller, 
1984; Pearson & Miller, 1987; Pearson etal., 1987; Rosenzweig etal., 1983). In rat 
pancreatic acinar cells, the CCK-AR was found to be a 85-95 kDa NH2-linked 
glycoprotein having a 42-44 kDa protein core (Pearson et al., 1987). The rat pancreatic 
CCK-AR was purified by using ion-exchange and multiple affinity chromatographic 
separations, followed by chemical/enzyme cleavage. Progressively purified receptor 
was detected using PH]L-364,718 binding assay (Wank etal., 1992a). This allowed 
partial peptide sequencing and the synthesis of degenerate oligonucleotides which were 
used successfully in cloning the CCK-AR cDNA from a rat pancreatic cDNA library 
(Wank et al., 1992a). The rat CCK-AR cDNA was further used to clone the human 
CCK-AR cDNA (de Weerth etal., 1993a). Briefly, a human placenta genomic library 
was screened using [3 2P] random primed probe derived from the rat CCK-AR cDNA. 
Primers were selected from the clone isolated from the human placenta genomic library 
(non-coding regions of the clone). The selected primers successfully amplified CCK- 
AR cDNA from the human gall bladder. The sequencing results showed a 428 amino 
acid protein with a molecular mass of - 48 kDa. A hydropathy plot using the criteria of 
Kyte and Doolittle (1982) and homology with the rat and guinea-pig CCK-AR (Wank 
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et al., 1992a; de Weerth et al., 1993b) identified seven regions of hydrophobic residues 
corresponding to putative transmembrane domains expected for members of the G- 
protein coupled superfamily of receptors (Dohlman et al., 1987). The sequence 
predicts four N-linked glycosylation sites, two in the amino terminus, one in the second 
extracellular loop and one in the third intracellular loop. There are five potential sites 
for protein kinase C phosphorylation and one for protein kinase A phosphorylation 
(Kennelly & Krebs, 199 1) all on serines in the third intracellular loop. 
Receptors with seven transmembrane domains are thought to have no intrinsic 
enzymatic activity; instead they are coupled indirectly to their target proteins by way of 
membrane-delimited G proteins and second messenger molecules. This group of 
receptors contains at least a 100 members and represents about 80% of all known 
receptors (Luetje et al., 1990). Despite a common overall structure, the amino acid 
sequences of these receptors are usually quite different. For example, the sequences of 
the closely related adrenergic 1 and 2 receptors am only 50% identical and the CCK-A 
and CCK-B receptors share 47% amino acid identity. All G protein-coupled receptors 
contain seven hydrophobic stretches of 20 to 25 amino acids. These form the helices 
that alternately are exposed either intracellularly or extracellularly. The amino acid 
sequences that represent the binding sites for ligands and G proteins and those that 
provide agonist and antagonist specificity have been identified using molecular biology 
techniques as mentioned above. Based on the location of the ligand binding site, 
GPCRs have been divided into two subclasses; receptors for glycoprotein hormones 
(such as thyroid-stimulating hormone) in which the binding site is thought to be in the 
extracellular domain (Goy, 1991) and receptors for small neurotransmitters 
(noradrenaline) and peptide hormones, in which the ligand binding site is likely to be 
within the hydrophobic transmembrane domain (Parmenter et al., 1989). Recent 
preliminary studies on CCK-A and CCK-B receptors indicate that the agonist binding 
site lies in the N-terminal close to the membrane and in the second extracellular loop, 
respectively, (Kennedy et al., 1995; Poirot & Wank, 1996). 
Heterotrimeric regulatory guanine nucleotide-binding proteins (G proteins) belong to 
the superfamily of GTP-binding proteins or GTPases and are extremely conserved 
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throughout the animal kingdom, underlining their pivotal role in cellular regulations 
(Bourne et al., 1990,1991). They play an important role in the transduction of 
extracellular signals into the cell and couple receptors for light, hormones, 
neurotransmitters, growth factors and other extracellular signalling molecules to their 
intracellular effectors. Heterotrimeric G proteins consist of an a (39-45 kDa), P (35-36 
kDa) and y subunit (7-8 kDa) (Boume etal., 1990,1991, see Figure 1.6). Each of the 
subunits is a product of a distinct gene. When aG coupled protein receptor (GCPR) is 
activated by the binding of an agonist, the molecule interacts with the heterotrimeric G 
protein. This interaction leads to the replacement of GDP, which is bound to the a 
subunit in the resting state with GTP. This nucleotide exchange induces the 
dissociation of the heterotrimer into the free, GTP-bound a subunit and the py-dimer. 
Both GTP bound a and py subunits can activate certain effectors (Tang & Gilman, 
1991). This activation can be terminated by the intrinsic GTPase activity of the a 
subunit which cleaves the bound GTP into GDP and inorganic orthophosphate (Pi). 
The GDP bound a subunit now reassociates with the Py dimer to the heterotrimer 
present in the resting state. 
A comparison of the amino acid sequence of the human CCK-AR with rat and guinea- 
pig CCK-AR shows a 90 and 91% identity respectively. The human receptor is one 
and two amino acids shorter than the rat and guinea-pig CCK-AR, respectively. 
Similar to the rat and guinea-pig CCK-AR there are conserved cysteines in the first and 
second extracellular loops which may form a disulphide bridge required for stabilisation 
of the tertiary structure as demonstrated for rhodopsin (Karnik et al., 198 8). A cysteine 
in the carboxy-terminus may be a membrane anchoring palmitoylation site similar to 
rhodopsin (O'Dowd et al., 1989). 
1.3.3.2 CCK-B receptors 
Affinity cross-linking studies of the CCK-BR using 1251-[Leu] or [N-Leu 15] gastrin- 
(2-17), disuccinimidyl suberate in either a 60-70% pure canine gastric parietal cell 
preparation or a solubilised porcine gastric mucosal extract identified a 78 and a 74 kDa 
glycoprotein, respectively (Baldwin etal., 1986; Matsumoto etal., 1987). 
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In the rat brain, the CCK-BR was found to be - 90 kDa NI-12-linked glycoprotein 
having a 48 kDa protein core (Wank et al., 1992b). The rat CCK-BR cDNA was 
cloned using low stringency hybridisation from a rat pancreatic acinar carcinoma cell 
line (AR42J) cDNA library known to express CCK-B/gastrin receptors (Svoboda et 
d., 1982) and shown to be identical to the cDNA cloned from the rat brain cDNA 
library (Wank etal., 1992b). The rat CCK-BR cDNA was used to isolate the human 
CCK-BR cDNA from the brain and stomach (Pisegna et al., 1992a). The sequencing 
results showed a 447 amino acid protein with a molecular mass of approximately 48.5 
kDa. A hydropathy plot using the criteria of Kyte & Doolittle and homology with other 
G-protein coupled receptor superfamily members identified seven regions of 
hydrophobic residues corresponding to putative transmembrane domains expected for 
members of the G-protein coupled superfamily of receptors (Lambert et al., 199 1; 
Merritt et al., 1986). The sequence allows for three potential N-linked glycosylation 
sites, all in the amino terminus. There are two potential sites for protein kinase C 
phosphorylation on serines in the first and third intracellular loop and three potential 
sites for protein kinase A phosphorylation on serines in the second intracellular loop 
and amino terminus and on threonine in the third intracellular loop (Kennelly & Krebs, 
1991, see Figure 1.4). 
Comparison of the amino acid sequence of the human CCK-BR with rat and canine 
CCK-B/gastrin receptor shows an - 90% identity. The human receptor is five and six 
amino acids shorter than the rat and canine parietal CCK-B/gastrin receptor, 
respectively (Kopin et al., 1992). Similar to the rat and canine CCK-B/gastrin receptor 
there are conserved cysteines in the first and second extracellular loops which may form 
a disulphide bridge and a cysteine in the carboxy-terminus may be a membrane 





Figure 1.4 Schematic models of the rat CCK-AR and CCK-BR, showing putative 
transmembrane domains, consensus sites for putative N-linked glycosylation (LP ), 
serine and threonine phosphorylations (PO3) and conserved cysteines in the lst and 
2nd intracellular loops forming disulphide bridges (S-S) and a conserved cysteine in in 
the cytoplasmic tail possibly palmitoylated (f ), (NH2, amino terminus; COOHs 
carboxy tenninus). 
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The greatest amino acid homology between CCK receptors and other G protein-coupled 
receptors occurs with the gastrin releasing peptide, tachykinin and neuropeptide Y 
receptor families and the N-adrenergic and D4 dopamine receptors. Comparison of the 
amino acid sequences for the rat, canine and human CCK receptor sequences to other 
known G-protein coupled receptors indicate that CCK receptors constitute a distinct 
neuropeptide receptor family within the G-protein coupled superfamily of receptors. 
1.3.4 CCK receptor gene structure 
71be genes for the CCK-A and the CCK-B receptor have been cloned in humans (Song 
etal., 1993). Both genes are organised in a similar manner, consisting of five exons 
and four introns. The receptor genes have homologous exon-intron splice sites, with 
exon 1 coding for the extracellular NH2-terminal sequence, exon 2 for the sequence 
from the beginning of transmembrane 1 to the first part of transmembrane 3, exon 3 
from transmembrane 3 to the beginning of transmembrane 5, exon 4 from 
transmembrane 5 to the first quarter of the third intracellular loop and exon 5 for the 
remainder of the receptor (see Figure 1.5). 
Recently, the gastrin/CCK-B receptor was shown to be composed of five exons with an 
alternative splice donor site in exon 4. 'Ibis results in two receptor isoforms that differ 
in the third intracellular cytoplasmic loop (Song et al., 1993; Ito et al., 1994). One 
receptor isofonn contains 452 amino acids (long isoform) and the other lacking the 
pentapeptide sequence (Gly-Gly-Ala-Gly-Pro), contains 447 amino acids (short 
isoform). However, there is little research done on these isoforms, but it has been 
postulated that by the generation of receptor isoforms with differences in the 
cytoplasmic domain, differing signalling mechanisms could result from ligand binding. 
The human CCK-AR gene has been localised to chromosome 4 (de Weerth et al., 






Figure 1.5 Schematic representation ot'genes for human CCK-AR and CCK-BR. 
Shown are positions of the five exons (shaded boxes) and four introns (open boxes) 
comprising the genes for the CCK-AR and the CCK-BR; Roman numerals refer to 
putative transmembrane-spanning regions encoded within each exon. ATG and TGA, 
putative start and stop codons, respectively. 
1.3.5 Receptor signalling 
1.3.5.1 CCK-A receptors 
The signal transduction mechanisms are best characterised in pancreatic acinar cells. 
Occupation of cell surface membrane CCK-AR by CCK initiates coupling to pertussis 
toxin-insensitive guanine nucleotide binding regulatory proteins (G proteins). G 
protein activation and subsequent coupling to phosphoinositide specific phospholipase 
C (PLC) (Smi-cka & Sternweiss, 1993; Taylor et al., 199 1) leads to the formation of 
inositol triphosphates (1p3) and diacyl glycerol (DAG) (Berridge, 1987, shown in 
Figure 1-6). Increase in IP3 results in release of intracellular calcium (Wakui et al.. 
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1990) and DAG activates protein kinase C (PKC). The increase in intracellular calcium 
appears to mediate enzyme secretion and generation of DAG is important in the 
sustained phase of enzyme release, which is dependent upon extracellular calcium. 
Enzyme secretion by CCK is mediated by both intracellular calcium and DAG and their 
effects on ultimate secretion are additive. Activation of PKC and intracellular calcium 
increase the activity of calcium-calmodulin dependent serine/threonine protein kinases 
and tyrosine kinases (Duan et al., 1994) which lead to the phosphorylation of multiple 
proteins and ultimately enzyme secretion by pancreatic acinar cells. Increases in 
intracellular calcium induced by CCK binding to the CCK-AR are also associated with 
changes in monovalent cation channel activity in the plasma membrane of pancreatic 
acinar cells (Maruyama & Petersen, 1982). CCK stimulation causes the opening of 
channels that allow the influx of sodium and calcium and the efflux of potassium. 
Potassium efflux depolarises the membrane and results in enzyme secretion. The 
molecular mechanisms for the actual signalling of zymogen granule exocytosis are 
largely unknown. In addition to the PLC pathway, CCK at high doses can stimulate 
the adenylate cyclase signal transduction pathway in pancreatic acini in the presence of 
phosphodiesterase inhibitors. 
1.3.5.2 CCK-B receptors 
The CCK-BR in isolated canine, porcine or rabbit parietal cells, like the CCK-A 
receptor, couples to a pertussis toxin-insensitive G protein (Roche et al., 1990), 
subsequently causing the activation of PLC, formation Of IP3 and DAG, release of 
intracellular calcium and translocation and activation of PKC (Tsunoda etal., 1988, 
1989). 
Stimulation of the CCK-B receptor expressed in mouse and rat fibroblasts results in the 
phosphorylation of a number of protein species including mitogen-activated protein 
kinase (MAPK) and focal adhesion kinase (FAK) (Taniguchi et al., 1994; Seufferlein 
et aL, 1995). The upstream mechanism by which CCK-BR interaction is coupled to 
the activation of MAPK has been recently examined by Seva and co-workers; (1996). 
They showed that stimulation of the CCK-B receptor phosphorylated the adaptor 
protein Shc. The phosphorylated Shc subsequently associated with a complex that 
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includes Grb2 and the p2l-Ras activator, SoS. 
Compared with the CCK-AR more work has been published on the CCK-BR 
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Figure 1.6 Schematic diagram showing the events following CCK-AR and CCK- 
BR activation. GCPR, G coupled protein receptor; PLC, phospholipase C; Ad. cyc, 
adenylate cyclase; cAMP, cyclic adenosine monophosphate; IP3, inositol triphosphates; 
DAG, diacylglycerol; PKC, protein kinase C; FAK, focal adhesion kinase; MAPK, 
mitogen activated protein Icinase; P, phosphorylated. 
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1.3.6 Novel CCK receptors 
1.3.6.1 'GastrinICCK-C receptors' 
The existence of an autocrine proliferative loop involving gastrin in colorectal 
carcinoma has resulted in the finding of a novel gastrin binding site named the 
'gastrin/CCK-C receptor'. The expression of high affinity CCK-B/gastrin receptors 
has been reported in membranes of colorectal carcinomas and correlated to 
histopathological tumour staging (Upp et al., 1989) but colon carcinoma cell lines 
generally do not possess high affinity gastrin-binding sites (Weinstock & Baldwin, 
1988; Frucht et al., 1992) or express CCK-A or CCK-B/gastrin receptor mRNAs 
(Bold et al., 1994). The proliferation of colon carcinoma cell lines was inhibited by 
CCK receptor antagonists, proglumide and benzotript, however, the specific 
antagonists L-364,718 (CCK-AR) and L-365,260 (CCK-B/gastrin receptor) had no 
effect (Thumwood et al., 199 1). This novel binding site was named the 'gastrin/CCK- 
C receptor' by Baldwin (1994). The 'gastrin/CCK-C receptor' binds both amidated 
and glycine-extended forms of gastrin-17 with equal affinity and thus is a target for 
incompletely processed progastrins as well as mature gastrin (Baldwin, 1995). 
The receptor is a 78 kDa membrane-associated protein and has been cloned from 
porcine gastric mucosa and found to encode a 763 amino acid protein. The protein has 
been shown to be a member of the hydratase/dehydrogenase family of fatty acid 
oxidation enzymes (Baldwin, 1995) and has been postulated to be involved in novel 
signalling pathways mediated by gastrin. 
1.3.6.2 Gly-GR receptors 
A distinct gastrin receptor subtype has been found on the rat pancreatic carcinoma cell 
line, AR42J (Seva et at., 1994). This receptor which has a high affinity for the gly- 
G17 requires both the N-terminal and C-terminal portions of gly-G17 for optimal 
binding. This receptor subtype does not recognise gastrin-17, CCK-8 or the CCK- 
B/gastrin receptor specific antagonists L-365,260 and PD134308. Gly-G17 has been 
shown to stimulate the proliferation of the rat pancreatic carcinoma cell line, AR42J 
(Seva et al., 1994). Both high and low affinity receptor subtypes exist, which appear 
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to be proteins of different sizes (Seva etal., 1995). 
Gastrin and gly-G17 stimulated the proliferation of Swiss 3T3 cells. Ilese cells do not 
express CCK-A or CCK-B receptors. The novel binding site binds amidated and 
glycine extended forms of gastrin with almost equal affinity and cross linking studies 
with 1251-G2-17 showed that the molecular mass of the gastrin receptors on these cells 
was approximately 45 kDa (Singh et al., 1995a). Whether this receptor subtype is the 
same as the 'gastrin/CCK-C receptor' that exists in different conformational states eg. 
glycosylation, phosphorylation, remains to be elucidated. 
A truncated isoform of the human CCK-B/gastrin receptor has been recently reported 
(Miyake, 1995). This isoform called delta CCK-B receptor, lacks the amino terminal 
extracellular domain of the CCK-B/gastrin receptor. It was isolated from the human 
stomach and shown to have differing ligand selectivity as demonstrated by transfection 
into COS-7 cells. In competition studies with the antagonists L-365,260 and L- 
364,718, delta CCK-BR showed the properties of a classical CCK-B/gastrin receptor. 
However, competition studies with the agonists CCK-8 and gastrin demonstrated that 
delta CCK-B and CCK-B/gastrin receptor showed approximately 100 fold and 10 fold 
higher affinities for CCK-8 than for gastrin, respectively. 
1.3.6.3 G11G2 receptor subtypes 
Recently evidence has been published to suggest the existence of two CCK-BR 
subtypes G, and G2 (Harper et al., 1996a; Roberts et al., 1996), due to the different 
affinities of the selective CCK-BR antagonist L-365,260. The studies in the rat cortex 
and guinea pig gastric glands gave two affinity values (pKi) that suggest two receptor 
sites, one with a high affinity (G2) and the other with low affinity (G 1). In the mouse 
cortex, rectangular hyperbolae of slope 1.0 implied the presence of a single population 
of binding sites (G2). No molecular evidence has been presented to support the 
subtypes. It has been suggested that these receptor subtypes may be explained by: i) 
both glycosylation and phosphorylation of the receptors and ii) the presence of the long 
and short isoforms of the CCK-BR (Song et al., 1993). 
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1.4 CCK RECEPTOR ANTAGONISTS 
The process of inhibition or prevention of agonist-induced response is termed 
antagonism, and the chemical entities with such properties am antagonists. Receptor 
antagonists for gastrointestinal peptides have several common characteristics. Many 
antagonists are peptides that were developed by modifying the structure of an agonist 
by substitution of one or more amino acids or by introducing a reduced peptide bond or 
cyclic configuration. 
In the 1980's cholecystokinin receptor antagonists were few and far between. This was 
mainly due to their rapid degradation by endogenous proteases, poor absorption and 
transport across the blood/brain barrier, low specificity and partial agonism (Freidinger, 
1989). Recently, however, a number of nonpeptide receptor antagonists have been 
developed, many of which are highly potent. 
CCK receptor antagonists can be classified into a number of groups: 
1.4.1 Cyclic nucleotides 
Studies of receptor antagonists for gastrointestinal peptides began with the observation 
that dibutyryl guanosine 3', 5' -cyclic monophosphate was a competitive antagonist of 
the action of CCK on pancreatic acinar cells (Peikin etaL, 1979). 17his antagonist is 
very weak in comparison to antagonists of CCK receptors that have since been 
developed. The dibutyryl group appears to be the major component for determining 
CCK antagonist activity (Freidinger, 1989). 
1.4.2 Amino acid derivatives 
Amino acid derivatives of glutamic acid have been found to possess CCK antagonistic 
properties. Proglumide and benzotript are more potent CCK antagonists than the cyclic 
nucleotide (Hahne et al., 19 8 1). However, compared with other CCK-R antagonists 
proglumide and benzotript are weak CCK-AR antagonists (Freidinger, 1989). They 
are active after oral administration (Verspohl et al., 1988) and proglumide has been 
shown to inhibit the growth of mouse colon cancer (Beauchamp et al., 1985). In 
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determining the structural requirements for the interaction of the amino acid derivative 
class of antagonists, analogues/derivatives of proglumide were developed. These 
include lorglumide (formerly CR 1409), loxiglumide (formerly CR1505) and KSG-504 
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Figure 1.7 The structure of lorglumide (formerly CR 1409, DL-4-(3,4- 
dichlorobenzoylamino)-5-(di-n-pentylamino)-5-oxo-pentanoic acid). 
Lorglumide and loxiglumide are competitive CCK-A receptor antagonists, lorglumide 
being approximately 5600-fold more potent than proglumide (Freidinger, 1989). 
KSG-504 and lorglumide inhibit CCK-8 stimulated amylase release in the isolated rat 
pancreatic acini and CCK-8 stimulated exocrine pancreatic secretion in the isolated 
perfused rat pancreas (Kihara, & Otsuki, 1995). In another study lorglumide inhibited 
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CCK-induced pancreatic turnour growth in rats (Douglas etal., 1989). 
Loxiglumide has been widely utilised in a number of pharmacological studies, 
including gall bladder, guinea-pig ileum and in feedback regulation of pancreatic 
secretion in man (Konturek et al., 1989; Adler et al., 1989). It also inhibits the gastrin- 
stimulated DNA synthesis in the rat pancreatic tumour cell line, AR42J (Seva et al., 
1990b). 
1.4.3 Peptide and pseudopeptide analogues 
JMV180, the CCK analogue, (Boc-Tyr (S03H)-Nle-Gly-Trp-Nle-Asp-O-CH2-CH2- 
C61-15), lacking the C-terminal amide function, exhibits partial agonist activity of CCK 
in rat pancreatic acini. It has been hypothesised that compound JMV180 interacts with 
both low and high affinity peripheral CCK-AR binding sites. It acts as an agonist at the 
high affinity binding sites and as an antagonist at low affinity binding sites (Martinez 
etal., 1985). 
Since the development of JMV180, several other analogues have been synthesised 
(JMV310, JMV320, JMV328 and JMV332) which exhibit high and selective affinity 
for CCK-B receptors in the rat and guinea pig brain (Rodriguez et al., 1990). As 
compared with the CCK nonpeptidic compounds (Bock et al., 1989) such as L- 
365,260, these analogues are approximately 20-100 times less potent. These peptides 
have however proven to be valuable in providing information about the active 
conformation of the CCK-B receptors. 
1.4.4 Benzodiazepine derivatives 
The CCK receptor antagonists in this class of compounds were synthesised after the 
discovery of asperlicin. The benzodiazepine, asperlicin was isolated from the fungus 
Aspergillus alliaceus. Aspercilin itself has low water solubility and poor oral 
bioavailability which led to the design and synthesis of more water soluble, highly 
potent compounds. The benzodiazepine derivative, devazepide (also known as L- 
364,718 and MK329) proved to be a potent, orally available CCK-A receptor 






Figure 1.8 The structure of devazepide (formerly MK329 and L-364,718; 3S(-)-N- 
(2,3-dihydro-I -methyl-2-oxo-5-phenyl- IH- 1,4-benzodiazepin-3-yl)-IH -indole-2- 
carboxamide); Chang & Lotti, 1986. 
Devazepide possesses potent CCK-A receptor blocking activity in various tissues. This 
antagonist inhibits pancreatic amylase secretion (Anderson & Dockray, 1988) with a 
potency 600-fold greater than CR 1409. Additional animal studies with devazepide 
have suggested that this agent can transiently increase food intake, enhance morphine 
analgesia and prevent the development of morphine-induced tolerance (Silverman etal., 
1987). 
L-365,260, another benzodiazepine-derivative, is a potent and highly selective CCK-B 
receptor antagonist (Bock et al., 1989; Lotti & Chang, 1989). This antagonist shows 
specificity for CCK-B receptors in numerous tissues including guinea-pig ileum 
(Botella etal., 1992; Bishai etal., 1993), guinea-pig gall bladder (Grider & Makhlouf, 
1990) and guinea-pig stomach (Lotti & Chang, 1989). Due to the lack of water- 










Figure 1.9 The structure of L-365,260; (3R)-(+)-N-(2,3-dihydro-l-methyl-2-oxo- 
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Figure 1.10 The structure of L-740,093; [N-[(3R)-5-(3-azabicyclo[3.2.2]nonan-3- 
yl)-2,3-dihydro- 1-methyl-2-oxo-IH- 1,4 -ben zod iazepin -3-y I]- N'-(3-m ethy lphenyl) 
urea]. 
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Onc cxccpdonally potcnt and watcr solublc CCK-B reccptor antagonist, L-740,093 has 
a lower IC50 in the guinea-pig cortex (approximately 80 fold lower) than L-365,260 
(Showell etal.. 1994). It is the most potent CCK-B receptor antagonist reported to 
date. 
1.4.5 Peptoids 
This group of compounds consists of both CCK-A and CCK-B receptor specific 
antagonists. Initially, these included CI-988 (formerly Cam-958 and PD134308, 
Hughes etal., 1990) and Cam-1028 (formerly PD135158), which are potent CCK-B 
receptor antagonists (Woodruff & Hughes, 1991). Both antagonists are active in vitro 
and in vivo (Horwell et al., 199 1). 
O: roo, CH2 
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Cam-1028 l(S)-endobomyloxycarbonyl- -NHCOCH2CH2CO2H 
Figure 1.11 The structures of CI-988 and Cam-1028; CI-988 (formerly Cam-958, 
PD134308-0553; 4-1[2-[[3-(IH-indol-3-yl)-2-methyl-l-oxo-2[[(tricyclo[3.3.1.13.7]dec- 
2-yloxy)carbonyl]amino] propyl]amino]-l-phenylethyll amino) -4-oxo-[R- (R*, R*)] - 
butanoate N-methyl-i>-glucamine. 
C am - 10 2 8; (4 -[[2- [[ 3- (I H- in do 1-3 -y 1) -2 -m ethy I- I-o xo -2 [1.7.7 
trimethylbicyclo[2.2. I]hept-2-yloxy]carbonyl]amino]-l-phenylethyllamino-4-oxo-IS- 
la2B[S*(S*)4cc]l-butanoateN-methyl-D-glucamine); Hughes etal., 1990. 
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More recently another group of these dipeptoid series have been synthesised with 
CCK-Areceptorantagonistic activity. These include PD140548 and PD142896 (Singh 
et al., 1995b). These antagonists induce potent anxiolytic-like action in rats and 
antagonise CCK-mediated contractions of the guinea-pig gall bladder (Singh et al., 
1995b) Interestingly, the enantiomers of these CCK-A receptor specific antagonists 
displayed reverse selectivity. 
1.4.6 Indoles 
Recently, IB93182 has been developed and shown to be a high affinity CCK-B/gastrin 
receptor antagonist with G, subtype selectivity (Harper et al., 1996b, see Figure 1.12). 
Both G, and G2 receptor subtypes are shown to be present in the rat cortex and guinea 




Figure 1.12 The structure of JB93182; (5[[[(IS)-[[(3,5-Dicarboxyphenyl)aminoI 





Cancer is a disease, the principal characteristic of which is the heritable alteration in 
genetic expression of the neoplastic cell compared with its normal counterpart (Pitot, & 
Dragan, 1991). 
Cancer has a multifactorial aetiology and is a multistep process involving initiation, 
promotion and tumour progression (Berenblum, 1941; Berenblum & Shubik, 1949). 
Chemical carcinogens, physical agents, ionising radiation, viruses and other agents 
have all been implicated and host factors are clearly involved (Harris, 1991; Schwab & 
Amler, 1990). Genetic changes have been demonstrated by virtually every possible 
type of mutation described, including transitions, transversions, deletions of various 
sizes, chromosomal rearrangements, gene amplification and insertional mutagenesis 
(Harris, 1991; Schwab & Amler, 1990; Gray, 1991). In a malignant neoplasm many 
different kinds of genetic alterations can be seen within cells of a single neoplasm. In 
addition such genetic alterations may evolve from simple to more complex types and 
numbers of mutations within the same neoplastic cell (Aldaz et al., 1987; Bremner & 
Balmain, 1990). 
Many chemical and physical carcinogens can induce one or more of a variety of 
mutations in cells when given chronically. Chemical carcinogens include aromatic 
amines (Neumann, 1986), polycyclic hydrocarbons (Pelkonen & Nebert, 1982) and 
methylating agents (Singer, 1986; Loeb & Preston, 1986). The main physical 
carcinogen is ionising radiation. Virtually all of these are capable of inducing cancer 
following the administration of a single or a few doses. This is found to be consistent 
with the fact that genetic alterations, even when induced acutely but without killing the 
cell, can result in cancer. However, a number of chemicals also exist that are 
carcinogenic only when administered in relatively high doses for extended periods of 
time. Many of these chemicals lack the ability to induce structural modifications 
directly in the DNA of the target cell. 
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Oncogenic viruses can cause structural defects in the DNA of affected cells. The 
structural organisation usually consists, at least initially, of the presence of all portions 
of the viral genome incorporated covalently into the host cell genome. Such viruses 
include papovaviruses, for example SV40, (Farced & Davoli, 1977), adenoviruses 
(Branton et al., 1985), and hepadnaviruses, such as hepatitis B (Slagle et al., 1992). 
In the case of retroviruses such as Rous sarcoma, reverse transcriptase must act to 
make a DNA copy of the viral genome before the incorporation of the viral DNA copy 
into the host cell genome (Varmus, 1988). Other viruses, such as Epstein-Barr virus 
(Ooka, 1985) and papillomavirus (Smith & Campo, 1985) may infect cells but their 
genomes are not incorporated into the host cell DNA. Rather the viral genomes exist 
and replicate within the nuclei of the infected cells as episomes. Such an alteration may 
be analogous to the 'epigenefic' chemical carcinogens that stimulate cell replication but 
do not directly alter the structure of the host cell genome (Grasso & Hinton, 199 1). 
Many of the oncogenic viruses have specific genes within their own genomes whose 
products appear to be primarily responsible for the conversion of a normal to a 
neoplastic cell. These genes, termed oncogenes, act in a dominant manner and in the 
case of retroviral oncogenes, have counterparts within the host cell genome (Bishop, 
1985; Ratner et al., 1985). Because there is significant evidence to suggest that 
oncogenes of retroviruses evolved by mutational events from their counterparts within 
normal cells, the term proto-oncogene has been used to denote the cellular form of such 
genes. 
1.5.1 The biology of carcinogenesis: Multiple stages 
The initiation and progression stages of cancer involve heritable genetic changes within 
cells. 'Ilie intermediate stage of promotion does not involve direct structural changes in 
the genome of the cell, but generally is characterised by an alteration in the expression 
of the genome of the initiated cell. Such alterations, resulting from the interaction of the 
genetic alterations that induced initiation and environmental factors, are termed 
4promoting agents". Unlike initiation and progression, the stage of promotion requires 
extended treatment with the promoting agent for the stage to be developed and to 
traverse into the stage of progression. These alterations in genetic expression involve a 
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selected enhancement of the replication of initiated cells, in the presence of the 
promoting agent, as well as genes (Dragan & Pitot, 1992). 
1.5.1.1 Molecular characteristics of the stage of initiation 
The stage of initiation has been studied in detail in few systems. The reason for this is 
the inability to identify, isolate and specifically characterise initiated cells. The 
experimental system in which the stage of initiation has been characterised and 
quantified is the rat liver (Pitot et aL, 1989; Moore et al., 1987). In this system, the 
genetic alterations leading to initiation do not result in chromosomal alterations but are 
the result of one or more simple mutations or small deletions. Most of these initiated 
cells do not continue through to the subsequent stages to cancer but remain in the 
organism, quiescent for a lifetime. Hence, adult organisms possess numerous initiated 
cells in most organs that are harmless throughout life. This first stage in the 
development of cancer is an extremely common event that often occurs spontaneously 
and may be readily induced in experimental animals and in the human (Pitot & Dragan, 
1991). 
1.5.1.2 The molecular biology of the stage of promotion 
ne stage of promotion does not involve growth of initiated cells or molecular changes 
in the structure of DNA but rather changes in the expression of the genome. Thus, 
molecular studies of this stage are primarily concerned with the transduction of 
information from environmental signals to the genome with its subsequent expression. 
Many chemically defined promoting agents mediate their effects through receptor 
molecules. These receptor molecules in combination with the promoting agent as a 
ligand interact or bind in a non-covalent manner to specific regions of the DNA, usually 
upstream from specific genes. The binding of receptor-ligand complexes in turn alters 
the expression of the downstream gene(s). It is proposed that specific promoting 
agents are capable only of promoting the replication and development of specific 
subsets of initiated cells, presumably those whose set of genetic alterations (induced 
during initiation) allow optimal interaction with the promoting agent for the induction of 
this stage (Dragan & Pitot, 1992). 
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1.5.1.3 The molecular biology of the stage of progression 
The stage of progression was originally designated by Foulds (1954) as the entire 
process of carcinogenesis following the stage of initiation. However, because the stage 
of promotion is a reversible, non-genetic process that immediately follows the stage of 
initiation, the original concepts of Foulds have now been modified. However at 
sufficiently high doses of carcinogenic agents or under specific conditions promotion 
does not always occur during carcinogenesis. More commonly the stage of 
progression develops from cells in the stage of promotion. 
The characteristics of this stage include the appearance of malignant neoplasms 
accompanied by major genetic alterations that involve structural changes within the 
karyotype of the cells. Such changes include the incorporation of viral genomes or 
fragments thereof into the host cell genome as a result of infection. Thus, the infection 
of a cell with an oncogenic virus whose genome is incorporated into the host cell 
genome in total or in part by definition results in a by-pass of the stage of promotion. 
In addition progression is characterised by a continuing evolution of chromosomal 
abnormalities within the cell, leading to multiple stages or changes (Foulds, 1954). 
Cells in the stage of progression can evolve in such a way that these independent 
characteristics such as invasion, metastatic growth, anaplasia and the rate of growth, 
progress to higher and higher degrees of malignancy. 
The molecular characterisation of the stage of progression as well as involving multiple 
molecular changes within the genome also results in the instability of its karyotype, 
whereas in the normal cell the structure of the genome and karyotype upon multiple cell 
divisions is regulated. The constant molecular shuffling is the basis also for most drug- 
resistance that develops in malignant neoplasms (Stark, 1986), the ability of neoplasms 
to escape host immune mechanisms (Goodenow et al., 1985) and the abnormal 
expression of genes such as those normally expressed only during fetal life (Mundy, 
1987). In the final analysis, the stage of progression is the one in which the physician 
must treat the disease in the hope of a cure. The stage of promotion has the greatest 
potential for preventing further development of the neoplastic process. 
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1.5.2 Critical molecular targets during the stages of initiation, 
promotion and progression 
The molecular study of cancer has identified two major classes of genes that are critical 
molecular targets for the development of cancer. These are oncogenes (Garrett, 1986) 
and turnour suppressor genes (Boyd & Barrett, 1990, see Figure 1.13). 
1.5.2.1 Proto-oncogenes 
Proto-oncogenes are genes present in normal cells controlling cell growth, proliferation 
and differentiation. These proto-oncogenes and the oncogenes seen in tumour cells are 
designated by a three letter abbreviation based on the animal or tumour in which they 
were first identified (for example, c-Abl, cellular homologue of oncogene product from 
Ableson murine leukemia virus). Proto-oncogenes are capable of regulating growth by 
producing various protein products that form an intracellular communication network 
that controls cell growth. Proto-oncogenes are thus crucial to growth regulation in 
normal tissues. The protein products of proto-oncogenes control growth at one or 
more steps in the growth signalling pathway. Some proto-oncogene products include 
growth factors and their receptors. 
1.5.2.2 Oncogenes 
Oncogenes are genes present in human cells, that were originally identified in 
retroviruses. Oncogenes are very closely related to proto-oncogenes but they have 
mutated to produce abnormal products, or control mechanisms have altered to allow 
gene over-expression losing the normal constraints on their activity. Oncogene 
products (oncoproteins) are often closely related to normal cell growth regulators such 
as growth factors, growth factor receptors, signal transducers or transcription 
regulators. 
Oncoproteins do not need external activation signals (StudzinsId, 1989) for stimulation. 
Oncogenes are associated with carcinogenesis but are not sufficient for tumour 
formation. Some carcinogenic agents such as viruses can affect proto-oncogenes by 
stealing genes, by inducing translocations, or by inserting DNA near or within proto- 
oncogenes and thereby influencing their activity. Some viruses may insert their 
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oncogenes into host DNA, other viruses can affect tumour suppressor genes. Chemical 
carcinogens or ionising radiation can also produce similar effects on proto-oncogenes. 
Proto-oncogenes can be activated by a number of oncogenic agents acting in one of 
four ways: i) Point mutations ii) Transduction and insertional mutagenesis iii) 
Chromosomal rearrangements and chromosome translocations iv) Amplification 
producing many copies of the proto-oncogene. 
Each oncogene may act in a distinct way in a cell and the subsequent changes may be 
complementary to the alterations induced by other oncogenes, hence working in 
collaboration in the development of carcinogenesis (Bishop, 1985). To date more than 
50 oncogenes have been identified and their associations with carcinogenesis are 
varied. Hence, oncogenes can lead to the uncontrolled or autonomous cell proliferation 
of malignant neoplasia. 
1.5.2.2.1 Oncogenes resulting in abnormal G proteins 
Gain of function mutations have been well characterised for seven transmembrane 
receptor G-protein a subunits (Gupta et al., 1992a). The activating mutations of G- 
protein a subunits are similar to transforming mutations in the low molecular weight 
GTP binding protein ras. These include the gsp oncogene and the gip2 oncogene 
(Lyons etal., 1990). 
Smaller G proteins such as p2lras function in an analogous manner to the 
heterotrimeric G proteins. p2lras is an important mediator of growth factor induced 
differentiation and proliferation. Ras proteins belong to an extended family of GT? ases 
(Bourne etal., 1990,1991) which includes proteins involved in protein synthesis and 
signal transduction (heterotrimeric G proteins). Signalling pathways from growth factor 
receptors, by p2lras, to several cellular effectors have been identified. p2lras is the 
general name for three proteins encoded by the H-ras, K-ras and N-ras proto- 
oncogenes. 'Mese proteins differ structurally at their C-termini only, and thus few, if 
any, functional differences between the proteins have been observed. 
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Figure 1.13 Schematic diagram showing the various oncogenes/tumour suppressor 
genes involved in signal transduction pathways in the control of cellular proliferation 
and differentiation. 
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p2lras is a small GTPase that cycles between an active GTP-bound form and an 
inactive GDP-bound form, and functions as a molecular switch in signal transduction 
(Shih et al., 1980). In a large number of turnours, one of the genes for p2l ras is 
mutated resulting in a constitutive active protein, and in pancreatic cancer mutated ras 
genes have been found. 
1.5.2.2.2 Oncogenes acting as protein tyrosine kinases 
The protein tyrosine kinases are a family of proteins built around a highly conserved 
domain capable of phosphorylating protein substrates on tyrosine residues. The 
physiologically powerful catalytic activity of this domain has been harnessed to a wide 
variety of metabolic demands, from transduction of extracellular growth stimuli (Yarden 
& Ullrich, 1988) to responding to changes within the cell (Bauskin etal., 1991). 
Members of this family consist of sensory, regulatory and effector domains and are 
known as receptor tyrosine kinases (RTKs). RTKs share a common transmembrane 
domain with a glycosylated N-terminal ligand binding domain, in the extracellular 
region, and an intracellular protein tyrosine kinase domain towards the C-terminus of 
the protein. A single hydrophobic transmembrane region lies between these two 
domains. Once the RTKs are activated they stimulate various cell signalling pathways 
by phosphorylation of tyrosine residues on protein substrates leading to growth and/or 
differentiation of cells. In tumours it has been found that these RTKs may be over- 
expressed (Slamon et al., 1987,1989) and/or inappropriately expressed or be 
expressed in a ligand-independent activated form (Janssen et al., 1991). 
The HER2/NEU RTK is a member of the epidermal growth factor (EGF) receptor 
family (RTK) and has been found to be over-expressed in breast and ovarian cancers 
(Slamon et al., 1989). The src: protein (a cellular homologue of an oncogene product 
from Rous avian sarcoma virus, pp60) is in the cytoplasmic membrane and may be 
involved in turnour promotion, it phosphorylates tyrosine and may affect vinculin in 
cell adhesion (Sefton et al., 198 1). Polyomavirus antigens bind strongly to src protein 
and such an alteration can induce cell transformation by preventing the interaction with 
cellular factors that normally maintain the c-src protein in a quiescent phase. 
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1.5.2.2.3 Oncogenes influencing DNA 
Oncogenes, such as myb and myc produce gene products that affect DNA replication 
and transcription, this can result in the production of growth factors or the expression 
of growth factor receptors. c-myb induces the expression of both insulin growth factor 
I (IGFI) and IGF1 receptor mRNAs (Reiss etal., 1991; Travali etal., 1991). As a 
consequence, when over-expressed in fibroblasts, the c-myb product abrogates the 
requirement for IGFI. C-myc is activated in a number of neoplasms. The myc 
oncoprotein is termed p62 and is a regulator of cell proliferation (Travali et al., 199 1). 
All types of activation of proto-oncogenes and cellular oncogenes have been described 
in cells during the stage of progression. However, there is no common pattern of 
oncogenic activation in tumours but certain neoplasms are closely correlated with the 
activation of specific oncogenes by a specific mechanism (Sandberg, 1982). 
1.5.2.3 Tumour suppressor genes 
The second major set of genes fulfilling the criteria of essential targets during the 
process of carcinogenesis are tumour suppressor genes. Tumour suppressor genes are 
genes whose expression is reduced or lost in cancer cells (Knudson, 1993). This lack 
of expression results from mutations in the genes encoding their proteins. Thus tumour 
suppressor proteins act as negative growth regulators. Loss of their expression in 
turnour cells leads to increased cell proliferation and contributes to malignant 
transformation. Tumour suppressors have normal functions critical to the development 
of differentiated tissues. There are a number of tumour suppressor genes that can be 
subclassified into nuclear and non-nuclear turnour suppressors. 
1.5.2.3.1 Nuclear tutnour suppressor genes 
Many of the events that culminate in growth suppression occur in the nucleus where 
different proteins directly interact with DNA to promote or inhibit gene transcription 
and the production of messenger RNA (Weinberg, 1991). These DNA binding 
proteins (transcriptional regulators) are intimately involved in the control of gene 
expression and regulate cell growth. Nuclear tumour suppressor genes may function 
here by modulating the expression of genes necessary for cell proliferation or 
differentiation. Alternatively, nuclear suppressor genes may interact with proteins 
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involved in regulating progression through the cell cycle. Nuclear tumour suppressor 
genes that alter the expression or function of cell cycle regulatory proteins disrupt the 
balance between cell proliferation and differentiation. 
The product of one class of nuclear tumour suppressor genes is comprised of proteins 
intimately involved in cell cycle regulation. These include proteins that phosphorylate 
cell-cycle regulatory proteins, such as p 15 or p 16 (Serrano et al., 1993; Kamb et al. , 
1994). p 15 and p 16 belong to the family of cyclin-dependent kinase inhibitory proteins 
that function to regulate cell growth negatively through direct interactions with other 
proteins involved in cell cycle progression. Other cell cycle regulatory proteins, eg. 
p2l-WAF/CIP, are involved in the formation of regulatory protein complexes that 
inhibit DNA polymerase and proliferating cell nuclear antigen (PCNA) (Li et al., 1994; 
Waga etal., 1994) resulting in cell cycle growth arrest. p2l-WAF/CIPI is also an 
inhibitor of cell cycle-dependent kinases like p15 and p16. Loss of expression of genes 
encoding these proteins would result in an increase in cell proliferation by allowing the 
cells to enter the cell cycle. p53, another nuclear tumour suppressor gene product 
(Hollstein, etal., 1991), acts as a regulator of p2l-WAF/CIPI so that its loss in 
turnours allows cells to progress through the cell cycle and proliferate. A final group of 
nuclear tumour suppressor proteins function as transcriptional activators and repressors 
such as the retinoblastoma (Rb) and Wilm's tumour (WT-1) proteins. These proteins 
are transcriptional regulators and their loss leads to unchecked cell proliferation. 
1.5.2.3.2 Non-nuclear tumour suppressor genes 
This class of tumour suppressor genes encodes proteins whose locus of action resides 
outside the nucleus. Non-nuclear tumour suppressor proteins exert their effects 
through a variety of mechanisms involving signal transduction pathways, cell 
membrane receptors and changes in the cytoskeleton. Some of these non-nuclear 
turnour suppressors have been identified through positional cloning of disease genes 
associated with specific familial cancer syndromes. 
Ibree colon cancer tumour suppressor genes have been identified by positional cloning. 
These genes include adenornatous polyposis coli (APQ (Groden et al., 199 1), deleted 
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in colorectal carcinoma (DCC) and mutated in colorectal carcinoma (MCC) which all 
code for cytoplasmic or membrane associated proteins. The APC protein is involved in 
the contact inhibition of cells, a process critical for the proper formation of tissues 
during differentiation and development. The other two colon cancer cytoplasmic 
turnour suppressor genes, DCC and MCC, are less well understood. The DCC protein 
is expressed at high levels in the brain and shares sequence homology with the family 
of cellular adhesion molecules (CAMs) (Fearon et d, 1990). CAMs are thought to be 
involved in cell adhesion (Narayanan etal., 1992) and neuronal differentiation (Lawlor 
& Narayanan, 1992). MCC codes for a protein with sequence similarity to the G 
protein-coupled muscarinic acetylcholine receptor (Joslyn etal., 1991). 
Neurofibromatosis I (NFI) gene is another tumour suppressor gene identified in the 
autosomal dominant disorder, neurofibromatosis I (Xu, et al., 1990). This gene 
encodes for a GTPase activating protein (GAP), which inactivates the ras protein that 
plays a critical role in cell differentiation and proliferation. Recent studies have 
demonstrated that NFI. can suppress cell growth and perhaps activate cell differentiation 
through mechanisms unrelated to p2lras regulation (Johnson etal., 1994). 
As with proto-oncogenes and cellular oncogenes, mutational alterations in tumour 
suppressor genes that result in neoplastic transformation most likely develop in the 
stage of progression (Bevilacqua & Caligo, 199 1). The genetic alteration of a single 
copy of a tumour suppressor may be a critical event for the stage of initiation with 
alteration of the other allele occurring in the transition from the stage of promotion to 
that of progression. 
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1.6 PANCREATIC CANCER 
Pancreatic cancer accounts for only 3% of adult cancers, yet, because of the high 
mortality associated with this neoplasm it is one of the most common and lethal cancers 
in the Western world. The five year survival rate for patients with pancreatic cancer is 
3% for whites and 5% for blacks (Silverberg et al., 1990) and only 10-20% of the 
pancreatic cancers are resectable when diagnosed (Casper & Kelsen, 1995). 
Cancer of the pancreatic ducts is the most common form of pancreatic cancer, 
accounting for over 90% of the cases (Kelly & Benjamin, 1995). Tumours of ductal 
origin include adenocarcinoma and cystadenocarcinoma, as well as giant cell, 
microglandular and adenosquamous carcinoma. A smaller number of tumours are 
thought to be of acinar cell origin (Warshaw & Fernandez, 1992). Islet cell (endocrine) 
tumours of the pancreas are rare. These tumours are not always malignant, and even 
when metastatic, they may be associated with long survival. In addition to epithelial 
tumours, sarcomas and lymphomas may be seen in the pancreas. 
1.6.1 Risk Factors 
The most important risk factors for pancreatic cancer are gender, age and residence. 
Pancreatic cancer is greater in men than women (Kelly & Benjamin, 1995) and is 
mainly a disease of elderly urban dwellers. 80% of persons with pancreatic cancers are 
between the age of 60 and 80 years old (Gordis & Gold, 1993). The recently reported 
increase of pancreatic cancer among women may reflect the greater life span of women 
(Riela et al., 1992). Other risk factors (urban residence, cigarette smoking, high fat 
diet and chronic pancreatifis due to alcohol) that are associated with pancreatic cancer 
can be modified significantly and may reduce the risk of this disease. For example the 
relative. risk for cigarette smokers compared with non-smokers ranges from 1.4 to 2.3 
(Zheng etal., 1993), and the age of onset of pancreatic cancer in smokers is 10 years 
younger than it is in non-smokers (Wynder, 1975). High fat diets have also been 
associated with cancer of the pancreas (Longnecker et al., 1985). Chronic pancreatitis 
and exposure to chemicals am two other risk factors that have a strong association with 
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pancreatic cancer Occupational exposure has been implicated in causing pancreatic 
cancer such as, fý-naphthylamine and benzidine in metal, mine and sawmill plant 
workers (Mancuso & El-Attar, 1967). In Japan, mortality due to pancreatic cancer is 
nearly five times greater among chemical product workers than among the general 
population (Himyama, 1989). 
Patients with chronic pancreatitis of any cause have a steadily increasing risk of 
pancreatic cancer. At 10 years, the cumulative risk is 1.8% and at 20 years it is 4% 
(Lowenfels et al., 1993). The major cause of chronic pancreatitis is alcohol abuse. 
Although the direct relationship between alcohol and pancreatic cancer is weak and 
inconsistent, eliminating alcohol abuse reduces the risk of chronic pancreatitis and 
thereby the risk of pancreatic cancer (Boyle et al., 1988). 
Risk factors other than alcohol that have a weak association or no association with 
pancreatic cancer include diabetes mellitus. Up to 80% of patients with pancreatic 
cancer have diabetes mellitus or impaired glucose tolerance when their cancer is 
diagnosed (Schwarts etal., 1978). Several studies suggest an association between 
diabetes mellitus and pancreatic cancer, but in many patients the diabetes is an early 
manifestation of the pancreatic cancer rather than a risk factor for the malignancy 
(Gordis & Gold, 1993). 
1.6.2 Clinical manifestations and physical findings 
The classic presentation of a patient with pancreatic adenocarcinoma includes abdominal 
pain, jaundice and weight loss. Abdominal or back pain is the presenting symptom in 
79% of patients (Kalser etal., 1985). As with abdominal pain, weight loss of more 
than 10% of ideal body weight is almost universal in patients with pancreatic cancer 
(Perez etal., 1983). Jaundice is a presenting symptom in 80-90% of patients with 
cancer of the head of the pancreas but in only 6-13% of patients with carcinomas of the 
tail of the gland (Warshaw & Swanson, 1988). Other symptoms or presentations are 
less common. Non-specific symptoms such as nausea, vomiting, weakness and 
anorexia occur in 30-36% of patients. 80% of patients with cancer of the head of the 
pancreas have hepatomegaly (Gullick, 1959; Howard & Jordan, 1977), and 37% have 
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a palpable gall bladder. In contrast patients with cancer of the body and tail of the 
pancreas can have abdominal tenderness and pain, but fewer than 30% have 
hepatornegaly and jaundice. The presenting signs and symptoms of cancers of the 
body or tail of the pancreas are so vague that these malignancies tend to be advanced at 
diagnosis. 
1.6.3 Staging 
A standard method is used for staging tumours in order to choose the most appropriate 
treatment and to compare the effectiveness of new methods. The Union Internationale 
Contre le Cancre (U1CC) method of staging is most widely used published by the 
American Joint Committee for Cancer Staging. 
Stage I TI-2, NO, MO: No direct tumour extension into adjacent tissue and no regional 
lymph node involvement. 
Stage H T2, NO, MO: Direct tumour extension into adjacent tissue; no regional lymph 
node involvement. 
Stage III T1-3, NI, MO: Regional lymph node involvement with or without direct 
tumour extension into adjacent tissue. 
Stage IV TI-3, NO-1, M I: Distant metastatic spread. 
1.6.4 Diagnosis 
Early detection of pancreatic cancers greatly improves the chances of cure. When 
turnours are detected at an early stage, resection of the pancreas results in a longer 
survival time (Wanebo & Vezeridis, 1996). A single method for evaluating patients 
suspected of pancreatic cancer has not been standardised; however several strategies 
have been proposed. 
1.6.5 Imaging techniques 
1.6.5.1 Plain abdominal X-rays 
If pancreatic calcifications are seen on abdominal films, a diagnosis of chronic 
pancreatitis can be made with 95% confidence. Primary adenocarcinomas of the 
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pancreas almost never calcify, but 10% of benign serous (microcystic) cystadenomas 
have a typical sunburst calcification in the center of the multiple microcysts that 
constitute the lesion (Piper et al., 1962; Freeny et al., 1978). In contrast mucinous 
(macrocystic) cystadenomas have malignant potential and may appear as a curvilinear 
calcification in the wall of the cyst. Loss of calcification in patients with chronic 
pancreatitis suggests development of pancreatic cancer, but it happens rarely (Tucker & 
Moore, 1963; Baltaxe & Leslie, 1967 ). 
1.6.5.2 Ultrasound and computed tomography (CT) 
Both ultrasound and CT am widely used to diagnose pancreatic cancer. CT is preferred 
as it provides better definition of the tumour and the presence of ascites or liver 
metastases (Kelly & Benjamin, 1995). In the absence of metastasis the CT provides 
information as to resectability of the cancer. 
1.6.5.3 Endoscopic retrograde cholangiopancreatography (ERCP) 
For differential diagnosis of tumours of the pancreatobiliary junction, endoscopic 
retrograde cholangiopancreatography (ERCP) is favoured. Ampullary and duodenal 
carcinomas can be biopsied at ERCP. However, chronic pancreatitis is sometimes 
difficult to differentiate from cancer on ERCP because fibrosis or pseudocysts may 
produce some of the radiological features of pancreatic cancer (Kelly & Benjamin, 
1995). 
1.6.5.4 Endoscopic ultrasonography (EUS) 
The use of EUS in diagnosing pancreatic cancer has gradually increased (Rosch etal., 
1991; Tio etal., 1990; DiMagno, etal., 1982; Yasuda etal., 1988). Compared with 
other tests EUS is more sensitive in detecting small tumours and in accurately 
predicting nonresectability by detecting the extension of the tumour into the vessels 
(Rosch et al., 1992). 
To complement imaging methods and simplify the diagnosis of pancreatic cancer, 
serum and genetic markers are being used. 
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1.6.6 Laboratory tests and serum markers 
The laboratory tests in pancreatic cancer are non-specific. Plasma glucose, serum 
amylase and serum Iipase may be elevated among patients with pancreatic cancer but 
these values are also elevated among those patients with pancreatitis. Similarly, serum 
bilirubin, alkaline phosphatase and aspartate aminotransfcrase frequently are elevated in 
patients who have cancer of the head of the pancreas, but these abnormalities also 
reflect other causes of biliary obstruction (Go et al., 198 1). Other laboratory findings 
common among patients with pancreatic cancer such as elevated lactate dehydrogenase 
and erythrocyte sedimentation rate and decreased serum albumin are also non-spccific 
(Fitzgerald etal., 1978). 
Currently no serum markers are sensitive or specific enough to diagnose pancreatic 
cancer when used alone. They generally lack enough sensitivity to detect early 
pancreatic cancer and are not organ specific (other tumours also give positive results). 
Although CA19-9 (an antibody against tumour associated antigens) is 70-80% sensitive 
it has no value in detecting early pancreatic cancer (Frebourg et al., 198 8). It is useful 
as an indicator of prognosis or a predictor of progression or recurrence of turnour after 
surgery. Galactosyltransferase isoenzyme II is 67% sensitive (Podolsky et al., 198 1) 
and 98% specific and the serum testosterone to dihydrotestosterone ratio in male 
patients is also 67% sensitive and 98% specific, but these tests are not useful in 
detecting early pancreatic cancer (Warshaw & Swanson, 1988). Leukocyte inhibition is 
useful in detecting early stage I pancreatic cancers, but is not sensitive enough for 
detecting stage II or 1111 cancers. Four of five patients with stage I but only 5 out of 16 
with stage III pancreatic cancer had a positive test (Meduri et al., 1989). 
At present, markers include K-ras mutations and plasma islet amyloid polypeptide 
(IAPP). K-ras gene mutations occur in 90% of cases of pancreatic ductal 
adenocarcinoma (Almoguera et al., 1988) and the site of mutation is restricted to codon 
12 of the K-ras gene. The diagnostic and clinical value of its detection in pancreatic 
juice, blood or stool is under intensive investigation. 
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IAPP is secreted by the islet cells and reduces insulin sensitivity. It is elevated in 
patients with pancreatic cancer who have diabetes (Permert et aL, 1994). Although 
IAPP levels contribute to diabetes, IAPP may be an ideal marker to detect early 
asymptornatic pancreatic cancer in the subset of 60-70% of patients with pancreatic 
cancer in whom glucose intolerance is secondary to the cancer. 
On the basis of the literature, in general, clinicians primarily perform an abdominal 
ultrasound to diagnose pancreatic cancer and follow it by an ERCP. Tumour markers 
are commonly used but pancreatic function tests rarely so. Current data suggest that 
CT is the best method to diagnose and stage pancreatic cancer and that EUS should be 
the next test to stage the tumour. In the future EUS may become the single best test to 
diagnose and stage the tumour simultaneously (Kinjo & DiMagno, 1995). 
1.6.7 Treatment of pancreatic cancer 
Treatment of patients with advanced pancreatic cancer and evaluation of new agents for 
this disease present a major problem. Patients with metastatic disease are frequently 
debilitated at diagnosis. Evaluation of therapeutic agents has been hampered by 
limitations of the diagnostic tests available. 
1.6.7.1 Surgical management and adjuvant therapy 
Although surgical resection provides the only realistic chance for cure, surgery is only 
possible in a small number of patients. In general of every 100 patients that are 
surgically explored for pancreatic cancer that is presumed to be resectable, resection is 
only possible in 25-30%. Pancreatoduodenectomy (the Whipple procedure) is the most 
widely accepted operation for the resection of pancreatic cancer Five year survival of 
patients with resected pancreatic carcinoma is only 20% (Geer & Brennan, 1993). 
Approximately 30-40% of patients explored with intent to resect are found to have 
metastases, usually to the liver at the time of laparotomy and another 30-40% of 
patients have locally advanced disease. Surgical resection for these two groups of 
patients is not feasible. 
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1.6.7.2 Radiation therapy 
Radiation therapy has been used in the management of pancreatic cancer both as an 
adjuvant following resection and for the treatment of locally advanced, unresectable 
turnours. The limitations of this treatment modality are due to the anatomic relations to 
the pancreas that prohibit the delivery of turnouricidal doses of radiation. The 
concomitant administration of 5-fluorouracil as a radiation scrisitiser appears to enhance 
the effect of radiation and improve survival (Kalser & Ellenberg, 1985). Although 
there is not much data evaluating the effect of radiotherapy on unresectable pancreatic 
cancer, it appears that the combination of radiation with 5-fluorouracil enhances local 
control (Whitington et al., 1984). The limitations of external beam radiation prompted 
the use of intraoperative radiation therapy (IORI), which is capable of delivering high 
doses of radiation to the pancreas without radiation injury to the surrounding structures 
(Dobelbower et al., 199 1). Combination of IORT with external beam radiation results 
in a good local control (Shipley etal., 1984). Overall the data available in the literature 
indicate that radiation therapy is unsatisfactory both as an adjuvant and in the 
management of locally advanced disease. However, radiation may be a recommended 
palliative method providing an improved quality of survival by relieving pain (Shipley 
etal., 1984). 
1.6.7.3 Chemotherapy 
Chemotherapy is of limited value in the palliation of pancreatic cancer. Single agent 
chemotherapy with 5-fluorouracil has given an increase in survival of 26% (O'Connel, 
1985). A similar response was observed with mitomycin C. 8-10% increase in 
survival was seen with doxorubicin, streptozotocin and ifosfamide (as reviewed in 
O'Connel, 1985). Combination chemotherapy failed to show improved responses 
compared to single agent treatment 
Combination of chemotherapy with radiotherapy has been shown to increase the 
survival of the patient compared with chemotherapy alone (Moertel et al., 1981). 
However, prognosis remains poor for patients with pancreatic cancer who cannot be 
surgically resected. 
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1.7 GROWTH FACTORS AND ONCOGENES IN 
PANCREATIC CANCER 
It is widely recognised that alterations in the functions of growth factors and their 
receptors and/or their aberrant expression may lead to abnormal cell growth progressing 
to neoplasia (Aaronson, 199 1). 
One characteristic includes the diminished or complete lack of requirement for serum or 
specific growth factors. Neoplastic cells in culture are presumed to have autonomous 
activating pathways in their growth system, namely: i) autonomous production of 
growth factors; ii) synthesis of an altered receptor for growth factors; and iii) activation 
of post-receptor pathway (Sporn & Todaro, 1980; Spom & Roberts, 1985; Goustin et 
aL, 1986). 
The loss of inhibitory influences (tumour suppressor genes) and the upregulation of 
stimulatory mechanisms of cell proliferation (growth factors, growth factor receptors 
and oncogenes) are important mechanisms in the pathogenesis of pancreatic cancer. 
1.7.1 Pancreatic cancer and growth factors and growth factor 
receptors 
1.7.1.1 Hepatocyte growth factor receptor (MET) 
The c-met proto-oncogene encodes a transmembrane tyrosine kinase receptor (MET) 
that has the capacity to modulate cell proliferation and differentiation (Cooper et A, 
1984). It is activated by the hepatocyte growth factor (HGF). HGF is a 105 kDa 
protein that is mitogenic toward hepatocytes, endothelial and epithelial cells (Montesano 
et aL, 199 1; Zarnegar et aL, 1990). The HGF action is dependent on its binding to 
MET, the HGF receptor. 
MET has been shown to be overexpressed in pancreatic cancer (Di Renzo et at., 1995) 
and the overexpression is associated with increased levels of HGF mRNA (Ebert et aL, 
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1994). However, the importance of this upregulation is not yet determined but it may 
be involved in motility or invasiveness of pancreadc turnour cells (Oikawa et aL, 1995). 
1.7.1.2 Fibroblast growth factor (FGF) 
Members of the fibroblast growth factor (FGF or heparin binding growth factor) family 
are potent mitogens for a wide variety of mesodermal and neuroectodermal cells and 
have been isolated from a variety of tissue and cell sources including tumour cells 
(Thomas & Gimenetz-Gallego, 1986; Gospodarowicz et al., 1987). This family of 
peptides currently includes acidic FGF (aFGF), basic FGF (bFGF), keratinocyte 
growth factor, FGF-4 (Kaposi FGF), FGF-5, FGF-6, the gene product of int-2, 
androgen-induced growth factor and FGF-9. FGFs promote angiogenesis and 
chemmmis and participate in the regulation of cellular differentiation and tissue repair. 
aFGF and bFGF have been shown to be overexpressed in pancreatic tumours and this 
overexpression is associated with a more advanced tumour stage (Yamanaka et aL, 
1993a). To date five distinct high affinity FGF receptors, designated as FGF-I, -2, -3, 
-4, and -5 (the latter is also known as flg-2) have been cloned and sequenced (Jaye et 
al., 1992). These receptors are tyrosine kinase receptors and the FGFR-1 type is 
overexpressed in pancreatic cancers (Kobrin et al., 1993). As with the FGFs the 
overexpression of the FGFR correlates with the extent of pancreatic tumour malignancy 
(Ohta et A, 1995), suggesting a role for autocrine stimulation in these turnours. 
1.7.1.3 Epidermal growth factor receptor (EGFR) 
The epidermal growth factor receptor (EGFR or HER) binds epidermal growth factor 
(EGF), transforming growth factor alpha (TGF-a), Shope fibroma virus growth factor, 
myxoma virus growth factor and amphiregulin (Soyab et aL, 1988). TGF-a is the 
most extensively studied of the EGF-like molecules. The EGFR is a 170 kDa protein 
that possesses tyrosine kinase activity. This receptor is closely related to three 
additional receptors, termed, c-erbB2 (HER2), c-erbB3 (HER3) and c-erbB4 (HER4) 
(Prigent & Lemoine, 1992; Plowman et A, 1993). HER exhibits a strong sequence 
homology with the oncogenic protein product of the avian erythroblastosis virus v- erb- 
B gene (Downward et aL, 1984). 
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Overexpression of the EGFR is associated with the malignant phenotype (Libermann 
et al., 1984; Ro et al., 1988) and with the enhanced ability of certain tumours to invade 
normal tissues and metastasise (Sainsbury et al., 1985; Neal et al., 1985). 
Overexpression of either EGF or TGF-a also leads to abnormal cell growth and 
acquisition of features that are characteristic of the transformed phenotype (Watanabe 
et al., 1987; Heidaran et al., 1990). Pancreatic cancer and pancreatic cancer cell lines 
have been shown to overexpress the EGFR (Korc etaL, 1986; Lemoine etal., 1992a) 
and EGF and /or TGF- a (Barton et aL, 199 1 a) indicating that autocrine and paracrine 
mechanisms of this receptor-ligand system play a crucial role in the pathogenesis of 
pancreadc cancer (Korc et A, 1992; Yamanaka et d, 1993b). 
1.7.1.4 c-erbB-2 
The c-erbB2 gene encodes a transmembrane receptor with a molecular weight of 185 
kDa. This receptor is activated through binding of specific ligands such as neu 
differentiation factor (NDF), glial growth factors and heregulin. c-erbB2 is shown to 
be overexpressed in 45% of pancreatic cancers (Yamanaka etal., 1993c). In contrast 
with the EGFR, the presence of c-erbB2 is not associated with advanced tumour stage 
or worse postoperative survival periods. 
The third member of the EGFR related family of growth factor receptors is c-erbB3 
(Kraus et al., 1989). Analysis of c-erbB3 mRNA expression indicates that pancreatic 
cancer cells also overexpress this growth factor receptor and that this overexpression is 
associated with advance tumour stages and a significantly post-operative survival 
(Friess et aL, 1994). Although the ligand that activates c-erbB3 has not yet been 
identified the above findings suggest that the overexpression of the EGF receptor 
and/or c-erbB3 seems to play an important role in pancreatic cancer progression and 
patient prognosis (Friess et al., 1994). 
Insulin-like growth factor (IGF) 
Insulin like growth factor-I is a polypeptide that exhibits structural homology to 
proinsulin and exerts growth-promoting and metabolic effects (Froesch et aL, 1985). 
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Its actions are dependent on the presence of specific cell surface receptors, the insulin 
like growth factor-I receptor (IGF-IR). This receptor is a tyrosine kinase receptor, 
which has a low affinity for insulin and a high affinity for IGF-I. IGF-I functions as 
an autocrine and a paracrine growth factor in a variety of mesenchymal and epithelial. 
turnours (Macaulay, 1992; Daughaday, 1990) and is essential for entry into the S phase 
of the cell cycle (DNA synthesis) (Baserga, 1995). 
Pancreatic turnours have been shown to overexpress mRNA for both IGF-I and IGF- 
IR. It has been suggested that IGF-I may play a role in the aberrant autocrine and 
paracrine activadon of IGF-IR in pancreadc cancer (Bergmann et d, 1995). 
1.7.1.6 Transforming growth factor beta (TGF-P) 
The transforming growth factor beta gene superfamily consists of numerous regulatory 
polypeptides that include several TGF-p isoforms as well as activins and inhibins 
(Massague, 1990). Mammalian cells express TGF-01, TGF-p2 and TGF-p3 which are 
isoforms of TGF-P. The TGF-P are multifunctional polypeptides that influence cell 
growth and differentiation, adhesion, migration, angiogenesis, extracellular matrix 
formation and immune functions (Massague, 1990). The effects of TGF-P on cell 
proliferation in vitro may be either positive or negative depending on the cell type and 
culture condition, in most cells of epithelial origin TGF-PS act as a potent growth 
inhibitors (Baldwin & Korc, 1993). All three isoforms are over-expressed in human 
pancreatic cancer (Friess et al., 1993a). This enhanced expression of TGF-p isoforms 
is correlated with decreased survival. The expression of TGF-p receptors, which are 
divided into three subgroups, shows an overexpression of TGF-p receptor II in 
pancreatic cancer while expression of TGF-P III is not altered compared to normal 
pancreatic tissue (Friess et al., 1993b). 
1.7.1.7 Somalostatin 
Somatostatin is a tetradecapeptide that participates in a variety of biological processes 
including inhibition of hormonal secretion and cell proliferation (Lewin, 1992). These 
properties are used for the treatment with stable somatostatin analogues of a number of 
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hormone producing turnours such as gastroeneteropancreatic cancers (Lamberts et aL, 
1991). The actions of the peptide are mediated by specific somatostatin receptors of 
which five have been cloned and referred to as SSTRI-SSTR5 (Bell & Reisine, 1993). 
Only SSTR2 and SSTR. 5 mediate the andproliferative effect of somatostatin analogues 
octreotide and vapreodde (Buscail et aL, 1994). Recently it has been shown that there 
is a loss of the SSTR2 in pancreatic cancers (Buscail etaL, 1996) and that the loss of 
this receptor type could represent a growth advantage in these turnours and provide an 
explanation for the lack of therapeutic effect of somatostatin analogues in such 
adenocarcinomas. 
1.7.1.8 Bombesin and gastrin-releasing peptide 
Bombesin and its mammalian counterpart, gastrin-releasing peptide (GRP), are 
hormonal peptides which can exert diverse physiological or pharmacological actions in 
various systems (Spindel, 1986). In the gastrointestinal system, bombesin and GRP 
stimulate gastric and pancreatic secretions, enhance the release of several 
gastrointestinal hormones and promote the growth of the exocrine pancreas. Bombesin 
and GRP can function as autocrine or paracrine growth factors and stimulate the growth 
of normal and malignant cells including gastric cancer cells (Yano et al., 1992) and 
CAPAN, a human pancreatic tumour cell-line (Avis et al., 198 8). B ombesin/GRP 
antagonist (RC-3095) has been shown to suppress the growth of nitrosamine-induced 
pancreatic cancers in hamsters (Szepeshazi et al., 199 1) and inhibit the growth of 
human pancreatic cancer cells in vivo and in vitro Qin etal., 1994). 
1.7.1.9 pS2 
pS2 is a 60 amino acid, cysteine rich, secretory polypeptide which shows some 
structural similarity to small growth factor-like peptides such as IGF-I (Jakowlew et 
aL, 1984). This protein belongs to a family of trefoil or three looped clover shaped 
structural polypeptides. These proteins are found throughout the gastrointestinal tract, 
particularly in association with mucosal inflammation where its primary function is 
thought to be as a growth factor (Wright, 1993). pS2 expression has been found in 
breast and colon cancers. pS2 has been shown to be expressed in pancreatic cancers 
but not in the norm al pancreas (Welter et aL, 1992; Collier et aL, 1995). This finding is 
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recent and the mode of action, nature of its receptor are unknown. However, its role as 
a secretory peptide is thought to be mediated by an autocrine or paracrine mechanism 
(Collieretal., 1995). 
1.7.1.10 Annexin 
The protein tyrosine kinase substrate, annexin H, has been implicated in the process of 
DNA replication and cell proliferation. Annexin 11 is phosphorylated by pp60 src 
kinase (Gerke & Weber, 1984), protein kinase C (Gould et al., 1986) and growth 
factor receptor kinases (Brambilla et al., 199 1). Annexin 11 is a member of the annexin 
family of proteins that are characterised by their ability to bind phospholipids in a 
calcium-dependent manner (Glenney, 1986). Annexin 11 stimulates DNA polymerase 
alpha (Jindal et al., 1991) and has been postulated to be involved in mitogenic signal 
transduction (Fava & Cohen, 1984). In recent years, elevated expression of annexin II 
has been demonstrated in carcinogen-induced Syrian hamster pancreatic 
adenocarcinoma (Kumble et al., 1992), human hepatocellular carcinoma (Frohlich et 
al., 1990) and in a multidrug resistant, small cell, lung cancer cell line (Cole et al., 
1992). Expression studies show annexin 11 expression is deregulated in pancreatic 
cancers resulting in an overexpression of annexin 11 mRNA and protein (Vishwanatha 
et al., 1993). The literature documenting these findings is shown in Table 1.1. 
1.7.2 Pancreatic cancer and oncogenes 
1.7.2.1 Ras 
Among the most frequent genetic changes in human pancreatic cancer are point 
mutations of the Kirsten-ras (rous sarcoma virus) proto-oncogene (K-ras). These have 
been identified in tumour needle biopsies and aspirations in 85-95% of pancreatic 
adenocarcinomas (Grunewald et al., 1989; Lemoine et al., 1992b; Smit et al., 1988). 
K-ras mutations occur in pancreatic cancer almost exclusively on codon 12 (Almoguera 
etal., 1988) which is located in the short arm of chromosome 21. 
p2lras is the general name for three proteins encoded by the H-ras, K-ras and N-ras 
proto-oncogenes. p2lras is an important mediator of growth factor induced 
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differentiation and proliferation. Ras proteins belong to an extended family of GTPases 
(Bourne etal., 1990; 1991) which includes proteins involved in protein synthesis (the 
elongation and initiation factors) and signal transduction (heterotrimeric G proteins). 
Signalling pathways from growth factor receptors, Wa p2lras, to several cellular 
effectors have been identified. H-ras, K-nis and N-ras proteins differ structurally at 
their C-termini only, and few, if any, functional differences between the proteins have 
been observed. p2lras is a small GTPase that cycles between an active GTP-bound 
form and an inactive GDP-bound form, and functions as a molecular switch in signal 
transduction. 
Early functional studies using ras neutralising antibodies showed that in a variety of cell 
types, p2lras is required for growth factor induced DNA synthesis and gene 
expression (Stacey & Kung, 1984), as well as for the induction of differentiation. A 
second approach to studying the function of p2lras has been the use of dominant 
negative mutants of p2lras (Feig & Cooper, 1988a, 1988b). One commonly used 
interfering mutant is p2lrasasnI7. This mutant displays a reduced affinity for GTP, but 
normal affinity for GDP, and interferes in the GDP-GTP cycling of normal p2lras. 
Introduction of this mutant also inhibits ligand-induced proliferation and differentiation 
in various cell types. All these results point to a function of p2lras in growth factor 
receptor-mediated signal transduction. 
1.7.2.1.1 Growth factor receptors activate p2l ras 
There is a large amount of literature showing the involvement of ras in receptor tyrosine 
kinase activation, eg, epidermal growth factor receptor (Gibbs et at., 1990). Most if 
not all receptor tyrosine kinases have been shown to activate p2lras. Ligands that 
activate (non-receptor tyrosine kinases) indirectly or certain members of the seven 
transmembrane receptor families also induce the activation of p2lras (Crespo et al., 
1994). 
1.7.2.1.2 Mechanism ofp2lras activation 
Two rate-limiting steps can be distinguished in the cyclic regulation of the nucleodde 
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content of p2lras (Bos, 1995). First the dissociation of GDP followed by the binding 
of GTP and secondly, the hydrolysis of p2lras-bound GTR p2lras exhibits a slow 
intrinsic guanine nucleotide exchange and a slow intrinsic GTPase activity. However, 
guanine nucleotide exchange proteins (GNEFs eg. Grb2/SOS) regulate rapid 
GDP/GTP exchange, and GTPase activating proteins (GAPs eg. p120GAP, 
neurofibromin) are present for the stimulation of GTP hydrolysis. p2lras can be 
activated by one of two mechanisms: an increase in guanine nucleotide exchange 
activity and/or an inhibition of GAPs. 
1.7.2.1.2.1 Nucleotide binding 
Rasp2l. binds GTP with high affinity (Hoshino et al., 1987; John et al., 1990). Three 
sequence motifs important for nucleotide interaction have been determined which are 
conserved between different guanosine nucleotide- binding proteins (Bourne et al., 
1991). The first, GXXGXGKS (amino acids 10-17 in p2l) is involved in the binding 
to the a- and fý- phosphates; in the second, DXXG (57-60 in p2l) the aspartate binds 
the magnesium and the glycine binds the y-phosphate when the GTP is bound; and the 
third, NKXD (116-119 in p2l) is important for binding to the guanine ring. In p2l, 
residues 144-146 are also important for interaction with the nucleotide. Single 
mutations of residues, 10,13,15,16,83,116,117,118,119,144 and 146 have been 
found to lower GTP binding (usually by 1-3 orders of magnitude), in most instances 
by lowering the dissociation rate constant (Feig & Cooper, 1988b; Sigal et al., 1986; 
Walter et al., 1986; Clanton et al., 1987; Feig et al., 1986; Der et al., 1986a; Clanton 
etal., 1986). 
1.7.2.1.2.2 Mechanism of GTP hydrolysis 
The ras GTPase activity results in the slow hydrolysis of bound GTP (Sweet et al., 
1984; Gibbs etal., 1984a; Manne etal., 1985), leaving the protein complexed with 
GDP. Mutation of residue 12 or 61 particularly effects this intrinsic rate which 
suggests that these amino acids are important for the p2l conformation mediating GTP 
hydrolysis (Der etal., 1986b; Sweet et al., 1984; Gibbs etal., 1984a; McGrath etal., 
1984). 
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As measured by various 111vestigators, tile rate ofhydrolysis gives a GIT p2l half-fife 
of 1-5 hours for norinal p2l with that of' activated versions being 3-9 times longer 
(John et al., 1988; Sweet et al., 1984; Gibbs et al., 1984a; Lacal et al., 1986). The 
16 catalytic" dornain ol'p2l is gencrally considered to be the conserved 164 N-terminal 
amino acids (Gideon etal., 1992). 
1.7.2.1.2.3 Intrinsicexchange 
The intracellUlar GTP concentration is inuch greater than that ol'GIV, thLIS, the GTP is 
bound to the native p2l protein as it is synthesised and acquires its tertiary structure. 
The intrinsic rate of' dissociation is very low, approximatcly 10-5 moles pci- second 
dissociating per mole ol'coiilplcx (John et al., 1990). 
@ Exchange: 
Sos, Cdc25 A 
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Figure 1.14 Model of ras signalling. Mitogenic signals activate guanine exchange 
factors and/or GAP, leading to binding of GTP to ras proteins. The GTP-bound 
activated ras, interacts with target proteins, whose activation results in the cellular 
changes that end with cell division/differentiation. 
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The p2l. that does dissociate will very rapidly rebind GTP which means that in the 
normal ras cycle, dissociation of bound GDP leads to the activation of the protein. 
Mutations of residues important for contacting the guanine nucleotide can affect the 
intrinsic dissociation rate, some so much that the rate of spontaneous loading with GTP 
exceeds the rate of intrinsic GTPase (Noda et al., 1985; Kataoka et al., 1985). 
Mutations with severe effects on exchange turn out to be activating mutations (Feig & 
Cooper, 1988b; Sigal et al., 1986; Walter et al., 1986 ) associated with abnormally high 
proportion of GTP p2l. (Patel et al., 1992; Zhang et al., 1992). 
1.7.2.1.3 Activating mutations 
Mutationally activated (transforming) p2l. proteins are associated with alterations in 
amino acids important for guanine nucleotide co-ordination. Depending on the location 
of the mutation, the abnormally high proportion of bound GTP results from a decrease 
in GTPase activity and/or an increase in nucleotide exchange rate. The ras oncogenes 
most commonly isolated from tumours have a single mutation in codon 12,13 or 61 
(Taparowsky etal., 1983; Tabin etal., 1982; Reddy etal., 1982; Yuasa etal., 1983). 
Substitution of the normal glycine 12 (Seeburg et al., 1984) or glutamine 61 (Der et al., 
1986b) by a wide range of amino acids reduces the intrinsic GTPase activity of the 
protein. This renders it GTPase resistant to GAP and neurofibromin (Trahey & 
McCormick, 1987; Adari etal., 1988; Martin etal., 1990) and makes the protein 
transforming. Ras can also be activated by mutation of alanine 59 to threonine (Velu et 
d., 1989), or glutamine 63 to lysine or histidine (Fasano et al., 1984; Higinbotham et 
d., 1992). The activation of ras that results from mutation of residues 116,199 or 146 
is associated with a substantial increase in the intrinsic nucleotide exchange rate (Feig & 
Cooper, 1988b; Sigal etal., 1986). In addition to carrying a codon 12 mutation, both 
v-H-ras and v-K-ras encode threonine 59, which (even in the presence of a normal 
glycine 12) reduces GTPase, reduces sensitivity to GAP, increases exchange and 
activates transformation (Adari etal., 1988; Gibbs etal., 1984b). 
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1.7.2.2 Pancreatic cancer and ras 
K-ras mutations occur in pancreatic cancer almost exclusively on codon 12 (Almoguera 
etal., 1988). These mutations lead to a constitutively active ras, protein that is GTPase 
resistant to GAP and neurofibromin. The most common observed activating mutations 
in pancreatic cancer are from the wild type glycine (codon 12) to either aspartate, valine 
or cysteine. 
Studies of ductal pancreatic tumours with different degrees of anaplasia have reported 
that K-ras mutations occur early in pancreatic carcinogenesis (Pellegata et al., 1994). 
No correlation has been found in adenocarcinoma of the pancreas between the K-ras 
codon 12 genotype and either tumour size or tumour stage (Grunewald et al., 1989; 
Motojimaetal., 1991). 
1.7.3 Cytoplasmic & nuclear oncogene products 
The scientific research in this area of pancreatic cancer is limited. Experimental 
evidence suggests that several genes in this group (raf, myc, jun etc. ) may have 
important roles in the development of pancreatic cancer but mom work needs to be done 
in this area of pancreatic carcinoma. 
1.7.4 Pancreatic cancer and tumour suppressor genes 
1.7.4.1 p53 
The p53 tumour-suppressor gene encodes a 53 kDa nuclear phosphoprotein which is 
thought to protect cells against the accumulation of genetic alterations. p53 tumour 
suppressor gene product plays a critical role in cell cycle regulation and also functions 
as a nuclear transcription factor. Overexpression of the wild-type p53 protein and an 
increase in transcriptional activity, following treatment with DNA damaging agents, 
lead to cell cycle arrest in the GI phase or the induction of apoptosis (Vogelstein & 
Kinzler, 1992; Lane, 1993; Levine et al., 1994). Abnormalities in the p53 gene are the 
most common genetic alteration in human cancer (Hollstein et al., 199 1). In normal 
tissue wild-type p53 protein is difficult to detect, whereas in cells with p53 mutations, 
conformational changes and a prolonged biological half-life leads to an accumulation of 
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mutant p53 protein. 
In human pancreatic cancer, a high level of p53 expression has been demonstrated in up 
to 60% of the tumours (Barton et d, 199 1 b; Scarpa et d, 1993). However, at the 
present time, results from studies on a possible correlation between overexpression of 
p53 and survival are inconclusive (Zhang et aL, 1994; DiGiuseppe et al., 1994). 
1.7.4.2 Deleted in colon cancer (DCQ 
DCC as its name implies, is important in the development of colon cancer (Fearon et 
al., 1990). The DCC gene encodes a protein with multiple immunoglobulin domains 
and fibronectin type III repeats. In pancreatic cancers the second copy of the DCC gene 
is frequently mutated (Hohne et d, 1992; Simon et aL, 1994). Furthermore, in some 
pancreatic cancers and their cell lines there is absence or a reduction in DCC expression 
(Hohne et aL, 1992). It has been hypothesised that the loss of this gene may result in 
pancreatic carcinoma cells that have a more invasive and undifferentiated phenotype. 
1.7.4.3 p16/MTS-1 and p15 
pI 6/MTS- I is a tumour-suppressor gene that is located on chromosome 9p2 1. The 
product of this gene is involved in cell cycle regulation. This protein binds specifically 
to cyclin D-cdk-4 complexes and inhibits cdk-4 mediated phosphorylation of several 
growth regulatory proteins. Among the species regulated in this manner are RB- I and 
the RB-1 related proteins p107 and p130 (Serrano et aL, 1993). Pancreatic tumours 
have been shown to possess mutations in the pl6/MTSI gene (Caldas etaL, 1994; 
Bartsch et aL, 1995). Tbere is a higher frequency of mutations in the p 16/MTS- 1 gene 
in human pancreatic tumour-derived cell lines compared to primary pancreatic cancers 
(Huang et aL, 1996) as has been found in other turnours. 
A closely related gene, p15, was simultaneously identified 25 kb from the p16 gene. 
Like p16, p15 is involved in the regulation of the cell cycle, by binding to and 
inhibiting CDK4 and CDK6. The alterations of p16 are more frequent than p15 in 
cancers. Aberrations have been detected in pancreatic cancer cell lines in the p15 
tumour suppressor gene (Naumann et d, 1996). 
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1.7.4.4 Deleted In pancreatic cancer, locus 4 (DPC4) 
A recently discovered tumour suppressor gene, DPC4, is lost or inactivated in 50% of 
pancreatic cancers (Hahn etaL, 1996). However, the function of the DPC4 protein has 
not been fully elucidated but it resembles the fruit fly protein Mad (mothers against dpp 
protein) implicated in a transforming growth factor beta-like signalling pathway (Hursh 
et aL, 1993, see Table 1.1 for summary). 
The loss of inhibitory influences (p53, p16, p15 and DCQ and the upregulation of 
stimulatory mechanisms of cell proliferation (growth factors, growth factor receptors 
and oncogenes) are important mechanisms in the pathogenesis of cancer of the 
pancreas. In addition to this, other molecular, cellular and environmental changes may 
contribute to tumour pathogenesis such as gastrointestinal hormones and their receptors 
and immunological alterations. The cocktail of these changes may give pancreatic 
cancer cells a major growth advantage and this could lead to the rapid and aggressive 
spread of the cancer and to unresponsiveness to therapeutic modalities such as 
chemotherapy and radiotherapy. 
Strategies employing gene therapy for pancreatic cancer are being pursued (Lemoine, 
1994). The introduction of the p53 gene into colon cancer cells using retroviral vectors 
resulted in suppressed tumorigenicity of these cells in vitro and in vivo (Baker et al., 
1990). Another approach using antisense oligonucleotides is based on the exogenous 
administration of short single-stranded oligonucleotide sequences which are thought to 
act predominantly by blocking translation of mRNA (Carter & Lemoine, 1993; Nellen 
& Lichtenstein, 1993). 
In conclusion growth factor antagonists, gene therapy and antisense oligonucleotides 
are an attractive and important therapeutic target for pancreatic cancer treatment. 
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Table 1.1 The status of various growth factors, growth factor receptors and 
oncogenes in pancreatic cancer. 
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1.8 PANCREATIC CANCER AND CHOLECYSTOKININ 
In the past few years considerable attention has been given to the possible honnone 
responsiveness of pancreatic cancer. Much of the work has focused on the 
gastrointestinal honnone cholecystokinin. 
1.8.1 Trophic effects of CCK in the normal gastrointestinal tract 
An increase in the size and weight of the pancreas in response to CCK was first 
described by Rothman & Wells (1967). Other early evidence for hypertrophic and 
hyperplastic effects of CCK-33, CCK-8 and caerulein on the rat pancreas has been 
reviewed by FoIsch (1984). Similar hypertrophic effects of CCK-8 and caerulein have 
been described on the pancreas of the Syrian hamsters (Pfeiffer et al., 1982) and mice 
(Niederau et al., 1987). The effects of exogenous CCK are mediated by the CCK-A 
receptor, since they can be mimicked by CCK-A receptor agonists and blocked by 
CCK-A receptor antagonists (Dawra et al., 1993; Povoski et al., 1993a). 
The evidence for the role of CCK-A receptor involvement in endogenous CCK in 
pancreatic growth is not as clear, because the findings vary according to different 
research workers. Administration of the CCK-A receptor antagonist, L-364,718 to rats 
by gavage (Wisner et al., 1988) or infusion (Axelson et al., 1990; Gasslander et al., 
1990) for 7 weeks caused decreases in pancreatic weight of 21 and 30%, respectively. 
However, several other groups observed no significant decrease in pancreatic weight 
during treatment with L-364,718 in rats and similar results have also been reported in 
guinea pigs and hamsters (Zucker et al., 1989). 
Trophic effects of CCK elsewhere in the GI tract are also uncertain. Although there 
have been reports that CCK-8 and caerulein stimulate epithelial cell proliferation in the 
mouse gallbladder (Lamote et al., 1982) and that caerulein promotes duodenal 
hyperplasia in rats (Morisset & Gernik, 1983), continuous subcutaneous infusion of 
CCK-8 in rats caused no changes in regions of the GI tract other than the pancreas 
(Axelson etal., 1990). 
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1.8.2 Experimental proliferative responses of CCK 
CCK is involved in the proliferative responses observed in the GI tract following 
dietary and surgical manipulations of experimental animals as described below. 
However, gastrin does not appear to be involved. 
1.8.2.1 Protease inhibitors 
The feeding of animals with protease inhibitors leads to pancreatic hypertrophy and 
hyperplasia (Chernick et al., 1948; Yonezawa, 1983). There is now abundant evidence 
that this is due to CCK. Circulating levels of CCK are elevated after treatment with 
protease inhibitors because there is no feedback inhibition of CCK release by excess 
active trypsin (Niederau et al., 1987). Furthermore, the simultaneous administration of 
the CCK-A receptor antagonist CR 1409 (Niederau et al., 1987) or L-364,718 (Wisner 
et al., 1988) markedly reduces the hypertrophic response. 
1.8.2.2 Surgical treatmems 
CCK is also a factor responsible for pancreatic hypertrophy and hyperplasia following 
pancreaticobiliary diversion (PBD) in both freely fed and fasting rats (Gasslander etal., 
1990; Chen etal., 1993a). PBD in the rat and hamster is achieved by transferring the 
part of the duodenum containing the pancreatic and bile ducts to the middle of the 
ileum. The operation results in elevated serum levels of CCK (Gasslander et al., 1990) 
and decreased serum levels of gastrin (Miazza et al., 1985; Chu et al., 1992). The 
increase in pancreatic weight by PDB is blocked by CCK-A receptor antagonists 
(Axelson et al., 1990; Gasslander et al., 1990; Rivard et al., 199 1). A similar 
association between plasma CCK levels and increased pancreatic growth has been 
observed following cholecystectomy in Syrian hamsters (Rosenberg et al., 1988). 
1.8.2.3 Pancreatitis 
CCK has also been implicated in pancreatic regeneration following pancreatitis induced 
by caerulein or ethionine. Treatment with exogenous CCK-8 accelerated regeneration 
following ethionine-induced pancreatitis, while spontaneous regeneration following 
caerulein-induced pancreatitis was inhibited by L-364,718 (Jurkowska etal., 1992). 
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1.8.3 Effects of CCK on spontaneous carcinogenesis 
At least one surgical treatment known to increase serum CCK levels may also enhance 
spontaneous pancreatic carcinogenesis. PDB resulted in the appearance of hyperplastic 
nodules in the pancreas of over 70% of treated rats (Miazza et al., 1987; Stace et al., 
1987). Similar results were obtained when serum CCK was elevated by feeding rats 
on raw soya flour (Roebuck et al., 1987; Morgan et al., 1977; McGuiness et al., 
1980), but no hyperplastic nodules were observed in mice fed on the protease inhibitor, 
camostate (Niederau et al., 1990). 
1.8.4 Effects of CCK on chemical ly-i nduced carcinogenesis 
Exogenous CCK and caerulein enhance chemicallY-induced carcinogenesis in the 
pancreas (Lamers et at., 1988). Both CCK-8 and caerulein stimulated the azaserine 
initiated development of acidophilic atypical acinar cell nodules (AACN), which are 
preneoplastic lesions in the mt pancreas (Douglas et al., 1989; Lhoste & Longnecker, 
1987). It has been demonstrated that azaserine-induced AACN contain a6 fold higher 
concentration of high affinity CCK receptors than internodular tissue (Bell et al., 
1992), and these receptors mediate the trophic actions of sCCK-8 since the effects were 
duplicated by a selective CCK-AR agonist (A-71623), but not by a selective 
gastrin/CCK-B receptor agonist (SNF-8815, Povoski etal., 1993a). In contrast to the 
enhancement of acinar tumour development by CCK, pancreatic ductular 
adenocarcinorna induced by N-nitroso (2-oxopropyl) amine (BOP) in hamsters is 
unaffected by treatment with CCK or caerulein following carcinogen treatment 
(Andren-Sandberg etal., 1984; Pour etal., 1988). 
Elevation of CCK by surgical manipulation also enhances c hemically- induced 
pancreatic carcinogenesis. PDB or partial gastrectomy both increased serum CCK in 
rats and the number and volume of acidophilic AACN were increased (Watanapa et at., 
1992; 1993; Stewart et al., 1991). Furthermore, the CCK-AR is presumably involved, 
since the number of AACN was reduced by 90% following treatment with the CCK- 
AR selective antagonist (CR 1409) (Watanapa et al., 1993). In another model, 
cholecystectomy also increased serum CCK levels and doubled the incidence of BOP- 
induced pancreatic ductular carcinomas in hamsters (Ura etal., 1986). 
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Chem ically-induced pancreatic carcinogenesis is also promoted by feeding protease 
inhibitors to rats. Increased numbers of AACN were observed in rats fcd raw soya 
flour and treated with either azaserine (Roebuck et al., 1987; Morgan et al., 1977; 
McGuincss etal., 1981) or BOP (Levison etal., 1979). The same increase was seen 
after feeding camostate to azaserine-treated rats (Lhoste etal., 1988). This effect was 
significantly reduced by treatment with the CCK-A receptor antagonist CR 1409. 
1.8.5 In vivo tumour xenograft models 
1.8.5.1 Immunodeficient mice 
Researchers have attempted to transplant turnours from one species to another for more 
than a century, the majority of such attempts was aimed at transferring human turnours 
into other species to allow controlled experimental investigations. However, this 
proved to be very difficult until genetically immunosuppressed animals were available. 
Since then, immunodeficient animals have played an important role in the studies of 
turnours in vivo. 
1.8.5.1.1 Nudemice 
In 1966, a spontaneous hairless mouse was bom in an animal colony in Glasgow, 
Scotland (Flanagan, 1966) and subsequently this mutant strain was successfully bred. 
It was noted that the mutant mouse had a greatly reduced fertility, failed to thrive and 
developed severe infections. These mice lack a normal thymus. The name 'nude' was 
adopted for this mutation which is inherited in an autosomal recessive pattern. Nude 
mice have normal precursors of B and T cells. However, the abnormal development of 
the thymic epithelium is incapable of inducing normal differentiation of T cells. 
Therefore, nude mice are severely depleted of thymic-derived lymphocytes. 
Characteristics of nude mice include failure to reject xenografts, lack of helper and 
suppressor T cell activity, inability to mount graft versus host response and inability to 
generate cytotoxic T cells. 
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1.8.5.1.2 SCIDmice 
In 1981, a spontaneous mutation arose in a breeding colony of C. 13-17 mice at Fox 
Chase Cancer Center and was first described by Bosma etal. (1983). The mutant allele 
SCID (severe combined immunodeficient) is inherited in an autosomal recessive 
pattern. This mouse is more severely immunocompromised than the nude mouse, 
lacking both functional B and T cells because of non-functional rearrangements of 
immunoglobulin and T-cell receptor genes (Schuler et at., 1986). However, natural 
killer cells, macrophages and other haemopoietic cell lineages do not appear to be 
affected by the autosomal recessive SCID mutation (Dorshkind et al., 1985). Although 
the SCID mutation affects only lymphocyte development, it is not clear what stage of 
differentiation is impaired. It is thought that the effects of the SCID mutation become 
manifest after commitment of lymphoid cells to the B and T cell pathways. 
These mice are now used widely to study tumour biology, biochemistry and 
experimental therapy. Tumours can be transplanted from primary tumour material or 
from turnour cell lines (Rygaard & Povlsen, 1969, Giovanefla etd, 1972). 
1.8.6 Effects of CCK on tumour growth in vivo 
There are a number of reports on the effects of CCK and its analogues on xenograft 
growth. In some studies exogenous CCK and caerulein have been shown to increase 
turnour weight and DNA content in xenografts of pancreatic tumour cell lines (Smith et 
d., 1990a; Roebuck etal., 1987; Upp etal., 1987). Caerulein injections induced the 
growth of pancreatic tumour (SKI with CCK-R) xenografts in nude mice (Upp et al., 
1987) and the CCK-9 analogue increased the growth of SW1990 cell line xenografts in 
nude mice (Smith etal., 1990a, 1991). No effects of exogenous cholecystokinin were 
seen with the human pancreatic cancer cell line xenografts of CaV (Upp et al., 1987), 
Mia PaCa-2, Panc-1, P1420 (Hudd etal., 1989,1985), PGER (Maani etal., 1988), or 
with xenografts of PC-TI (Nio et aL, 1993). A decrease in the volume of PC-YY 
xenografts following CCK injections has also been observed (Nio et al., 1993). The 
combination of caerulein and secrefin also increased tumour weight and DNA content of 
the pancreatic ductular adenocarcinoma H-2-T in hamsters (Townsend et al., 198 1) and 
SW 1990 in mice (Smith et al., 1990a). 
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CCK-R antagonists have been used to investigate the role of pancreatic cancer in vivo. 
These antagonists have been given in combination with exogenous CCK to demonstrate 
that changes associated with CCK administration are specific receptor-mediated effects. 
Antagonists have been used alone to investigate the role of endogenous CCK in 
pancreatic cancer. Proglumide was shown to inhibit the increases in caerulein-induced 
tumour size, weight, protein and RNA in xenografts of the human SKI cell line (Upp 
etal., 1987). Loxiglumide caused the inhibition of the turnour growth ratio of PC-Tl 
cell xenografts in nude mice (Nio etal., 1993). L-364,718 reversed the growth effects 
of CCK-9 in SW1990 cell xenografts (Smith etal., 1990b). Aspercilin and devazepide 
have been shown to reduce turnour size of xenografted turnours in nude mice 
(Alexander et at., 1987; Maani et al., 1988). 
Some experiments that are difficult to explain have shown stimulatory effects of both 
cholecystokinin. and cholecystoldnin antagonists on pancreatic cancer when used alone, 
but no stimulation when these are used in combination (Smith et A, 1990b). 
1.8.7 Effects of CCK on turnour growth in vitro 
In vitro cell culture studies on the trophic effects of exogenous CCK have given rise to 
conflicting results. CCK has been shown to stimulate growth of the human pancreatic 
cancer cell line, KP-lN (Funakoshi & Kono, 1992), and to increase the uptake of 
[3H]-thymidine in the PC-F3 cell line, derived from ascites in a patient with pancreatic 
adenocarcinorna (Morimoto et aL, 1993). The growth of six human pancreatic cancer 
cell lines (SW-1990, Panc-1, Mia PaCa-2, BxPc-3, RWP-2 and Capan-2) was 
stimulated by CCK (Smith etal., 1990a; Smith etal., 1991; Smith etal., 1993) in 
either the sulphated or unsulphated form (Heald et at., 1992). CCK also stimulated the 
growth of the rat pancreatic carcinoma cell line, AR42J (Scemama et al., 1989). 
However, other experiments have shown no effect of these peptides on tumour cell 
growth in vitro and some studies have even shown inhibition (Morimoto et al., 1993; 
Liehr etal., 1990; Nio etal., 1993). Liehr etal. (1990) observed no change in DNA, 
protein or cloning efficiency in Panc-I and Mia PaCa-2 cells after incubation with 
CCK-8 or a CCK-9 analog. 
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Conflicting results have been published from in vitro experiments designed to 
determine the effects of various CCK-R antagonists on the growth of pancreatic cancer 
cells in the absence of exogenous CCK. Some studies have shown no effect of CCK- 
R antagonists on growth. In an experiment using serum-free media without exogenous 
CCK, Smith etal. (1993) found that devazepide and L-365,260 had no effect on the 
growth of the human Panc-I cell line. Studies by Morimoto etal. (1993) with the 
human pancreatic cancer cell line PC-HN in vitro also showed no effect of devazepide 
on growth. Earlier studies have shown stimulation of pancreatic cancer cells by 
receptor antagonists (Smith et at., 1990b) but other in vitro experiments show 
inhibition of pancreatic cancer cell lines by CCK-R antagonists in the absence of 
exogenous CCK. Loxiglumide inhibited [3H]-thymidine uptake in serum-free medium 
without exogenous CCK in various human pancreatic cancer ceR lines (Morimoto et al., 
1993; Nio etal., 1993). 
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1.9 PANCREATIC CANCER AND GASTRIN 
1.9.1 Trophic effects of gastrin in the normal gastrointestinal 
tract 
The observation that the removal of the source of gastrin by antrectomy led to atrophy 
of the remainder of the gastric mucosa was the first indication that gastrin was involved 
in the control of gastric mucosal growth (Lees & Grandjean, 1968; qurldsen et al., 
1968). In the rat this atrophy could be reversed by the administration of pentagastrin 
(Johnson & Chandler, 1973). Conversely, the elevated levels of serum gastrin which 
are a characteristic of patients with the Zollinger-Ellison syndrome, lead to gastric 
mucosal hyperplasia (Neuberger et al., 1972) which can be reversed by the surgical 
removal of the gastrinoma (Pisegna et al., 1992b). There is now general agreement that 
in fed animals gastrin stimulates the growth of the gastric mucosa only (Ryberg et al., 
1990; Crean et al., 19 69). 
1.9.2 Experimental proliferative responses of gastrin 
1.9.2.1 Small bowel resection 
The adaptation of the residual small bowel following the resection of the small intestine 
was not prevented by the removal of the source of gastrin by antrectomy (Oscarson et 
d., 1977) or gastrectomy (Tilson & Axtmayer, 1976). Pancreatic hyperplasia observed 
in rats after small intestine resection is not a consequence of hypergastrinaernia as it was 
unaltered by prior antrectomy or vagotomy. 
1.9.3- Effects of gastrin on spontaneous carcinogenesis 
Although gastrin does not appear to have any effects on the rate of spontaneous 
pancreatic carcinoma development, there is now evidence to show that elevated serum 
gastrin increases the frequency of gastric carcinoid tumours in rats (Tielemans et al., 
1990; Brenna & Waldum, 1992). 
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1.9.4 Effects of gastrin on chemically-induced carcinogenesis 
The effects of gastrin in chemically-induced pancreatic carcinogenesis have not been 
determined. However, the effects of gastrin on gastric and colonic cancer induced by 
mutagens is still controversial. When given together with the mutagen N-methyl-N'- 
nitro-N-nitrosoguanidine (MNNG), pentagastrin increased the incidence of gastric 
carcinoma in rats (Tahara & Haizuka, 1975) and dogs (Kurihara et at., 1979). 
However, when G-4 was administered after the mutagen, the incidence of gastric 
carcinoma was reduced (Tatsuta et al., 1980). Similar confusions exist on the effect of 
gastrin on colonic carcinogenesis. Subcutaneous injection of G-4 has been reported to 
reduce the incidence of MNNG-induced colonic carcinomas in rats (Tatsuta et al., 
1983), conversely reduction of serum gastrin levels by feeding rats a chemically 
defined diet resulted in an increased incidence of azoxymethane-induced colonic 
carcinoma (Tatsuta et al., 1985). 
1.9.5 Effects of gastrin on tumour growth in vivo 
Compared to CCK very little work has been done on the effects of gastrin on the 
growth of pancreatic cancer both in vivo and in vitro. However, recently it has been 
shown that pentagastrin stimulated the growth of pancreatic tumour cell line xenografts 
in nude mice. This was shown by an increase in volume, DNA and protein content of 
the xenografted tumours and the growth response was inhibited by a CCK-BR 
antagonist, L-365,260 (Smith etal., 1995). 
1.9.6 Effects of gastrin on tumour growth in vitro 
Gastrin promotes the growth of pancreatic tumour cell lines in culture (Smith et al., 
1995) and the rat pancreatic tumour cell line AR42J has also been shown to respond to 
gastrin by an increase in DNA synthesis (Seva et al., 1990b). 
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1.10 AIMS 
The aim of these studies is to determine the role of CCK-A and CCK-B receptors in the 
growth of human pancreatic cancer combining three different areas of work; a) 
molecular determination of the expression of CCK receptors in human pancreatic 
cancers and cell lines b) in vitro cell culture studies to evaluate CCK agonist and 
antagonists effects on tumour growth c) in vivo xenograft studies to evaluate the effects 
of CCK agonist and antagonists on human pancreatic tumour growth. 
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MATERIALS AND METHODS 
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CHAPTER 2 
CELL CULTURE STUDIES 
III 
CIIA PTER 2 
2.1 Cell culture 
Human pancreatic tumour cell lines were grown in 175 CM2 tissue culture flasks in a 
sterile incubator (Leec) at 370C with 10% carbon dioxide under the following growth 
condidons: - 
Mia-PaCa-2: 10% foetal calf serum (FCS) and 2.5% horse serum in Dulbecco's 
modified eagle's medium (DMEM) with sodium bicarbonate. 
BxPc-3, Capan-2, Panc-I : 10% FCS in RPMI 1640. 
Capan-I : 15% FCS in RPMl 1640. 
AsPcI : 20% FCS in RPMI 1640 containing 100 U/ml penicillin and streptomycin. 
Hs766T: 10% FCS in DMEM with sodium bicarbonate. 
KPan: 10% FCS in DMEM/Ham's F12 with sodium bicarbonate supplemented with 
15 mM HEPES, 16 nM epidermal growth factor, 1.4 pM hydrocortisone, 1 gM insulin, 
5.0 gM isobutylmethylxanthine and 5 mM glutamine. 
Jurkatts (J6, T-lymphonza cell line): 10% FCS in RPMI 1640. 
NIHM: 10% bovine calf serum in DMEM 
NIH3T3CCK-BR: 10% bovine calf serum in DMEM. 
All culture medium contained 100 U/ml of penicillin and streptomycin. 
When the cells reached 70% confluency (between 5-12 days) tissue culture medium 
was decanted and 4 ml of trypsin added to the cells for 5 min at room temperature. 
Once the cells were detached from the flask the appropriate medium (as above) for each 
cell line was mixed into the trypsinised cells. A sample of the cells were counted using 
trypan blue (Sigma). 
All materials, kits and solutions for these cell culture experiments are contained in 
appendix I, p 277-279. 
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2.2 Cell counting 
50 gI of the trypsinised cells were added to an equal volume of trypan blue, mixed and 
applied to a haemocytometer slide. Using the the trypan blue exclusion technique dead 
cells were stained blue but the unstained live cells were counted as follows: 
Total number of live cells = Cells counted x dilution factor (2) x W04 x total volume 
The cells were split into a number of flasks (4 x104 cells per flask) topped up with 
growth medium and incubated at 37*C in 10% carbon dioxide under sterile conditions. 
'niis procedure was repeated as required. 
2.3 Freezing and reconstitution of cells 
Cells grown in culture were sometimes stored frozen in a freezing medium containing 
10% DMSO (Sigma) in foetal calf serum. The cells were harvested by trypsinisation 
and centrifugation then resuspended in the freezing medium at a density of IX106 
cellsIml, in 1 ml aliquots in cryovials. The vials were placed in a cell freezing unit, Mr. 
Frosty 7M (Sigma), containing isopropanol. and cooled in a -70*C freezer overnight and 
subsequently stored in a liquid nitrogen safe. 
Frozen stocks were reconstituted by thawing a cryovial at 37*C and the cells were then 
gently transferred into Falcon tubes (14 ml) containing 10 ml nutrient medium at room 
temperature. The cells were centrifuged for 10 min at room temperature at 130 xg 
(super minor centrifuge, Fisons). 'Me cells were again resuspended in nutrient medium 
at 4x 103 cells per flask and given fresh nutrient medium every 2 days. 
2.4 Growth of Mia PaCa-2 and BxPc-3 cell lines 
The cells were plated out in 24 well plates at a cell density of 0.3 x 104 cells per well in 
1.0 ml of the appropriate tissue culture medium as described in 2.1.1 plate of cells 
from each cell line was harvested for cell counting every 24 hr by aspirating the spent 
medium and adding 100 gl of trypsin per well for 5 min. Ibe cells were counted using 
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the trypan blue technique 2.2. 
2.5 The effects of sCCK-8 and nsG-17 on the growth of Mia 
PaCa-2 and BxPc-3 cell lines 
The cells were plated out as described in section 2.4 in FCS for 5 days (i. e. allowed to 
reach log phase of growth). Following this incubation the cells were washed twice 
with serum free medium and incubated for a further 4 days in serum-free medium 
before stimulating with growth agents. The cells were stimulated with various 
concentrations of i) sCCK-8 ii) nsG-17 (10 pM, 0.1 nM, I nM, 10 nM and 100 nM) 
iii) 10% foetal calf serum for varying lengths of time. Ile medium plus growth factors 
were replaced every 24 hr but those cells to be counted were harvested every 48 hr with 
100 W of trypsin per well for 5 min and counted using trypan blue. 
2.6 The effects of CCK-AR and CCK-BR antagonists on the 
growth of Mia PaCa-2 and BxPc-3 cell lines 
The cells were plated out as described in section 2.4 in FCS and then in serum-free 
medium. Following the 4 day incubation in serum-free medium the cells were 
incubated in medium containing either i) 10% foetal calf serum ii) 10% foetal calf serum 
in the presence of varying concentrations of antagonists (I nM, 100 nM and 10 IN) iii) 
serum-free medium iv) serum-free medium in the presence of varying concentrations of 
antagonists (1 nM, 100 nM and 10 gM). The medium was replaced every 24 hr. On 
day 6 (post-antagonist incubation) the cells were harvested with trypsin and counted 
utilising trypan blue. The following antagonists were investigated; RPR-X, L- 
740,093, L-365,260, L-364,718 (devazepide), CR 1409 (lorglumide). These 
antagonists were made in sterile 100% DMSO at a concentration of 100 gM except the 
antagonist L-740,093 which was dissolved in phosphate buffered saline (PBS) at 100 
gM. 71be vehicle effect was also determined by incubating the cells with the vehicle in 
medium. 
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2.7 The effects of sCCK-8 and nsG-17 on the growth of 
N1113T3CCK-BR cells 
NIH3T3CCK-BR cells were plated out at Ix 104 cells per well in 24 well plates in 
DMEM containing either 10% bovine calf serum, sCCK-8 or nsG-17 at various 
concentrations (10 pM, 100 pM, I nM, 10 nM and 100 nM). The medium was 
replaced every 24 hr. Ile cells were counted every 48 hr by trypsinisation for 5 min 
followed by counting (trypan blue technique). 
2.8 The effects of CCK-AR and CCK-BR antagonists on the 
sCCK-8 induced growth response in NIH3T3CCK-BR cells 
NIH3T'3CCK-BR were plated out at Ix 104 cells per well in 24 well plates in DMEM 
tissue culture medium containing either 10% bovine calf serum, 100 nM sCCK-8 in the 
presence or absence of varying concentrations of antagonists (I pM, 0.1 nM and 10 
nM). The medium was replaced every 24 hr and the cells counted on day 8. The 
antagonists investigated were ; C1988, RPR-X, L-740,093, L-365,260, L-364,718 
(devazepide), CR 1409 (lorglumide). The vehicle effect was also determined. 
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CHAPTER 3 
FAK PHOSPHORYLATION STUDIES 
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CHAPTER 3 
3.1 Stimulation of cells 
NIH3T3CCK-BR cells were plated out at IX106 per petri-dish in 10 ml DMEM 
containing 10% calf serum (bovine donor) and 100 U/ml penicillin and streptomycin. 
The cells were grown for 48 hr before replacing the medium with serum free DMEM 
containing low sodium bicarbonate. 48 hr later the cells were stimulated for 5 min with 
100 nM sCCK-8,100 nM nsG-17,10% calf serum and PBS as control in a sterile 
incubator at 37*C in 10% carbon dioxide. 
Mia, PaCa-2 cells were plated out at W06 per petri-dish in 10 ml DMEM containing 
10% FCS, 2.5% horse serum and 100 U/ml penicillin and streptomycin. Ile cells 
were grown for 48 hr before replacing the medium with serum free DMEM containing 
low sodium bicarbonate. 48 hr later the cells were stimulated for 5 min with varying 
concentrations of sCCK-8 and nsG-17 (10 nM, 50 nM, 200 nM and 500 nM), 10% 
calf serum and PBS as control in a sterile incubator at 37*C in 10% carbon dioxide. 
In order to determine the effects of CCK-R antagonists on basal FAK phosphorylation 
in Mia PaCa-2 cells, the cells were plated out in FCS containing medium as above in 
the presence of various antagonist concentrations (0.1 nM, 10 nM and I PM). The 
cells were grown for 48 hr before replacing the medium with serum free DMEM 
(containing low sodium bicarbonate) containing the appropriate concentration of 
antagonist for 48 hr 
All materials and solutions for these studies are contained in appendix I, p279-28 1. 
3.2 Preparation of cell extract for protein analysis 
Following the 5 min stimulation with the agonists and 48 hr incubation with the 
antagonists, the medium was rapidly aspirated and the cells were washed once with 5 
ml of 2 mM sodium vanadate. The cells were lysed with 500 91 of 
immunoprecipitation (IP) buffer and the lysate scraped into a clean eppendorf with the 
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aid of a cell scraper. Ile cell lYsate was agitated on a rotating wheel for 30 min at 4*C 
then microfuged at 6500 xg for 15 min. The resulting supernatant was transferred to a 
fresh eppendorf. The concentration of protein in the sample was determined by the 
Bradford assay. 
3.3 Bradford Assay 
5.0 ml of Bradford solution was aliquoted into bijoux bottles to whieh varying amounts 
of bovine serum albumin was added (0.5 pg-10.0 pg, used as standards). 2.0 gl of 
sample was added to 5.0 ml of the Bradford solution. The sample plus Bradford 
solution was allowed to stand at room temperature for 30 min before taking the 
absorbance readings at a wavelength of 595 nm. 
3.4 Preparation of protein A beads and primary antibody 
250 mg of protein A beads (Sigma) were resuspended in 9 ml of phosphate buffered 
saline (PBS containing 0.1% BSA, 0.01% azide, 0.5% NP40 and 0.1% SDS) and 
agitated at 4*C for 30 min (binding capacity = 20 mg of human IgG/ml of beads). The 
beads were stored at 4*C and washed with PBS prior to use. 100 gl of protein A beads 
were used per sample to be immunoprecipitated. 10 Vg of rabbit anti-mouse IgG 
(Zymed) was added to 100 pl of beads and incubated overnight at 4*C. The beads 
were then centrifuged at 6500 xg for 30 see, the supernatant discarded and the pellet 
resuspended in 500 pl of IP buffer, mixed and centrifuged again. In total, the beads 
were washed 3 times and finally resuspended in 100 W of IP buffer. 2.5 Pg of FAK 
antibody (Affiniti) was added to the beads and mixed at 4*C for 30 min. Following this 
incubation, the beads were washed 3 times with IP buffer as before. After the third 
wash the beads were resuspended in 500 pl of 2x IP buffer 
3.5 Immunoprecipitation of FAK 
250 Vg of cell lysate protein (approximately 250 W) was added to the above prepared 
protein A beads (bound to IgG-FAK antibody). The final volume of the 
immunoprecipitation step was made up to 1 ml with sterile distilled water (250 gl). 
This cocktail was agitated for 1.0 hr at 4*C. The immunoprecipitate was centrifuged at 
6500 xg for 4 min and the supernatant discarded. The pellet was washed twice with 
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Ix IP buffer. Following the second wash the beads were resuspended in 50 gI of 2x 
sample buffer. The samples were immediately subjected to clectrophoresis. 
3.6 Preparation of SDS-polyacrylamide gels for protein 
separation 
For each gel, a pair of front and back plates were washed with Hibiscrub and water. 
The plates were rinsed with distilled water and dried with a lint-free paper towel and 
finally wiped with 70% ethanol. The gel apparatus was assembled according to the 
manufacturer's instructions (Anachem, 17.5 x 20.5 cm) with 0.4 mm uniform 
thickness spacers and clamped. 6.5% polyacrylamide solution mix was made to which 
the TEMED was added just before pouring the gel between the plates. The separating 
gel was introduced in between the plates using a syringe, leaving sufficient space above 
for the stacking gel. Ile separating gel was overlaid with 70% ethanol and allowed to 
polymerise for 30 min. Ile overlaying solution was drained by inverting the apparatus 
and the gel rinsed with ddH20 to remove any unpolymerised acrylamide. The 
remainder was filled with the 3.5% polyacrylamide stacking gel mix and the comb 
inserted immediately. The gel was allowed to set for 30 min. The comb was then 
gently removed, to avoid stretching of the gel and the wells rinsed with Ix running 
buffer. The bottom reservoir of each gel apparatus was filled with lx running buffer so 
that the gels would be submerged 2-3 cm. in buffer. Each gel sandwich was 
unclamped, placed in a Western electrophoresis apparatus and clamped. Ix running 
buffer was poumd into the top reservoir rifling the wells. 
3.7 Electrophoresis of protein gels 
The immunoprecipitated samples with the protein A beads were heated at 100*C for 5 
min. The boiled samples were centrifuged at 6500 xg for 4 min and 50 gI of the 
supernatant loaded into each well. The samples were subjected to electrophoresis; at 50 
mA until the bromophenol blue tracking dye had entered the separating gel. The current 
was then increased to 55 mA and electrophoresis continued for approximately 3 hr 
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3.8 Electroblotting of proteins 
Following clectrophoresis the gel was dismantled and cut, removing the stack and 
unrequired regions of the gel. Nitrocellulose membrane (Schleicher and Schuell) was 
cut according to the size of the gel and immersed in Ix transfer buffer for 5 min with 
gentle agitation. Whatman 3MM paper (x2) was also cut to the size of the gel and 
soaked in Ix transfer buffer. Ile components were set up for transfer by sandwiching 
the gel and nitrocellulose membrane between 2 pieces of Whatman 3MM filter paper, 
and then between two Scotch-Brite pads (20 x 20 cm and 0.5 cm. thick). These were 
placed in a plastic transfer cassette and lowered into the clectroblotting apparatus 
(BioRAD) in correct orientation with the membrane on the anode (positively charged) 
side of the tank. The tank was topped up with Ix transfer buffer and the proteins were 
electrophoretically transferred from gel to membrane overnight at 200 mA at 4*C. After 
electroblotting the membrane was used for immunoprobing whereas the gel was 
Coomassie Blue stained to verify the transfer of proteins onto the membrane. 
3.9 Immunoprobing for phosphorylated proteins 
The membrane with the blotted proteins was cut so that one lane containing the 
immunoprecipitated FAK was removed from the rest of the blot enabling the protein in 
this well to be probed with FAK antibody while the remainder was probed with 
phosphotyrosine antibody (PY20, Affiniti, U. K). 
The membrane was washed in TBS for 10 min with agitation at room temperature and 
transferred to a plastic container with blocking buffer (2% BSA in 0.1% TBST) and 
agitated for 1 hr at room temperature on a shaker. The membrane was rinsed with 
0.1% TBST and incubated in 0.1% TBST containing the primary antibody, 0.4 tIg/Al 
PY20 for a further 1 hr with agitation at room temperature. The PY20 solution was 
discarded and the membrane washed 6 times for 5 min in 0.1% TBST with constant 
agitation at room temperature. The secondary antibody, 0.5 ng/gl horse-radish 
peroxidase (DAKO) in 5% powdered milk in 0.1 % TBST was added to the membrane 
and incubated for 45 min at room temperature with shaking. Following this, the 
membrane was washed 6 times for 5 min in 0.1% TBST with constant agitation at 
room temperature. Finally the membrane was rinsed in double distilled water (ddH20) 
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for 10 min. 
3.10 Immunoprobing for FAK protein 
The membrane was washed in TBS for 10 min with agitation at room temperature and 
transferred to a plastic container with blocking buffer (5% powdered milk in 0.1% 
TBST), incubated for I hr at room temperature on a shaker. The membrane was rinsed 
with 0.1% TBST and incubated in 0.1 %TBST containing the primary antibody, 0.25 
p&I FAK antibody (Affiniti, U. K) for a further I hr with agitation at room 
temperature. The FAK antibody solution was discarded and the membrane washed 6 
times for 5 min in 0.1% TBST with constant agitation at room temperature. The 
secondary antibody, 0.5 ngIgI horse-radish peroxidase in 5% powdered milk in 0.1% 
TBST was added to the membrane and incubated for 45 min at room temperature with 
shaking. The membrane was washed 6 times for 5 min in 0.1% TBST with constant 
agitation at room temperature (see Figure 3.1). Following this the membrane was 
rinsed in ddH20 for 10 min. The original PY20 blot was put together with the lane 
probed with the FAK antibody and the proteins were detected by enhanced 




Rinse the membranes In T13S buffer for 10 mins on a shaker 
1 hour block 2%BSAinO. I%TBST 5% powdered milk In 0.1% TBST 
I hour Incubation with primary antibody 
0.4 pg/gl PY20 in 0.1% TBST 0.25 pg1W FAK In 0.1% TBST 
Wash membranes 
Six 5 minute washes In 0.1% TBST on shaker 
45 min Incubation with secondary antibody 0.5 nglW of horse-radish peroxidase (DAKO) in 5% powd&ed milk In 0.1% TBST 
Wash membranes 
Six 5 minute washes in 0.1% TBST on shaker 
Wash membranes 
10 minutes in double distilled water on shaker 
Aion 
ECL for 30 seconds (Amersham) 
Figure 3.1 Flow diagram summarising the immunoprobing procedures using PY20 
and FAK antibodies. 
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4.1 Determination of CCK-R expression In human pancreatic 
cancer cell lines by PCR. 
4.1.1 Cell culture 
All chemicals, solutions and kits for these molecular studies are referred to in appendix 
Lp277-287. Eight human pancreatic tumour cell lines (Mia-PaCa-2, Panc-1, Capan-2 
, BxPc-3 , Capan- I, AsPc-1, Hs766T and KPan) and Jurkatts (J6, T-lymphoma cell 
line)weregrown in the appropriate medium (as described in 2.1) intissucculture 
flasks in a sterile incubator at 37*C in the presence of 10% carbon dioxide. When the 
cells reached 70% confluency, total ribonucleic acid (RNA) was extracted from the 
cells. 
4.1.2 Isolation of total RNA from cultured cells 
Total ribonucleic acid (RNA) was extracted from each of the pancreatic tumour cell 
lines by the method of Chomczynski and Sacchi (1987) using RNAzol (Biogenesis, 
U. K). At 70% confluency tissue culture medium was discarded and the cells 
trypsinised with 5 ml of Ix trypsin (Difco) until complete detachment of the cells from 
the flask was achieved (approximately 5 min). The cells were transferred into 50 ml 
falcon tubes (Coming) and the trypsin inactivated by the addition of culture medium 
containing serum. The cells were centrifuged at 130 xg for 10 min. Ile supernatant 
was aspirated and 3 ml of RNAzol added to the cell pellet (approximately Ix 106 cells) 
which were lysed by vigorous vortexing. Chloroform (0.3 ml, a tenth of the volume of 
RNAzol) was added and the mixture vortexed and placed on ice for 5 min. The 
suspension was centrifuged in a Sorvall RC-5 superspeed refrigerated centrifuge at 
12,000 xg for 15 min. Ile top aqueous phase was transferred to a sterile tube and an 
equal volume of propan-2-ol (BDH) added and RNA precipitated overnight at -20*C. 
71be precipitated RNA was centrifuged at 40C for 15 min at 12,000 x, g, the supernatant 
was decanted and the RNA pellet washed in 70% ethanol and centrifuged again at 6000 
xg for 10 min at 4*C. The supernatant was decanted and the pellet resuspended in an 
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appropriate volume (50-150 gl) of diethylpyrocarbonate (DEPQ treated water. 
4.1.3 Isolation of total RNA from tissues 
All the apparatus used was pre-cooled, the Wheaton homogenisers were stored at 4*C 
and the metal pounders were supercooled at -70*C for a minimum of 15 min. Frozen 
tissue (200 mg) was rapidly ground into powder form by hammering the pounder while 
keeping the tissue frozen with liquid nitrogen. The resultant ground tissue was rapidly 
transferred to a homogeniser containing RNAzol B (3 ml) and homogenised on ice (5 
min). Ile homogenised tissue was transferred to a clean snap-top tube (Greiner) and 
500 gl of chloroform (a tenth of the volume of RNAzol) was added and the mixture 
vortexed and held on ice for 5 min. The cells were centrifuged in a Sorvall RC-5 
superspeed refrigerated centrifuge at 12,000 xg for 15 min. The top aqueous phase 
was transferred to a sterile tube and an equal volume of isopropanol added and RNA 
precipitated overnight at -20*C. FoHowing the precipitation, the RNA was centrifuged 
at 4*C for 15 min at 12,000 x g, the supernatant was decanted and the RNA pellet 
washed in 70% ethanol at 6000 xg for 10 min at 4*C. The supernatant was removed 
and the pellet resuspended in an appropriate volume of DEPC treated water. 
4.1.4 Determination of the integrity of RNA 
The sample of RNA (5 pg) was prepared to a final volume of 10 gl with DEPC water 
and 1.7 W of 6x RNA loading buffer. Ile samples (5 gg of RNA) were heated at 90*C 
for 2 min then rapidly transferred to ice for 2 min and microfuged before loading onto a 
formaldehyde agarose gel (see appendix). Ile RNA samples were electrophoresed for 
I hr at 70 volts. The integrity of the RNA was examined by visualisation of the 28s 
and l8s ribosomal RNA bands under UV light. If the 28 and 18s bands were sharp 
and clear then the mRNA was assumed to be intact. 
4.1.5 Reverse transcription of RNA into 1st strand cDNA 
Pancreatic tumour cell line RNA was reverse transcribed into first strand 
complementary deoxyribonucleic acid (cDNA) using the Superscript RNase H- Reverse 
Transcriptase kit (Gibco BRL U. K). 
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5.0 Vg of total RNA and 500 ng of random hexamers in a total volume of II pl was 
incubated at 70*C for 10 min and then placed rapidly on ice. The contents of the tube 
were briefly (30 sec) centrifuged and 4 pl of 5x first strand buffer, 2 gl of 0.1 M DTT, 
I pl of mixed dNTP stock and 1.0 pl of superscript reverse transcriptase were added, 
vortexed to mix, microfuged and the mixture incubated at 37*C for I hr. Following 
transcription, the reverse transcriptase, was heat inactivated at 70*C for 10 min. The 
cDNA was either stored at -20*C or immediately used for polymcrase chain reaction 
(PCR). 
4.1.6 CCK-R polymerase chain reaction 
The CCK receptor primers were based on the CCK-A and CCK-B receptor sequences 
published by deWeerth etal. (1993a) and Pisegna etal. (1992a) and chosen using the 
oligo primer analysis software Rychlik et al. (1989) distributed by Medprobe (Oslo, 
Norway). 
Two sets of gene specific primers were made and used to exclusively amplify a 340 
base pair fragment from the CCK-A receptor and a 430 base pair fragment from the 
CCK-B receptor. Polymerase chain reaction (PCR) was performed on 2.0 gI of the 
first strand cDNA. Each 100 gI amplification reaction contained :- 200 [tM of each 
dATP, dCTP, dGTP and dTTP (Gibco BRL, UK); I gM of each cholecystokinin 
receptor specific primer; 10 [il of IOx Taq reaction buffer and 2.5 units of DNA 
polymerase (Promega, UK). The cDNA was amplified for 35 cycles using I min at 
94*C (denaturation), I min at 56*C (annealing) and 2 min at 72*C (elongation). 
4.1.7 Electrophoresis of PCR products 
The PCR products were electrophoresed on a 1% agarose gel containing ethidium 
bromide (0.3 gg/ml). 8.3 jil of 6x DNA loading buffer was added to 50 PI of the PCR 
product. The samples were loaded into each well of a 1% agarose gel, along with 0.5 
pg of 1 kb DNA molecular weight marker (Gibco BRL) and electrophoresed at 70 volts 
for approximately 1 hr 
126 
4.1.8 Gel Purification of PCR product 
The PCR fragments were cleaned using the Qiaex II kit (Qiagen). The desired DNA 
bands were excised from the gel under UV light and placed in a preweighed cppendorf 
tube. The PCR products were exposed to a minimum amount of UV light in order to 
reduce nicking of the DNA. The weight of the agarose slice was determined. 3 
volumes of buffer QX I was added to 1 volume of gel and heated at 50*C for 5 min in 
order to allow the gel to melt. 10 gl of Qiaex beads were added to approximately 2 pg 
of DNA in the melted agarose. The agarose was heated at 50*C for 10 min with 
mixing every 2 min. The sample was then centrifuged at 6000 xg for 30 see (Pelleting 
the Qiaex beads) and the supernatant discarded. The pellet was washed with 500 gI of 
buffer QX2, by resuspending the beads in the buffer and centrifuging for 30 sec as 
above. Following this, the Qiaex beads were washed twice with 500 gI of buffer QX3 
as above. After the second wash the pellet was air-dried for 15 min and resuspended in 
sterile water (approximately 10 jil) and incubated for 5 min at 50*C. The Qiaex bead 
suspensions were centrifuged at 6000 xg for 30 sec: and the supernatant containing the 
DNA transferred to a clean tube. This step was repeated giving a final DNA volume of 
20 gl. The DNA concentration of the sample was determined as described in the 
following section. 
4.1.9 Spectrophotometric determination of DNA and RNA 
Samples were diluted I in 100 with ddH20 and absorbance was measured at 260 nrn 
and 280 nrn wavelengths. The absorption at 260 nm allows calculation of the 
concentration of nucleic acid in the sample whereas 280 nm is an indication of protein 
contamination. An OD260 Of I is equivalent to approximately 50 gg/ml double stranded 
DNA or 40 gg/ml of RNA. 
4.1.10 Purity of DNA and RNA 
The ratio of OD260 over OD280 gives an approximation of the purity of the nucleic acid. 
The DNA and RNA are considered pure if the ratio is between 1.8 and 2.0. If the ratio 
is lower than 1.8 the sample could be contaminated with proteins and the quantitation 
of the amount of nucleic: acid will prove difficult. 
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4.2 Cloning of the PCR amplified DNA 
The CCK-A and CCK-B receptor PCR products were cloned using the TA cloning kit 
according to the manufacturers instructions (In vitrogen, UK) followed by plasmid 
DNA preparation as described below; 
4.2.1 Ligation 
Ligations were set up by incubating 2 pl of either the CCK-AR or CCK-BR PCR 
product in 5 pi of sterile water, I gI of IN ligation buffer, 50ng pCRIM vector and 1 
gI of T4 DNA ligase (I unit) at 12*C overnight. 
4.2.2 Transformation 
One 50 W vial of competent Ecoli cells per ligation-transformation and a vial of 0.5 M 
i3-mercaptoethanol was thawed on ice. 2 gl of B-mercaptoethanol was added to each 
vial of competent cells and mixed by gently tapping the tube. I gl of each ligated 
product was pipetted directly into the competent cells and mixed by gentle tapping. The 
vials were incubated on ice for 30 min followed by a 60 sec: incubation at 42*C and 
rapidly placed on ice for a further 2 min. 450 gI of pre-warmed SOC medium was 
added to each vial of cells and incubated at 37*C for 1 hr with gentle agitation. 
Following the incubation, the transformed cells were placed on ice and 25 41 and 100 
gI was spread on separate NZY agar plates (containing 40 mg/ml X-gal (Promega) and 
50 gg/ml ampicillin). The plates were kept at room temperature for 5 min before 
inverting them and incubating at 37*C overnight. 
4.2.3 Isolation of plasmid DNA-mini-preparation 
White colonies were picked from the LB agar plates and grown for 10 hr at 37*C in L- 
broth containing 50 Vg/ml ampicillin. Following their growth, 1.0 ml of the culture 
was transferred into eppendorf tubes and centrifuged at 1300 xg for 2 min, the pellet 
was resuspended in 100 gl of TE buffer, followed by lysis with 200 41 lysis buffer and 
placed on ice for 5 min. The lysate was treated with 150 [il of 3M potassium acetate 
(pH 4.8) and centrifuged at 6000 xg for 10 min. The supernatant was transferred to a 
fresh eppendorf and extracted with an equal volume of phenol/chloroform (BDH). Tlie 
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aqueous phase containing the DNA was precipitated with 2.5x volume of 100% ethanol 
at -20*C for 15 min. The DNA was pelleted, washed with 70% ethanol and 
resuspended in 30 gI of sterile water. The concentration of the DNA was determined 
by measuring the optical density reading at 260 nm. 
4.2.4 Enzyme restriction of plasmid DNA 
To determine the presence of the desired insert, a digest was set up as follows: 10 Al of 
plasmid DNA (from miniprep, approximately 1.0 Vg), 4 gI of one phor all buffer (10x, 
Gibco BRL), 5 pI of water and 2 units of EcoRl (Gibco BRL) in a microcentrifuge 
tube. The digestion mix was briefly (30 see) microfuged followed by incubation at 
37*C for 1 hr. The digested products were electrophoresed on a 1% agarose gel. To 
each tube containing the EcoRl restricted plasmid 3 gI of 6x DNA loading buffer was 
added and the samples loaded onto the gel. The samples were electrophoresed at 70 
volts for 1 hr, along with 0.5 gg of aI kb DNA molecular weight markers (Gibco 
BRL). The presence or absence of the DNA fragments was determined under UV 
light. 
4.2.5 Isolation of plasmid DNA-maxi-preparation 
500 ml of LB-broth containing 100 gg/ml ampicillin was inoculated with 10 ml of an 
overnight culture (harbouring the plasmid of interest) from above and allowed to grow 
at 37*C for 5 hr in a shaker at 400 rpm. The culture was centrifuged at 6000 xg for 15 
min at 4*C. The pellet was resuspended in 5 ml of 25% sucrose in 50 mM Tris (pH 
8.0) and placed on ice for 15 min. 0.5 ml of freshly prepared 20 mg/ml lysozyme in 
0.25 M Tris (pH8.0) was added to the resuspended culture followed by the addition of 
1.0 ml 0.5 M EDTA. The culture was gently mixed and held on ice for 10 min. 0.5 ml 
of 20% SDS was added, mixed gently, followed by the rapid addition of 2.5 ml of 5M 
sodium chloride. The lysed cells were gently mixed and incubated on ice for 1 hr. The 
lysate was centrifuged at 20,000 xg for 1 hr at 4*C. The supernatant was transferred 
to 50 ml falcon tubes and the volume made up to 25 ml with TE. 10 ml of phenol 
followed by 10 ml of chloroform was added to the supernatant, which were mixed well 
and centrifuged at 560 xg for 15 min. Ile upper (aqueous layer) was re-extracted with 
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25 ml of chloroform (560 x g, 10 min). Following the second organic extraction, the 
aqueous layer was transferred to a fresh tube and 0.6 volumes of isoPropanol was 
added, the precipitated DNA was recovered by centrifuging the mixture at 15,000 xg 
for 10 min. The supernatant was discarded and the pellet dried (by inverting the tube 
on a tissue for 10 min). The dried pellet was resuspended in an exact volume of 9.8 ml 
TE containing 40 gg/ml RNAse (4 gl of 10 mg/ml) and incubated at 37*C for 30 min. 
Ile plasmid DNA was further purified by centrifugation in caesium chloride-ethidium 
bromide density gradients. 
4.2.6 Caesium, chloride-ethidium bromide equilibrium 
centrifugation 
Caesium chloride (9.8 g) was added to 9.8 ml of TE buffer (containing the DNA) and 
the resulting mixture was loaded into quick seal ultracentrifuge tubes, prior to layering 
with 200 W of 10 mg/mI ethidium bromide. The tubes were sealed, mixed by inversion 
and placed in a Beckman W65 rotor and ultracentrifuged for 24 hr at 350,000 xg at 
20*C. The top of the tube was then cut off and the plasmid DNA (visible as a thin 
band) was recovered by suction using an 18GA needle. The DNA was transferred to a 
50 ml falcon tube topped up to 0.5 ml with TE buffer and extracted with isopropanol 
saturated caesium chloride. The tube contents were mixed thoroughly and centrifuged 
at 360 xg for 5 min at room temperature. The upper pink organic layer was discarded 
and the extractions repeated until the organic layer became colourless. To precipitate the 
DNA the sample was then diluted with 2 volumes of water and 6 volumes of cold (4*Q 
ethanol, mixed and incubated at 4*C for 30 min followed by centrifugation at 18,000 x 
g for 30 min at 4*C. The supernatant was discarded and the pellet was washed several 
times to remove any traces of caesium chloride in 70% ethanol. Once the pellet was 
washed, it was dissolved in sterile water and the DNA concentration determined by 
measuring the optical density at UV wavelength 260 nm. 
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4.3 DNA sequencing 
The DNA was sequenced using the Pharmacia sequencing kit (appendix 1, p286) as 
described below; 
4.3.1 Annealing of primer to double stranded template 
8 gI of 2M sodium hydroxide was added to 1.5 gg of DNA template (in a volume of 
32 gl) and incubated at room temperature for 10 min. 7 gI of 3M sodium acetate (pH 
4.8) was added followed by 120 gI of 100% ethanol; the DNA was precipitated at - 
20*C for 15 min followed by centrifuging at 6000 xg for 15 min at 4*C. The pellet 
was washed with 70% ethanol and resuspended in 7 gI of water. 10 pmol of primer 
(2W, universal primer), 2 gI of annealing buffer and 3 gI of DMSO were added to the 7 
gI of the denatured DNA template, mixed and incubated at 37*C for 20 min. Following 
this, the annealing mixture was placed at room temperature for 10 min before 
proceeding with the labelling reaction. 
4.3.2 Labelling reaction 
To the tube containing the annealed primer and DNA template, 3 gl of labelling mix A 
(see appendix I, p286), 5 gCi of 35S-dATP, and 2 gI (3.2 units) of T7 DNA 
polymerase was added, mixed and incubated at room temperature for 5 min. For each 
template to be sequenced 2.5 gI of each short mix of G, A, T and C were pipetted into 
eppendorfs and prewarmed at 370C. 
4.3.3 Termination reaction 
Following the labelling reaction, 4.5 91 of this mix was added to 2.5 gl of the 
prewarmed short mix and incubated for a further 5 min at 37*C. The reaction was 
terminated by the addition of 5 91 of stop buffer. The terminated reactions were either 
electrophoresed immediately or stored at -20*C. 
4.3.4 Preparation of PAGE sequencing gels 
For each gel, a pair of front and back glass gel plates were washed meticulously with 
Hibiscrub and water. The plates were rinsed well with ddH20 and dried with lint-free 
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paper towel and then wiped with 70% ethanol. A film of 5% dimethyldichlorosilane in 
chloroform was carefully applied to one of the plates in a fume cupboard with a 
Kimwipe soft tissue. Once the film dried, the plate was wiped with 70% ethanol and 
dried. The plates were assembled according to the manufacturer's instructions with 0.4 
mm uniform thickness spacers and clamps. For each gel, 50 ml of desired acrylamide 
gel solution (see appendix I for details) in a 100 ml beaker was prepared. The solution 
was thoroughly mixed with 200 gl of 20% ammonium persulphate prior to pouring. 
The acrylamide solution was gently pulled into a 60 ml syringe avoiding any air 
bubbles. The gel apparatus was raised to a 45* angle from the bench top (with the short 
plate on top) and the acrylamide solution slowly delivered between the plates down one 
side. When the solution reached the top of the short plate, the gel sandwich was 
positioned with the top edge 5 cm above the benchtop. The flat side of a 0.4 mm 
sharktooth comb was inserted 2 to 3 mm into the solution below the top of the short 
plate avoiding air bubbles and extra acrylamide solution was layered onto the comb to 
ensure full coverage. Ile gel was allowed to polymerise overnight before use. 
4.3.5 Electrophoresis of sequencing gels 
The comb was removed gently from the set gel sandwich, avoiding pulling or 
stretching the top of the gel. The bottom reservoir of each gel apparatus was filled with 
lx TBE buffer such that the gels would be submerged 2-3 cm in buffer. Each gel 
sandwich was then placed in a sequencing electrophoresis, apparatus and plates clamped 
in position. Ix. TBE buffer was poured between the plates, and the top of the gel rinsed 
by syringe with TBE buffer. Each gel was pre-heated at a constant power of 60 W for 
approximately 30 min before loading the sequencing samples. The comb was inserted 
into the pre-heated gel and any bubbles removed by syringe. The labelled reactions 
were heated at 70*C for 2 min and 3 gI loaded per well on each gel to be run. The 
samples were electrophoresed for approximately 2.5 hr at 50 W. 
4.3.6 Fixing of gels 
The buffer was drained from the sequencing apparatus following gel electrophoresis 
and the gel sandwich dismantled by removing the clamps and carefully separating the 
smaller plate from the larger plate. Once separated, the spacers were removed and the 
132 
plate with the gel was placed horizontally in a shallow tray. The gel was gently covered 
to a depth of 2 cm with 10% acetic acid/10% ethanol fixer solution for 15 min. The 
fixer solution was then discarded and the gel plate removed to a benchtop. Two pieces 
of dry blotting paper cut to the gel size were placed together on top of the gel, 
beginning at one end of the gel and working slowly towards the other to prevent 
bubbles forming between the paper and the gel. The blotting paper was then peeled off 
the plate with the gel and covered with saran wrap and placed on a preheated gel dryer 
for 15 min at 80*C. Once dried the saran wrap was removed and the gel placed in an 
X-ray cassette containing Kodak XAR-5 film. Following an overnight (16 hr) 
exposure at room temperature the X-ray film was removed and processed. 
4.4 Determination of CCK-R expression in human pancreatic 
cancer cell lines by RNase protection assay 
The RNase protection assays were carried out using the RPA II kit purchased from 
AMS Biotechnology (UK, see appendix I, p287). 
4.4.1 Construction of DNA templates 
The plasmids containing the DNA fragments (described in sections 4.2.5-4.2.6) were 
digested with the appropriate restriction enzymes to enable synthesis of anti-sense and 
sense RNA probes. The plasmid DNA (100 gg) was digested in 100 gI total volume as 
follows: 10 gI of lOx digestion buffer, 2 gI of enzyme, x. gI of plasmid DNA (100 gg) 
and sterile water added to make the 100 gl volume. BamHI (Promega, UK) in buffer E 
was used to construct templates for the synthesis of an antisense CCK-AR and sense 
CCK-BR RNA probe. Templates for the synthesis of an antisense CCK-BR and sense 
CCK-AR RNA probe were constructed using AvaI (Promega, UK) in buffer B. The 
digestion was allowed to proceed at 37*C overnight (16 hr) followed by DNA 
purification the following day: An equal volume of phenol/chloroform (1: 1) was added 
to the digestion reaction and the samples vortexed and microfuged for 2 min at 6000 x 
g in an eppendorf tube. The upper aqueous layer was transferred to a fresh tube and 
the extraction repeated with phenol/chloroform. The aqueous layer was re-extracted 
with chloroform (100 gl), vortexed and microfuged for 2 min. 2.5x the volume of 
100% ethanol was added to the aqueous layer and incubated at -200C for 15 min ajid 
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microfuged for 10 min as above. The supernatant was decanted and the pellet washed 
in 70% ethanol and air dried prior to dissolving in water. UV absorbance at 260 nm 
wavelength was measured and the concentration of DNA calculated. The sense RNA 
probe being an internal control for the RNase protection assay. 
4.4.2 Synthesis of high specific activity radiolabelled RNA 
probes 
The RNA probes were synthesised using the AMS biotechnology (UK) maxi-script kit. 
Briefly 1.0 gg DNA template was transcribed as follows: all solutions were allowed to 
reach room temperature before use. 
Nuclease free water 4 gI 
Transcription buffer (10x) 2 gl 
200 mM DTIF I gl 
ATP, GTP and UTP (2.5 mM each) prepared by mixing I volume of water 
with one volume of each 10 mM ATP, GTP and UTP stocks supplied) 4 gl 
rRNasin ribonuclease inhibitor (20 U) 141 
Linearised DNA template (1.0 pg/gl) 141 
100 gM CTP I PI 
[CC 3 2p] CTp (10 MCi/Ml) 5 gI 
SP6 polymerase (CCKB) or T7 polymerase (CCKA) (20 U) I PI 
Total volume 20 gl 
The above reaction was incubated at 370C for 60 min: following this, 2 units of DNase 
I was added and further incubated for 15 min to remove the template DNA. The 
reaction was terminated by the addition of 21 gl of sample buffer and the labelled 
transcript was purified by polyacrylamide gel electrophoresis (4.4.3). This resultant 
probe had a specific activity of approximately 4x 108 CpM/[tg. An internal GAPDH 
RNA probe was also synthesised using GAPDH (gl yceral dehyde- pho sp hate- 
dehydrogenase) DNA template (AMS Biotechnology) and 73 polymerase. 
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4.4.3 Gel purification of 3 2p. labelled RNA probe 
2W of the terminated reaction was transferred into a fresh eppendorf tube containing 
198 gI of TE buffer with 100 gg of carrier RNA (yeast RNA) and the remaining sample 
was treated at 95*C for 4 min and loaded onto a 6% polyacrylamide gel (see 4.3.4). 
The probe was electrophoresed for 3 hr and the gel covered with saran wrap and 
exposed to X-ray film for approximately 2 min. During exposure, a designated comer 
of the film was marked for orientation and lines were drawn with a felt-tip pen across 
the comers and sides of the film. The film was developed and used to precisely localise 
the area of the gel containing the full-length labelled transcript. The film was aligned 
with the gel and the area of the gel containing the probe was excised with a scalpel and 
transferred with clean forceps to a microfuge tube containing 350 gI of elution buffer. 
The elution of the probe was carried out overnight (16 hr) at room temperature. The 
following day the gel was removed from the elution buffer and 1 tit of the elution 
buffer containing the probe was transferred into 3 ml of scintillation fluid and the 
radioactivity measured in a Packard 2000CA counter. 
4.4.4 Calculation of probe specific activity 
100 gl of the probe diluted in TE buffer (containing yeast RNA) was counted directly 
in 3 ml of scintillation fluid (total count). The amount of 32p incorporated into the 
RNA probe was determined by trichloroacetic acid (TCA) precipitation. The remaining 
100 gl of the diluted reaction was added to 2 ml of cold 10% TCA, vortexed and held 
on ice for 5 min. The precipitate was collected by filtering under vacuum on GF/C 
glass fibre filters and then was washed once with 2 ml of cold 10% TCA and twice 
with 95% ethanol. The filter was oven dried and transferred into scintillant Q ml) for 
counting (Packard 2000CA counter). Calculation of the specific activity of the probe; 
Proportion of 32p-CTp incorporated into RNA: 
1.1 x 1-0-6cpm-TCA xlOO =50% 
2.6 x 106 cpm total 
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No of MCi32pin reaction =5 glx. MjnCL-x Iml 0.05 mCi 
ml 100041 
No of MMOI 32P-CTP = 0.05 mCi xI mmol xI Ci 0.05 mmol 
400 Ci low mci 4x 105 mmol 
0.0125 x 10-5 mmol = 0.125 nmol in reaction 
No of moles of cold CTP: 
100 4mol x 141 x -Lml 
loo X 10-6 = 0.1 nmol 
1000 ml 100041 
Total moles of CTP = 0.125 nmol of 32p- CTP + 0.1 nmol cold CTP = 0.225 nmoles 
0.225 nmol in reaction x 50% incorporation = 0.1125 nmol incorporated 
RNA synthesised in nanogrammes = 1320 xI Qý n P- x 0.1125 nmoles 
109 nmol 
= 148.5 ng 
42 pI x 1.3 x 106 cpm/gl = 54.6 x 106 cpm of TCA-precipitable material (i. e. RNA) 
Specific activity of the product 
54.6 x lQý £pM x 1000 = 3.68 x 108 cpm/lig 
148.5 ng 
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4.4.5 Hybridisation of probe and sample 
RNA (50 gg) from each cell line and positive control samples was hybridised with 600 
pg of radioactively labelled RNA probe at 42*C for 12 hr in 20 gI of hybridisation 
buffer. Following hybridisation 200 gI of digestion buffer containing 1.0 Rg of 
RNase, was added to the hybridised samples and incubated at 37*C for 30 min to 
degrade any remaining single-stranded RNA. The protected RNA was precipitated at - 
20*C for 30 min with 300 pI of solution Dx and centrifuged for 30 min at 6000 x g. 
The pellet was resuspended in 8 pl of RNA loading buffer and then treated at 95T for 
4 min prior to electrophoresis on a 6% polyacrylamide gel for 3-5 hr at 50 W. 
Following electrophoresis, the buffer was drained from the gel apparatus and the gel 
sandwich dismantled by separating the plates carefully. The gel was fixed and dried as 
in section 4.3.6. Kodak XAR-5 film was exposed to the gel in an X-ray cassette at - 
70*C in the presence of an intensifying screen. Five days later the X-ray film was 
removed and processed. 
4.5 Radioligand binding studies to determine the presence of 
CCK-BR in Mia PaCa-2 cells 
4.5.1 Preparation of cells 
Tle cell lines Mia PaCa-2 and NIH3T3CCK-BR were grown in culture as described in 
2.1. The cells were treated with versene (Sigma) rather than trypsin in these 
experiments. Ix 109 cells were harvested with versene and centrifuged at 800 xg for 
10 min. The cells were resuspended in Hepes-NaOH buffer (pH 7.2 at 21*Q to give a 
concentration of 1 x109 cells per 10 ml. 
4.5.2 Incubation conditions 
The cells were aliquoted at various concentrations, (3 x 107,1 X 107,3 x 106,1 X 1069 
3x 105,1 X 105,3 x 104) in a 400 [il. volume and incubated with 50 gl of 1.0 nM 
[3H]-PD140,376, for 150 min at 21*C. Total and non-specific binding of [3141- 
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PD140,376 (a specific CCK-BR antagonist) were defined in the absence and presence 
of 50 gl of 10 gM L-365,260 (a specific CCK-AR antagonist) respectively. The assay 
was terminated by rapid filtration through presoaked Whatman GF/B filters which were 
washed (3 x3 ml) with 50 mM Tris HCI (pH 7.4 at 4*Q using a Brandell cell harvester. 
The filters were transferred into scintillation vials containing 5 ml Meridian Goldstar 
liquid scintillation cocktail. The bound radioactivity was determined after 4 hr by 
counting Q min) in a Beckman LS6500 liquid scintillation counter. 
4.6 Analysis of K-ras status 
4.6.1 Isolation of genomic DNA from cell lines 
The cell lines were grown in the appropriate culture medium to 70% confluency. 
Genomic DNA from the cell lines was prepared as follows: Cells from culture flasks 
were harvested with trypsin, centrifuged (as mentioned previously) and lysed at 55*C 
for 24 hr with 1 ml TNE containing 0.66% SDS and 1.5 ng proteinase K. Following 
the digestion the cell lysate was extracted with an equal volume of phenol for 20 min 
and centrifuged at 440 xg for 10 min to separate the two phases. The aqueous phase 
was transferred to a fresh eppendorf and re-extracted with phenol for 20 min followed 
by an extraction with chloroform. Following separation of the two phases the bottom 
organic (chloroform) layer was removed and discarded appropriately. The aqueous 
DNA phase was treated with 0.1 gg of RNase at room temperature for 20 min. The 
DNA phase was re-extracted with an equal volume of phenol. The upper aqueous 
phase was transferred to a fresh eppendorf tube and the DNA precipitated with 2-3 
volumes of chilled absolute alcohol at 4*C for 30 min. The tube was gently inverted a 
few times and the precipitated DNA removed with a clean tip and rinsed in 70% 
ethanol. The DNA was left to air dry and finally dissolved in a small volume of sterile 
water. The DNA concentration was determined as described in 4.1.9. 
4.6.2 K-ras polymerase chain reaction 
The sequence of the K- ras primers was obtained from the work of Caldas et aL (1994) 
and Sumi et aL (1994) for exons I and 2 respectively. The primers were synthesised 
by Oswell (Southampton, U. K, see appendix I, p282) 
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4.6.2.1 PCR amplification of exon 1 
50 ng of genomic DNA from each pancreatic tumour cell line was amplified by PCR- 
Each 20 gI amplification reaction contained; 200 gM of each dATP, dCTP, dGTP and 
dTTP (Gibco BRL, UK); I gM of each primer; 2 gI of lOx Taq reaction buffer and 
0.5 units of DNA polymerase (Promega, UK). The genomic DNA was amplified for 
35 cycles using 30 s at 95*C (denaturation), 30 s at 58*C (annealing) and 30 s at 72*C 
(elongation). 
4.6.2.2 PCR amplification of exon 2 
50 ng of genomic DNA was amplified as above for 30 cycles using I min at 96*C 
(denaturation), 1 min at 56*C (annealing) and I min at 74*C (elongation) followed by a 
time delay at 74*C for 7 min. 
The PCR products were electrophoresed on a 1.8% agarose gel and stained with 
ethidiurn bromide. The PCR product was gel purified and cloned using the Qiaex II kit 
(section 4.1.8) and TA cloning kit (section 4.2), respectively. 
4.6.3 T7/T3 PCR to determine the presence of K-ras PCR product 
PCR was performed on the selected colonies. A colony was selected by a pipette tip 
and dipped into the PCR mix and then this same tip with the colony remains was 
transferred to a snap-top tube containing NZY broth with 50 pg/mI ampicillin. Each 20 
[tl amplification reaction contained :- 200 ttM of each dATP, dCTP, dGTP and dTI?; 1 
gM of each primer, T3 and T7; 2 gl of lOx Taq reaction buffer and 0.5 units of DNA 
polymerase (Promega, UK). The DNA was amplified for 30 cycles using I min at 
94*C (denaturation), I min at 55*C (annealing) and 3 min at 72*C (elongation). The 
PCR products were electrophoresed on a 1.8% agarose gel containing ethidiurn 
bromide (0.1 gg/ml). 
The presence of the desired fragment was determined and plasmid DNA isolated (mini- 
prepamtion in 4.2.3). 
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4.6.4 PCR-Single strand conformational polymorphism (SSCP) 
PCR of K-ras exon I was carried out described in 4.6.2.1. but in the presence of 2 40 
of 3000 Ci/mmol deoxy-cytidine triphosphate (dCTP) (Amersham). Following 
amplification, 10 pI of the PCR product was diluted with 125 gl of 10 mM EDTA 
containing 0.1%SDS. 4 pl of loading buffer was added to 4 gI of the diluted PCR 
product and the sample treated at 95*C for 5 min, rapidly cooled on ice and 
electrophoresed on a 6% polyacrylamide gel containing 10% glycerol at 5W for 14 hr 
in Ix TBE. Ile gel was transferred to 3MM Whatman paper and exposed to Kodak 
film for 24 hr at -70*C. 
4.7 Semi-quantitative CCK-R RT-PCR 
RNA was extracted from pancreatic tumours along with their matched normal 
counterparts as described in section 4.1.3 and the RNA integrity determined as in 
section 4.1.4. cDNA was synthesised from 5 [tg of total RNA (section 4.1.5). Semi 
quantitative PCR was carried out as follows: PCR was performed on 1.0 gi of the neat 
or diluted cDNA. The cDNA was diluted 1: 10,1: 100,1: 1000 and 1: 10,000 fold with 
sterile water. Each 50 gI amplification reaction contained :- 200 4M of each dATP, 
dCTP, dGTP and dTTP (Gibco BRL, UK); I gM of each cholecystokinin receptor 
specific primer, 0.5 pM of each B-actin primer; 10 gl of lOx Taq reaction buffer and 2.5 
units of DNA polymerase (Promega, UK). The cDNA was amplified for 35 cycles 
using 1 min at 94*C (denaturation), 1 min at 56*C (annealing) and 2 min at 72*C 
(elongation). The PCR products were electrophoresed on a 1% agarose gel containing 
ethidium. bromide (0.1 pg/ml). 
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CHAPTER 5 




The immunodeficient mice were purchased from Charles River Ltd. (UK). Male CD-1 
nude and CB-17 SCID mice were purchased at 5 weeks of age. The mice were housed 
in sterile plastic flexible film isolators (Isotech Ltd., UK) with autoclaved bedding, 
food and water. They were acclimatised to a 12 hr light/dark cycle. The temperature 
and humidity in the isolator were maintained at 23*C and 40-55%, respectively. Mice 
were housed 3 per cage. 
5.2 Xenografting of primary pancreatic tumours 
Fresh pancreatic cancer specimens obtained from theatre were removed to a class II 
cabinet and immediately minced with the aid of a scalpel in tyrode solution (Gibco 
BRQ at room temperature and the resultant suspension of cells taken up into a syringe 
with a 23 gauge needle. The syringe and needle were wiped with virkon (sterilising 
solution) before passing into the isolator. The male CD-1 nude mice were injected (0.1- 
0.3 ml) subcutaneously into the left flank and monitored daily. 
0.1-0.3 ml of the tumour suspension was also grown in vitro in 10% FCS in 
DNENVHam's F12 with sodium bicarbonate supplemented with 15 mM HEPES, 16 nM 
epidermal growth factor, 1.4 gM hydrocortisone, I gM insulin, 5.0 gM 
isobutylmethylxanthine, 5 mM glutamine and 100 U/ml penicillin and streptomycin in a 
sterile incubator (Leec) at 37*C with 10% carbon dioxide. When the cells reached 70% 
confluency (between 7-12 days) tissue culture medium was decanted and 4 ml of 
trypsin added to the cells for 5 min at room temperature. Once the cells were detached 
from the petri-dish the above medium was mixed into the trypsinised cells. A sample 
of the cells were counted using trypan blue (see section 2.2) and the remaining cells 
replated in a petri-dish at 5x 104 in fresh medium. This procedure was repeated as 
required. 
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5.2.1 Passaging of xenografted turnours 
When the xenografted tumours reached approximately 10% of the mouse body mass, 
the mouse was killed by ether inhalation followed by cervical dislocation and the 
tumour removed utilising aseptic techniques. The tumour was trimmed of any adhering 
fatty tissue, washed with tyrode and blood removed prior to mincing into a suspension 
with a scalpel and a pair of forceps in 5 ml of tyrode solution. The cell suspension was 
taken up into a 1.0 ml syringe and the cells injected subcutaneously through a 23 gauge 
needle into the left flank of a nude mouse. The maximum volume of cell suspension 
injected was 0.3 ml. The mice were monitored daily and when the tumour approached 
10% of the body mass the above procedure was repeated. 
5.3 Extraction of DNA from xenografts 
The tumour (approximately 300 mg) was homogenised (60 sec) using a Silverson 
Polytron tissue grinder in 900 gl of Ix TNE at room temperature. Following this 1.5 
ng of proteinase K and 0.66% SDS was added to the ground tissue (1.0 ml). The 
tissue was incubated overnight at 55*C. The following day DNA was extracted from 
the tissue as described in 4.6.1 and the concentration determined as in section 4.1.9. 
5.4 CCK-R and K-ras status in the passaged turnours 
RNA was extracted from the original and passaged tumour as described in section 
4.1.3. The RNA was reverse transcribed (section 4.1.5) and the cDNA subjected to 
CCK-R (section 4.1.6) and K-ras amplification (sections 4.6.2.1-2). The K-ras PCR 
products were cloned and sequenced (sections 4.2.1-3 and 4.3 respectively). 
5.5 Cell culture 
The cell lines (Mia PaCa-2, Panc-1, BxPc-3 and Hs766T) were grown as described in 
2.1. When sufficient number of cells were obtained the cells were centrifuged as above 
and resuspended in serum-free DMEM at a cell density of 2.5 x 107 cells per 1.0 ml. 
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5.5.1 Xenografting of human pancreatic cancer cell lines 
The vial containing the cells was wiped with virkon before passing into the isolator. 
Prior to injecting the cells the mice were randomly grouped into cages of 3.0.2 ml of 
the cells (5 X 106 cells) were injected subcutaneously into the left flank of the male CD- 1 
nude mice and CB-17 SCID mice using a 19 gauge needle. Each mouse was 
individually marked for identification purposes. The tumour was allowed to grow to a 
maximum of 10% of the mouse body mass. 
5.5.2 Agonist and Antagonist studies 
The Mia PaCa-2 ceUs were cultured and injected on day 0 into male CD-1 nude mice as 
described in section 5.5.1. On day 15 the presence of palpable and visible tumours 
(approximately 2 mm x2 mm) was determined. The mice were weighed every 
fortnight from this point onwards to the end of the study. All drugs were injected 
subcutaneously into the scruff of the neck in 0.1 ml of the appropriate vehicle. The 
mice were injected on a daily basis with appropriate doses of sCCK-8, nsG-17 (15 
gg/kg, 30 gg/kg and 100 gg/kg), or 1 mg/kg of the various antagonists, 20 mg/kg of 
IB93182 or vehicle controls. The mice were treated for 49 days and then sacrificed on 
day 64. 
5.5.3 Autopsy procedures and sample collection 
71be pancreatic tumours and spleens were removed carefully, trimmed of adhering fatty 
tissue and weighed. A specimen of the tumour was stored in 10% formalin and the 
remaining tumour and whole spleen were snap frozen and stored in liquid nitrogen. 
Each mouse was macroscopically examined for any visible abnormalities as well as any 
metastasis to the abdomen, lungs and axilla. 
5.5.4 Determination of protein and DNA content 
The tumour specimens from the agonist/antagonist studies were divided in two for 
storage in liquid nitrogen. Approximately 300 mg of tumour was used for DNA 
extraction and the remainder used for protein extraction. The DNA and protein contents 
were determined as described in sections 5.3 and 3.3 respectively. 
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6.1 Protein kinase PCR 
All buffers, kits, chemicals and solutions used are referred to in appendix 1, p288-290. 
PCR was performed on 2.0 gI of the first strand cDNA synthesised from total RNA 
extracted from 2 human pancreatic cancers, PTI and PT3 as described in 4.1.3 and 
4.1.5. Each 100 gI amplification reaction contained :- 200 4M of each dATP, dCTP, 
dGTP and dTTP (Gibco BRQ; 20 pM of each primer PTKI and PTKII, 10 gI of lOx 
Taq reaction buffer and 2.0 units of DNA polymerase (Promega, U. K). The cDNA 
was amplified for 30 cycles using 90 see at 93*C (denaturation), 2 min at 45*C 
(annealing) and 4 min at 72*C (elongation). 
6.2 Gel electrophoresis of the PCR product 
The PCR products were electrophoresed on a 1.8% low melting point agarose gel (15 x 
13 cm) containing 0.1 gg/ml ethidium bromide. The samples were loaded into each 
well along with 0.5 gg of I kb, DNA molecular weight markers (Gibco BRL) and 
electrophoresed at 70 volts for approximately I hr. The DNA was visualised under UV 
light. 
6.3 Phenol/chloroform purification of the PCR product 
The PCR product (220 base pairs) was excised from the gel using a sharp blade and 
placed in a preweighed eppendorf tube. The excised gel weight was determined and 
then melted at 70*C. To the melted agarose, 10% of the total volume of lOx TNE was 
added. The agarose was extracted with equal volume of water saturated phenol (BDH), 
vortexed and microfuged at 6000 xg for 2 min. The upper aqueous layer was 
transferred to a fresh eppendorf tube and the remaining bottom organic layer was re- 
extracted with an equal volume of lx TNE. The phenol phase was discarded. The 
upper layer was pooled into the clean eppendorf following microcentrifugation and 
extracted with an equal volume of phenol/chloroform, vortexed and microfuged as 
above. The upper aqueous layer was extracted with an equal volume of chloroform 
(BDH), vortexed and microfuged at 6000 xg for 2 min. The lower organic layer was 
removed and discarded. To the remaining aqueous layer 2.5x volumes of 100% 
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ethanol was added and the sample stored at -20*C for 30 min followed by a 15 min 
centrifugation at 6000 x g. The supernatant was decanted and the pellet washed in 70% 
ethanol. The washed pellet containing the 220 bp PCR fragment was air-dried and 
dissolved in 35 pI of sterile water. 
6.4 Enzyme restriction of the purified PCR products 
The 220 bp PCR fragment was digested by the enzymes ECoRl (Gibco-BRL) and 
XhOl (Gibco-BRL) as follows: 35 gI of DNA (clean PCR product from above), 4 gI 
of enzyme restriction buffer D, 1 unit of ECoRI and 2 units of XhOl. The digestion 
was carried out at 37*C for 2 hr. The digested product was electrophoresed on a 1.8% 
agarose gel (15 x 13 cm) as in 6.2. 
6.5 Gel purification of the digested PCR product 
Ile digest was purified using the Qiaex H kit (4.1.8) and dissolved in a final volume of 
20 gl. The concentration and purity of the DNA in suspension was calculated having 
measured the OD at UV wavelength 260 nm (4.1.10). 
6.6 Ligation of enzyme- restricted PCR products into phage 
vector 
The digest was ligated into the phage vector using the ZAP expressTM predigested 
vector kit from Stratagene. The ligation reaction was set up in a final volume of 20 gl 
as follows; 1 gg (1 gl) of phage arms, 15 pI of diluted insert (DNA from above), 2 41 
of lOx ligase buffer and 8 units of T4 DNA ligase (I gl). The ligation was carried out 
on ice overnight. 
6.7 Packaging of ligated DNA into lambda vector 
Packaging of ligated DNA was performed using the Packagene lambda DNA packaging 
system from Promega. The packagene extract (50 gl) was thawed on ice and 0.5 gg 
(10 gl) of the ligated DNA fragment added. This extract was mixed by gentle tapping 
of the eppendorf and then incubated at room temperature (22*C) for 3 hr. Following 
this, phage buffer (445 [11) and chloroform (25 gl) was added to the 60 gl packaging 
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mix and gently agitated allowing the chloroform to settle at the bottom of the eppendorf 
tube. The packaged phage was now stored at 40C if not used immediately. 
6.8 Preparation of bacterial culture for Infection 
E. Coli cells (XLI) were grown overnight at 37*C in NZY broth containing 0.2% 
maltose and 10 mM magnesium sulphate. The following day OD readings at 600 nm 
wavelength were measured against water. The required OD of 0.5 was obtained by 
altering the density of the bacterial cells in 10 mM magnesium sulphate (i. e. cells were 
pelleted and resuspended in an appropriate volume of 10 mM magnesium sulphate). 
6.9 Titration of the packaged phage on NZY plates 
200 gI of the above diluted bacterial cells were incubated with i) 2 gl and ii) 10 gl of 
the packaged phage stock at 37*C for 15 min. Meanwhile NZY agar plates were placed 
in a 37*C oven to pre-warm and top agar was melted in a microwave and incubated at 
48*C once molten. To 3 ml of the top agar 15 gl of 0.5 M IPTG and 50 gI of 250 
mg/mI X-gal was added. This was rapidly added to the cocktail of bacterial cells and 
packaged phage following the 15 min incubation and then mixed and poured onto the 
NZY agar plates. The agar was allowed to set at room temperature and the plates were 
incubated at 37*C overnight. The following day the plaques were counted. (NB. If no 
plaques were obtained then further titrations of the packaged phage would have to be 
carried out until plaques were formed). 
Day 1: Once a sufficient number of plaques were obtained, they were cored out from 
the NZY agar plates with the aid of a Pasteur pipette and transferred into 500 gl of SM 
buffer containing 20 gl of chloroform. This extract was vibrated for 2 hr (allowing the 
phage to diffuse into the solution) resulting in the phage stock. The XL1 bacterial cells 
were grown overnight in NZY broth at 30*C. 
Day 2: Following the overnight incubation, the XLI cells were diluted 1: 50 and grown 
for a further 4 hr in NZY broth containing 10 mM magnesium sulphate and 0.2% (w/v) 
maltose at 37*C. They were then resuspended in 10 mM magnesium sulphate to give 
148 
an OD of 1.0. To 200 gI of these XLI cells I jil of EXAssist helper phage and 250 91 
of the phage stock was added. This cocktail was incubated at 370C for 15 min and 
transferred to 3 ml NZY broth followed by an overnight incubation in a shaker at 37*C. 
NZY agar plates containing kanamycin at a concentration of 50 mg/I were prepared for 
the following day. XLOLR (Exo1i strain) bacterial cells were also grown overnight at 
37*C in NZY broth for use the following day. 
Day 3: The overnight culture of XLOLR cells was diluted 1: 100 into NZY broth and 
grown for a further 4 hr at 37*C in a shaker The cultures containing the phage stock 
were treated at 70*C for 15 min then centrifuged at 4000 xg for 15 min. The 
supernatant containing the filamentous phage stock was transferred to a fresh tube and 
stored at 4*C until used. 4 hr later the XLOLR cells were pelleted and resuspended to 
an OD of 1.0 in NZY broth. 200 gI of the resuspended XLOLR cells were transferred 
into eppendorfs to which 5 til of the filamentous phage stock was added. The cocktail 
was incubated at 37*C for 15 min and spread onto NZY plates containing kanamycin. 
The plates were incubated overnight at 37*C in a humid incubator. 
Day 4: A colony was selected from each plate and grown overnight in NZY broth 
containing kanamycin at 37*C in a shaken 
Day 5: Following the overnight growth DNA was extracted from the cultures by the 
mini-preparation method and sequenced as in sections 4.2.3 and 4.3 respectively. Once 
the sequence of each kinase extracted was determined bacterial stocks were prepared for 
each different kinase. 
6.10 Freezing of bacterial stocks 
1.0 ml of bacterial culture with the appropriate kinase DNA insert was centrifuged at 
1300 xg for 2 min. The resultant supernatant was discarded and the pellet resuspended 
in 1.5 ml of 50% glycerol (Sigma) in NZY broth. The stock was stored at -70*C for 
use at a later date. 
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6.11 Determination of isolated protein kinases in human 
pancreatic cancers and cell lines. 
6.11.1 Protein kinase PCR 
Total RNA was extracted from 4 human pancreatic specimens (PT1, PT2, PT3 and 
PT4), 3 normal pancreas tissues (PN I, PN2 and PN3) and 4 human pancreatic cancer 
cell lines (Mia PaCa-2, Capan-1, Hs766T and BxPc-3) as mentioned in sections 4.1.3 
and 4.1.2 respectively. First strand cDNA was reverse-transcribed as in section 4.1.5 
using 0.1 gg of oligo dT'IT rather than random hexamers. 
The kinase PCR was carried out as in section 6.1 in a final volume of 20 gI using I gl 
of the prepared cDNA. To 20 gl of the PCR product 3.3 gl of DNA loading buffer was 
added and the sample electrophoresed on a 1.8% agarose gel at 70 volts for 
approximately I hr. The band corresponding to the 220 bp PCR product was cut out 
and cleaned using the Qiaex II kit (4.1.8). The DNA was eluted into a final volume of 
18 gl. 
6.11.2 Synthesis of 3 2p labelled DNA probe 
6 gI of the cleaned PCR product DNA from above was denatured at 99*C for 10 min 
mixed with 5 gI of OLB (5x) and 5 gl of sterile ddH20 and rapidly placed on ice for 2 
min. 1 gI of 10 mg/mI bovine serum albumin (BSA), 1 unit of Klenow and 20 gCi of 
a32P-dCTP (DuPont) was added to the denatured DNA, vortexed briefly, centrifuged 
and incubated at room temperature for I hr. The DNA was denatured again after the 1 
hr incubation at 99*C for 2 min, rapidly placed on ice and held for 2 min followed by 
the addition of I unit of Klenow. The mixture was briefly vortexed, centrifuged and 
incubated for a further 1 hr at room temperature. The labelling reaction was tenninated 
by the addition of 70 W of sterile water. 
The unincorporated nucleoddes were removed by passing the labelled reaction through 
sephadex G50. This was carried out by centrifuging I ml of sephadex G50 in spin-X 
centrifuge filter columns (Costar) at 6000 xg for 30 sec. The eluate was discarded and 
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the step above repeated with a further 500 gl of sephadex G50. The labelled reaction 
was applied to the sephadex G50 and the sample centrifuged at 6000 xg for 30 sec. 
The upper filter unit containing the sephadex plus unincorporated nucleotides was 
disposed of appropriately and the eluate containing the radioactive probe stored at -70*C 
(if not used immediately). 
6.11.3 Dot blotting of DNA 
A dot blot with the DNA from each kinase elucidated was set up using a hybrid dot 
manifold apparatus (Bethesda research Labs, USA). Some preliminary work was 
required prior to the manifold assembly. Pieces of 3MM Whatman filter paper and 
nylon membrane (BDH) were cut to the size of the manifold. The filter paper and 
membrane were immersed in 6x SSC for 10 min and then placed onto the bottom plate 
of the manifold with the nylon membrane on top of the filter paper. The top plate of the 
manifold was placed ontop of the nylon membrane and assembled according to the 
manufacturers instructions to ensure it was air-tight. 200 gl of 6x SSC was added to 5 
gg of DNA and the samples denatured at 100*C for 10 min then placed on ice 
immediately. The suction to the manifold device was applied and 500 gI of 6x SSC 
pipetted into each well used (unused wells were blocked with masking tape). The DNA 
samples were microcentrifuged and applied to the wells in the top plate without 
touching the nylon membrane. On completion of filtration, the apparatus was 
dismantled and the membrane placed on a 3MM Whatman paper presoaked in 
denaturation buffer for 10 min. The membrane was then transferred to a 3MM 
Whatman paper presoaked in neutralisation buffer for 5 min. The membrane was dried 
on 3MM Whatman filter paper and DNA immobilised by irradiating at 1200 Joules for 
1 min in a UV transilluminaton The membrane was stored dry between sheets of 
3MM Whatman filter paper at room temperature. 
6.11.4 Hybridisation of DNA dot blots 
The membrane carrying the immobilised DNA was presoaked in 6x SSC for 5 min then 
transferred to a plastic bag with hybridisation buffer and sealed (ensuring that all air 
bubbles were removed). The pre-hybridisation was carried out at 42*C for 2 hr. The 
radioactive DNA probe was then denatured at 99*C for 2 min, held on ice for 2 min and 
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added to the membrane by snipping a comer of the bag and introducing the probe by 
pipette. Any air bubbles were removed and the bag resealed. The membrane was 
incubated overnight (18 hr, 42*Q in a shaking water bath and then was removed from 
the bag and washed twice in 2x SSC for 10 min at room temperature with agitation. 
The blot was then rinsed in 2x SSC and washed in a solution consisting of 0.1% SDS 
and 0.2% SSC twice for I hr each at 42*C in a shaking water bath. Following these 
washing stages, the blot was Saran wrapped and exposed to Kodak film overnight at 
-70*C. 
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CHAPTER 7 
CHARACTERISATION OF CHOLECYSTOKININ RECEPTORS AND 
THEIR GROWTH RESPONSE IN ESTABLISHED HUMAN 




Pancreatic cancer is one of the most lethal cancers in the Western world with only 10- 
20% being resectable at diagnosis (Silverberg et al., 1990) and the present alternative 
treatments are ineffective. This poor prognosis has stimulated research scientists to 
develop other approaches to combat the problem, including the possible role of 
hormones such as cholecystokinin in pancreatic cancer growth. 
7.2 Aims 
The aims of this study were i) to investigate the effect of gastrointestinal hormones, 
sCCK-8 and nsG-17 on the growth of established human pancreatic cancer cell lines; ii) 
to determine the CCK-R status in the cell lines using well developed molecular 
techniques and radioligand binding assays; iii) to evaluate the effects of novel specific 
CCK-R antagonists on the growth of the human pancreatic cancer cell lines. 
7.3 Effects of sCCK-8 and nsG-17 on the growth of two human 
pancreatic cancer cell lines in vitro 
7.3.1 Methods 
The methods are described in section 2.5 for Mia PaCa-2 and BxPc-3 cells. The cells 
were plated out in serum and allowed to reach log phase of growth. Following this, the 
cells were exposed to serum-free conditions in order to reach a quiescent stage before 
stimulating with the peptide agonists. The cells were counted every 48 hr for a period 
of 10 days. 
7.3.2 Results 
7.3.2.1 Mia PaCa-2 
Figures 7.1 and 7.2 show that there was no significant growth response to either 
varying concentrations of sCCK-8 or nsG-17 in the Mia PaCa-2 cells respectively. P 
values ranged from a minimum of 0.11 at day 2 of incubation with 10 pM and 0.72 at 
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day 8 of incubation with 100 nM sCCK-8. P values obtained with varying 
concentrations of nsG-17 ranged from a minimum of 0.08 at 10 pM on day 2 and a 
maximum of 1.0 at 100 nM on day 10 of incubation. Figures UF and 7.2F show that 
the cells had reached a quiescent stage in growth in serum-free medium whereas tissue 
culture medium supplemented with 10% foetal calf serum maintained the increase in 
growth of these cells (P<0.02 from day 2 onwards). 
7.3.2.2 BxPc-3 
Figures 7.3 and 7.4 show that the cells did not respond to either CCK-R agonists 
sCCK-8 ornsG-17 respectively. P values ranged from aminimum of 0.15 at day 8 of 
incubation with 10 nM and 1.0 at day 2 of incubation with 10 pM sCCK-8. P values 
obtained with varying concentrations of nsG-17 ranged from a minimum of 0.04 at 100 
pM on day 6 and a maximum of 1.0 at 100 nM on day 8 of incubation. Figures 7.3F 
and 7AF show that the cells had reached quiescence in serum-free medium. 10% foetal 
calf serum stimulated the growth of the BxPc-3 cells, during the growth assay. 
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Figure 7.1 Effects of sCCK-8 on growth of Mia PaCa-2 cells in culture. Cells 
were grown in the absence (0), presence of various concentrations of sCCK-8 (10 
pM-100 nM, A-E) in serum-free DMEM (0) or 10% foetal calf serum in DMEM (F, 0) 
for 10 days. Figure F is on a different scale to A-E. Each point represents the mean ± 
s. e. for each group. Three wells of cells were tested for each concentration and each 
experiment was performed six times (n=18/treatment group). sCCK-8 had no effect on 
growth of Mia PaCa-2 cells. 
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Figure 7.2 Effects of nsG-17 on growth of Mia PaCa-2 cells in culture. Cells were 
grown in the absence (0), presence of various concentrations of nsG-17 (10 pM-100 
nM, A-E) in serum-free DMEM (0) or 10% foetal calf serum in DMEM (F, 0) for 10 
days. Figure F is on a different scale to A-E. Each point represents the mean ± s. e. for 
each group. Three wells of cells were tested for each concentration and each 
experiment was performed six times (n=18/treatment group). nsG-17 had no effect on 
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Figure 7.3 Effects of sCCK-8 on growth of BxPc-3 cells in culture. Cells were 
grown in the absence (0), presence of various concentrations of SCCK-8 (10 pM-100 
nM, A-E) in serum-free RPMI (0) or 10% foetal calf serum in RPMI (F, 0) for 10 
days. Figure F is on a different scale to A-E. Each point represents the mean ± s. e. for 
each group. Three wells of cells were tested for each concentration and each 
experiment was performed six times (n=18/treatment group). sCCK-8 had no effect on 
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Figure 7.4 Effects of nsG-17 on growth of BxPc-3 cells in culture. Cells were 
grown in the absence (0), presence of various concentrations of nsG-17 (10 pM-100 
nM) in serum-free RPMI (0) or 10% foetal calf serum in RPMl (F, 0) for 10 days. 
Figure F is on a different scale to A-E. Each point represents the mean + s. e. for each 
group. Three wells of cells were tested for each concentration and each experiment was 
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7.4 Effect of sCCK-8 and nsG-17 on the growth of 
NIH3T3CCK-BR cells in vitro 
7.4.1 Methods 
The methods are described in section 2.7. The cells were plated out in serum-free 
medium in the presence of the agonists and counted every 48 hr for 10 days. 
7.4.2 Results 
7.4.2.1 NIH3T3CCK-BR cells 
The NIH3T3CCK-BR cells were kindly donated by Dr. Matsui in Japan. These cells 
are mouse fibroblasts transfected with human CCK-BR. Figures 7.5 and 7.6 show 
that both sCCK-8 and nsG-17 significantly promoted the growth of NIH3T3CCK-BR 
cells in serum-free medium, respectively. sCCK-8 significantly induced growth 
responses at 1,10 and 100 nM concentrations. P values varied from a minimum of 
<0.005 to a maximum value of 0.05. nsG-17 induced significant growth responses at 
concentrations of 1,10 and 100 nM. Significant P values varied from a minimum of 
<0.005 to a maximum value of 0.013. The EC50 values for sCCK-8 and nsG-17 were 
calculated as 6.0 ± 1.3 nM and 5.1 ± 1.6 nM (n=18), respectively. Figure 7.5F shows 
that the cells had reached quiescence in serum-free medium and that the cell growth was 
maintained in 10% bovine calf serum during the assay (P < 0.005). 
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Figure 7.5 Effects of sCCK-8 on growth of NIH3T3CCK-BR cells in culture. 
Cells were grown in the absence (0), presence of various concentrations of sCCK-8 
(10 pM-100 nM, A-E) in serum-free DMEM (0) or 10% bovine calf serum in DMEM 
(F, 0) for 10 days. Figure F is on a different scale to A-E. Each point represents the 
mean ± s. e. for each group. Tbree wells of cells were tested for each concentration and 
each experiment was performed six times (n=18/treatment group). sCCK-8 stimulated 
the growth of NIH3T3CCK-BR cells. 
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Figure 7.6 Effects of nsG-17 on growth of NIH3T3CCK-BR cells in culture. 
Cells were grown in the absence (0), presence of various concentrations of nsG-17 
(10 pM-100 nM, A-E) in serum-free DMEM (0) or 10% bovine calf serum in DMEM 
(F, *) for 10 days. Figure F is on a different scale to A-E. Each point represents the 
mean ± s. e. for each group. Three wells of cells were tested for each concentration and 
each experiment was performed six times (n=18/treatment group). nsG-17 stimulated 
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7.5 Effects of CCK-R antagonists on the growth of two human 
pancreatic cancer cell lines in vitro 
7.5.1 Methods 
The methods are described in section 2.6 for Mia PaCa-2 and BxPc-3 cells. The cells 
were plated out in serum and allowed to reach log phase of growth. Following this the 
cells were either grown in 10% foetal calf serum or in serum-free conditions in order to 
reach a quiescent stage before incubating with the various CCK-R specific antagonists. 
The cells were counted on day 6. 
7.5.2 Results 
7.5.2.1 Mia PaCa-2 
Figures 7.7 show that the various CCK-R antagonists had no significant effect on the 
serum maintained growth of Mia PaCa-2 (P > 0.22). The antagonists also had no 
effect on the cells in culture in serum-free medium as shown in Figures 7.8 (P > 0.12). 
7.5.2.2 BxPc-3 
Figures 7.9 show that the various CCK-R antagonists had no significant effect on the 
serum maintained growth of BxPc-3 cells (P > 0.40). The antagonists also had no 
effect on the cells in culture in serum-free medium as shown in Figures 7.10 (P > 
0.35). 
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Figure 7.7 Effects of CCK-R antagonists on growth of Mia PaCa-2 cells in culture. 
Cells were grown in the presence of various concentrations of antagonists (I nM-10 
gM) in DMEM containing 10% foetal calf serum for 6 days when they were counted. 
Each point represents the mean ± s. e. for each group. Two wells of cells were tested 
for each concentration and each experiment was performed six times (n=12/treatment 
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Figure 7.8 Effects of CCK-R antagonists on growth of Mia PaCa-2 cells in culture. 
Cells were grown in the presence of various concentrations of antagonists (I nM-10 
gM) in serum-free DMEM for 6 days when they were counted. Each point represents 
the mean ± s. e. for each group. Two wells of cells were tested for each concentration 
and each experiment was performed six times (n=12/treatment group). CCK-R 
antagonists had no effect on the growth of Mia PaCa-2 cells in serum-free medium. 
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Figure 7.9 Effects of CCK-R antagonists on growth of BxPc-3 cells in culture. 
Cells were grown in the presence of various concentrations of antagonists (1 nM-10 
gM) in RPMI containing 10% foetal calf serum for 6 days when they were counted. 
Each point represents the mean ± s. e. for each group. Two wells of cells were tested 
for each concentration and each experiment was performed six times (n=12/treatment 
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Figure 7.10 Effects of CCK-R antagonists on growth of BxPc-3 cells in culture. 
Cells were grown in the presence of various concentrations of antagonists (1 nM-10 
gM) in serum-free RPMI for 6 days when they were counted. Each point represents 
the mean ± s. e. for each group. Two wells of cells were tested for each concentration 
and each experiment was performed six times (n=12/treatment group). CCK-R 






























-log M antagonist 
10 
987654 
-log M antagonist 
178 
7.6 Effects CCK-AR and CCK-BR antagonists on the sCCK-8 
induced growth response in NIH3T3CCK-BR cells. 
7.6.1 Methods 
The methods are described in section 2.8. The cells were incubated with 100 nM 
sCCK-8 in the presence or absence of the various CCK-R specific antagonists and 
counted on day 8. 
7.6.2 Results 
Figure 7.11 shows the inhibitory effects of the CCK-R antagonists on the sCCK-8 
induced growth response in the NIH3T3CCK-BR cells. The most potent antagonist 
was shown to be RPR-X followed by L-740,093 > Cl 988 > L-365,260 as shown in 
Table 7.1. These 4 CCK-BR antagonist produced significant inhibition at all three 
concentrations (I pM, 100 pM and 10 nM) used (P<0.005). The CCK-AR 
antagonists, L-364,718 and CR 1409 only produced a significant inhibition of the 
sCCK-8 induced growth response at the higher concentrations of 100 pM and 10 nM 
(P<0.005). 
Antagonist CCK-R Ics 0 sem n 
Type (nM) 
L-364,718 CCK-A >10 12 
CR 1409 CCK-A >10 - 12 
L-365,260 CCK-B 5.7 1 11 
C1988 CCK-B 4 0.8 11 
L-740,093 CCK-B 3.3 0.8 12 
RPR-X CCK-B 0.03 0.008 12 
Table 7.1 Comparison of the affinities of the CCK-R antagonists for human CCK- 
BR in NIH3T3CCK-BR cells. RPR-X (ICSO 0.03 nM) was the most potent antagonist 
of sCCK-8 stimulated growth of NIH3T3CCK-BR cells. 
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The degree of inhibition by the CCK-AR antagonists was much lower than the specific 
CCK-BR antagonists, resulting in ICSO values >10 nM. 10 nM of L-364,718 and CR 
1409 inhibited the sCCK-8 response by a maximum of 28.8 ± 1.2% and 12.4 ± 1.0% 
respectively. 
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Figure 7.11 Effects of CCK-R antagonists on sCCK-8 stimulated growth of 
NIH3T3CCK-BR cells in culture. Cells were grown in the presence of various 
concentrations of antagonists (I pM, 100 pM and 10 nM) in DMEM containing 100 nM 
sCCK-8 for 8 days. Each point represents the mean ± s. e. for each group. Two wells 
of cells were tested for each concentration and each experiment was performed six 
times (n=12/treatment group). CCK-R antagonists inhibited sCCK-8-stimulated 
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7.7 Radioligand binding studies in Mia PaCa-2 and 
NIH3T3CCK-BR cells 
7.7.1 Methods 
The methods are described in section 4.5. Whole cells were incubated for 150 min 
with the CCK-BR antagonist, [3H]-PD140,376. The bound radioactivity was 
determined by counting in a Beckman LS6500 liquid scintillation counter. Total and 
non-specific binding were defined in the absence and presence of L-365,260 
respectively. 
7.7.2 Results 
7.7.2.1 Mia PaCa-2 and NIH3T3CCK-BR cells 
The CCK-BR antagonist bound to both cell types (Figure 7.12A and B). The total and 
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Figure 7.12 Total (0) and non-specific binding (0) of [3H]-PD140,376 to 
NH13T3CCK-BR and Mia PaCa-2 cells. Each point represents one experiment carried 
out in triplicate. Total and non-specific binding of [3H]-PD140,376 increased with an 
increase in cell number. 
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The binding of [3H]-PD140,376 increased linearly upto 3x 107 Mia PaCa-2 cells and 3 
X 106 NIH3T3CCK-BR cells (Figure 7.13). The NIH3T3CCK-BR cells have 
approximately 12.5 fold more CCK-BR than the Mia PaCa-2 cells, assuming that the 
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Figure 7.13 Graph comparing the linearity of [3H]-PD140,376 binding to Mia PaCa- 
2 (0) and NIH3T3CCK-BR cells (40). Each point represents one experiment carried 
out in triplicate. The binding of [3H]-PD140,376 increased linearly with cell number 
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7.8 Molecular studies to determine CCK-R status In human 
pancreatic cancer cell lines 
7.8.1 Methods 
7.8.1.1 RT-PCR 
The methods are described in section 4.1. Total RNA was extracted from all the cell 
lines grown and reverse-transcribed into cDNA. The cDNA was amplified using the 
CCK-R specific primers using PCR and the amplified products subjected to agarose gel 
electrophoresis. 
7.8.2 Results 
The two sets of gene specific primers were effective in amplifying either a 340 bp 
fragment exclusively from the CCK-AR or a 430 bp fragment exclusively from the 
CCK-BR. Comparison of sequencing studies with published data (de Weerth et al., 
1993a and Pisegna etal., 1992a) confirmed that the amplified PCR products were 
fragments of the CCK-A and CCK-B/gastrin receptor gene. 
The RT-PCR showed the expression of both CCK-A and CCK-B/gastrin receptors in 
all 8 pancreatic turnour cell lines investigated (Capan- 1, AsPc- 1, BxPc-3, Hs766T, Mia 
PaCa-2, Panc-1, KPan, Capan-2) as shown in Figure 7.14. AT cell lymphoma cell 
line which is known to express both CCK receptor types was utilised as a positive 
control. 
7.8.3 Methods 
7.8.3.1 RNase protection assay 
The methods are described in section 4.4. Total RNA from each cell line and positive 
control was hybridised with the radioactively labelled CCK-AR or CCK-BR probe 
overnight. The unhybridised RNA (single stranded) was digested with RNase and the 
remaining product electrophoresed on a polyacrylamide gel. The gel was exposed to 
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Figure 7.14 Agarose gel electrophoresis ofCCK-AR and CCK-BR RT-11CR products 
In 8 hUman pancreatic cancer cell lines. 
The size of the amplified products were 340 bp and 430 bp for the CCK-A (labelled as 
A) and CCK-B/, YastrIn (labelled its B) receptor fragments, respectively. A T-cell 
lyniphorna cell line was used as a positive control in this assay. 
Lanes I A, I B: Capan- I -, 2A, 213: AsPc- 1', 3A, 313: BxPc-3,4A. 413: 1 ls760T; 5A, 513: 
Mia PaCa-2; 6A. 613: Panc- 1,7A. 7B: KPan-, 8A, 8B: Capan-2,9A, 913: T-cell line" III: 
molecular markers. 
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7.8.4, Results 
The RNase protection assay revealed a clear band of the expected size for both the 
protected CCK-A (340 bp) and CCK-B/gastrin (430 bp) receptor mRNA from human 
gall bladder and stomach mucosa rcspectively. The expression of both CCK-A and 
CCK-B/gastrin receptors utilising 50 gg of total RNA was undetectable in all the 
pancreatic tumour cell lines investigated as shown in Figure 7.15 and 7.16. 
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Figure 7.15 A1.1toradiography of a Vl,, PAGE gel following the RNP assay. 
The CCK-AR mRNA was not detected in 7 human pancreatic tumour cell lines but was 
present in human -all bladder (lanc 1). 
Thesizes of the full length probe and protected CCK-AR fragment were 530 hp all(] 340 
bp respectively. H1.1111,111 gall bladder (lane 1) Was Used as Positive COIIII-01 for the CCK- 
A receptor. 
Lanes 1: positive control, 2: Capan- 1; 3: AsPc- 1,4: BxPc-3: 5: Il. "766T, 6: Mia PaCa- 
2,7: Panc- I -, 8: KPan, m: molecular markers. The protected were resolved 












Figure 7.16 Autoradiography ofa 6% PAGE gel following the RNP assMl. 
The CCK-BR mRNA was not detected in 7 huniall pancreatic tLI111OL11- Cell IIIICS hLit Was 
present in human stomach mucosa (lane I). 
The sizes of tile full len-th probe and protected CCK-BR fragment were 620 hp and 430 
bp respectively. Human stomach mucosa (lane I) was used as positive control for tile 
CCK-B receptor. 
Lanes 1: positive control-, 2: Capan-I -, 3: AsPc-I -, 4: BxPc-3-, 5: 1-Is760T-, 6: Mia PaCa-2, 
7: Panc- I -, 8: KPan, m: molecular markers. The protected fragriiients were resolved oil a 
6% polyacrylamide gel at 55W for 5 hrs in Ix TBE bLit't'ci*. 
189 
7.9 Discussion 
The 7 human pancreatic cancer cell lines (Capan-1, AsPc-l, BxPc-3, Hs766T, Mia 
PaCa-2, Panc-1, KPan) expressed both CCK-A and CCK-B receptors as detected by 
RT-PCR. However, the RNase protection assay (utilising 50 Ag of RNA) was not 
sufficiently sensitive to detect the levels of CCK-R expression. Demonstration of 
receptor mRNA by RT-PCR alone does not always reflect the presence of functional 
receptor proteins in the cell membrane, since theoretically only one molecule of mRNA 
is needed for detection by RT-PCR. The RNP assay is the most sensitive quantitative 
method known to date to detect low levels of message expression. 
The NIH3T3CCK-BR cells were originally used to study CCK-BR signalling 
transduction pathways by Dr. Matsui (see Taniguchi et at., 1994). Thus, these mouse 
fibroblasts have been artificially transfected with a high proportion of the human CCK- 
BR. The CCK-B receptor was detected by RT-PCR as well as by RNP assay in the 
NlH3T3CCK-BR cells. Furthermore, the radioligand binding assay, with the CCK- 
BR antagonist [3H]-PD140,376 showed the NIH3T3CCK-BR cells to have 
approximately 12.5 fold more CCK-BR than the Mia PaCa-2 cells. This 12.5 fold 
difference may be a critical difference in the sensitivity limit of the RNP assay. Thus 
from the molecular (see Figure 9.4 in Chapter 9) and binding studies in NIH3T3CCK- 
BR cells, one can assume that RNP is indicative of a certain density of functional 
receptors that can result in a biological response. Moreover, the cell lines Mia PaCa-2 
and BxPc-3 were unresponsive to both sCCK-8 and nsG-17 in proliferation studies in 
vitro. This finding can best be explained by the lack of sufficient CCK-A or CCK- 
B/gastrin receptors (as indicated by RNP assay) to elicit a trophic response. 
In vitro published studies on the trophic effects of exogenous CCK have given rise to 
conflicting results. Studies on pancreatic tumour cell lines show either stimulation, 
inhibition or no effect. Funakoshi & Kono, (1992) found that CCK stimulated growth 
of the human pancreatic cancer cell line KP- IN, while Morimoto et aL (1993) observed 
that CCK-8 increased the uptake of [3H]-thymidine in only one pancreatic tumour cell 
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line (PC-F3) out of five. Smith et al. (199 1) reported trophic responses to CCK-8 or 
CCK-9 analogs in the cell lines Mia PaCa-2, BxPc-3, Capan-2 and Panc-1. However, 
other experiments have shown no effect of these peptides on tumour cell growth in 
vitro and some studies have even shown inhibition (Morimoto et al., 1993; Liehr et al., 
1990; Nio et al., 1993). Liehr et al. (1990) observed no change in DNA, protein or 
cloning efficiency in Panc-I and Mia PaCa-2 cells after incubation with CCK-8 or a 
CCK-9 analog. Nio et al. (1993) observed an inhibitory effect in in vitro DNA 
synthesis by CCK-8 in 2 pancreatic cancer cell lines, PC-YY and PC-TI. Robertson 
etal. (1995), have also shown a lack of effect of G-17 on Mia PaCa-2 cell growth and 
this correlated with an absence of [125I]iodo tyrosyl G-17 binding sites. Our finding of 
very low expression of mRNA for both CCK receptor-types, indicating a low CCK-A 
and CCK-B/gastrin receptor population, are consistent with a poor trophic response in 
these cell lines to CCK or gastrin. 
Smith et al. (1995) have shown that gastrin- 17 had a proliferative effect on the 
pancreatic cancer cell lines, Panc- 1, BxPc-3, MDA-Panc-28 and MDA-Amp-7 and that 
the gastrin-induced proliferation was inhibited by L-365,260 (CCK-BR antagonist) and 
not L-364,718 (CCK-AR). As mentioned earlier we found a lack of response of BxPc- 
3 to nsG- 17 and sCCK-8 used at a range of concentrations. A possible explanation for 
the differential findings is that the cells in our laboratory are at a different passage 
number, hence displaying different characteristics. It has been found that receptors can 
be lost upon passaging of cell lines in vitro and in the passaging of xenografted 
turnours (Singh et al., 1991). However, no molecular or binding studies were carried 
out by this group in order to confirm the extent and presence of the receptors for 
comparison. 
CCK receptor binding studies in homogenised human pancreatic turnours-and tumour- 
derived cell lines have also given conflicting results (Singh et aL, 199 1; Smith et al., 
1993,1994). Smith and co-workers (1992) have reported a binding site of CCK in the 
nuclear fmction and minimal or no binding to the membranes of the Panc-1 cell line. 
However, further work on this same cell line from the same laboratory reported CCK- 
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R in the membrane fraction and not in the nucleus (Smith et A, 1994). Membrane- 
bound CCK-BR have also been reported in cell lines Mia PaCa-2, BxPc-3 and Capan- 
1, but no data have been published on CCK binding in whole cells by this group. 
Singh etaL (1991) found no CCK-R in whole Mia PaCa-2 cells using ligand binding 
assays. These conflicting results make it important to determine initially the receptor 
status of the cell lines being investigated using well developed techniques. 
Both sCCK-8 and nsG-17 induced the growth of NIH3T3CCK-BR cells in vitro. The 
agonists had equal affinity for the CCK-BR. It is well documented in published 
literature that both sulphated and non-sulphated analogues of cholecystokinin and 
gastrin have similar affinities for the CCK-BR (Saito etal., 1981). 
Comparison of the results between the various antagonists correlate well with published 
data (see Table 7.2). All the CCK-BR antagonists inhibited CCK-BR stimulated 
growth in the nanomolar range. The rank order of potency of the antagonists for the 
CCK-BR are in agreement with work carried out by Saito et al. (198 1), Woodruff & 
Hughes (1991), and Showell et al. (1994). The three groups measured the 
displacement of CCK-8 from the rat pancreas CCK-AR, and the mouse/guinea pig 
cortex CCK-BR. 
The CCK-AR specific antagonists L-364,718 (devazepide) and CR 1409 had IC50 
values greater than 10 nM. This result is not surprising as these antagonists are not 
known to act on CCK-BR at these concentrations. Woodruff and Hughes (1991) 
showed that the IC50 value of CR 1409 was greater than that of L-364,718 for the 
mouse cortex CCK-B binding sites, indicating that CR 1409 is less likely to bind to the 
CCK-BR than L-364,718.77his finding indirectly confirms our results since 10 nM of 
L-364,718 had a greater inhibitory effect on the sCCK-8 induced growth response than 
CR 1409. 
More importantly the results show that these CCK-BR antagonists are capable of 
inhibiting CCK-BR induced cell growth in vitro as shown in the NIH3T3CCK-BR 
cells. 
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Antagonist Rat pancreas Mouse cortex Reference 
(receptor-type) ICS 0 (nM) ICS 0 (nM) 
L-364J18 (A) 0.2 31 (>10) Woodruff & Hughes, 1991 
CR 1409 (A) 130 3x 105 (>10) Saito etal., 1981 
C1988 (B) 2717 1.7(4) Woodruff & Hughes, 1991 
L-365,260 (B) 240 5.2 (5.7) Woodruff & Hughes, 1991 
Rat pancreas Guinea pig cortex 
ICS 0 (nM) ICS 0 (nM) 
L-365ý260 (B) 736 8.5 (5.7) Showell et al., 1994 
L-740,093 (B) 1604 0.1 (3.3) Showell etal., 1994 
Table 7.2 Showing selective CCK-R antagonist receptor affinities. Values in 
brackets obtained in NIH3T3CCK-BR by Mandair et al., 1997. 
The CCK-R antagonists had no effect on the basal growth of the pancreatic cancer cell 
lines, Mia PaCa-2 or BxPc-3. These results indicate that the CCK-AR and CCK-BR 
are not involved in an autocrine manner in these cancer cells in vitro. Our molecular 
studies confirm this data and support the view that there are not enough CCK-R 
expressed in these cells to play a role in cell growth in vitro. 
Recently, Smith et al. (1996) have shown that the growth of the human pancreatic 
cancer cell line, BxPc-3 is tonically stimulated by the autocrine production of gastrin. 
They showed this by incubating the BxPc-3 cells in serum-free medium in the presence 
of L-365,260. The results obtained in our laboratory are contradictory to this finding. 
The concentration of the antagonist L-365,260 that significantly inhibited the growth of 
the BxPc-3 cells in serum-free medium by this group was 100 JIM. This concentration 
was toxic to the BxPc-3 cells in our laboratory. Thus, their results may be explained by 
the toxicity of the antagonist at these high concentrations. Another possible explanation 
(as mentioned previously) for the difference in results is that the cells in our laboratory 
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may be at a different passage number, hence displaying different characteristics. The 
BxPc-3 cells in serum-free medium had a doubling time of 3 days and 10 days 
respectively in Smith's laboratory and our laboratory which is indicative of differences 
in cell characteristics. It has also been shown that receptors can be lost upon passaging 
of cell lines in vitro and in the passaging of xenografted turnours, (Singh et al., 1991) 
which may also explain the differences in the results. 
In 1993, Morimoto and co-workers showed no effect of devazepide on the basal 
growth of the human pancreatic cancer cell line, PC-HN. Later Seva etal. (1994) 
reported the lack of effect of the CCK-BR antagonists, L-365,260 and PD-134308 on 
the basal proliferation of the rat pancreatic cancer cell line, AR42J. However autocrine 
growth regulation has been shown to be important in other human cancers such as 
colon cancer (Hoosein et al., 1990) and small cell lung cancer (Rehfeld et al., 1989). 
Ibis work highlights the importance of (1) characterisation of human pancreatic cancer 
cell lines irrespective of published data (2) pancreatic tumour cell lines as a poor model 
of the primary turnour. 
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CHAPTER 8 
K-RAS STATUS AND FAK PHOSPHORYLATION IN ESTABLISHED 




Cancer is a disease with many different kinds of genetic alterations which may evolve 
from'simple or more complex types and numbers of mutations within the same 
neoplastic cell (Aldaz et al., 1987, Bremner & Balmain, 1990). Among the most 
frequent genetic changes in human pancreatic cancer are point mutations of the K-ras 
proto-oncogene (K-ras, Smit et al., 1988; Grunewald et al., 1989; Lemoine et al., 
1992b). K-ras mutations occur in pancreatic cancer almost exclusively on codon 12 
(Almoguera et al., 1988) resulting in a constitutively active ras protein. There is 
increasing evidence that most GPCR such as the CCK-BR (Seva et al., 1996) feed 
through the ras protein upon activation. In late 1994, Taniguchi and co-workers 
reported that the stimulation of the CCK-BR expressed in transfected mouse fibroblasts 
(NIH3T3CCK-BR) resulted in the phosphorylation of a kinase called focal adhesion 
kinase (FAK). FAK phosphorylation is independent of ras but is thought to be 
dependent on another small G protein, rho (Secki et al., 1995). In view of this 
literature we investigated the effects of cholecystokinin and gastrin upon the 
phosphorylation of FAK, a more immediate event upon receptor stimulation, by- 
passing the effects of constitutively active ras. 
8.2 Aims 
The aims of this study were i) to determine the K-ras status in the established human 
pancreatic cancer cell lines; ii) to investigate the effect of sCCK-8 and nsG-17 on 
tyrosine phosphorylation of FAK in Mia PaCa-2 cells and iii) to determine the effects of 
various CCK-R antagonists on FAK tyrosine phosphorylation in Mia PaCa-2 cell line 
using the NIH3T3CCK-BR as a control. 
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The methods are described in section 4.6.4. Single strand conformation polymorphism 
(SSCP) was carried out by the amplification of K-ras exon 1 from genomic DNA from 
each cell line in the presence of a. [32P]deoxy-cytidine triphosphate. The amplified 
products were subjected to polyacrylamide gel electrophoresis. Autoradiography film 
was exposed to the gel overnight and developed. The PCR products of K-ras exons 1 
and 2 were cloned and sequenced as in methods section 4.6. Autoradiography film 
was exposed to the gel overnight and developed. 
8.3.2 Results 
The PCR of K- ras exon 1 and exon 2 resulted in fragments of 120 bp and 111 bp 
respectively, as shown in Figures 8.1 and 8.2. The SSCP data showed genetic 
variability in exon 1 of the K-ras gene in cell lines Capan-1, AsPc-l, Mia PaCa-2, 
Panc-1 and Kpan when compared with the normal pancreas (Figure 8.3). The cloning 
and sequencing results of the K- ras PCR products are summarised in Table 8.1. In 2 
of these cell lines, Capan-1 and Mia PaCa-2, there was a substitution from the wild 
type glycine to a valine in exon I at codon 12 as indicated by a base point mutation 
from guanine (G) to a thymine (T). The remaining 3 cell lines, AsPc-l, Panc-1 and 
KPan showed a substitution from glycine to aspartate due to a point mutation from 
guanine (G) to adenine (A). Figure 8.4 shows the various point mutations detected in 
K-ras exon I in the pancreatic cancer cell lines examined. There was no mutation 
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The PCR product was amplified from huniall pancreatic Cancer cell line "'C1101111C 
DNA. 
Lancs 1: Capan- I -, 2: AsPc-1.3: BxPc-3-, 4: Hs766T-, 5: Mia PaCa-2-, 6: Panc-l -, 7: 
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Figm-e 8.2 Agarose , el elect roplioresis ot'amplilicd K-no exon 2,111 hp product. 11 
The PCR product was amplified froin human Pancreatic cancer cell line oenomic 
DNA. 
Lanes 1: Capan- I -, 2: AsPc- I -, 3: BxPc-3-, 4: IJs766T-, 5: Mia PaCa-2,6: Panc- 1,7: 
KPan, in: molecular markers. 198 
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Figtire 8.3 Autoradio-raphy of 6% PAGE get with representative SSCP analysis 
ofexon I of K-ras gene in 7 human pancreatic tuniour cell lines. 
Lanes 1: Capan- 1,2: AsPc- 1,3: BxPc-3-, 4: Hs766T; 5: Mia PaCa-2; 6: Panc- I -, 7: 
KI"an, 8: 1101-111al human pancreas. 
Flectrophoresis conditions shown are 6% nondenaturing polyacrylarnide with 10% 
glycerol and 1.0 x TBE buffer at 4'C. 
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Figure 8.4 Sequences ofthe K-ras gene exon I in codon region I 1- 18 111 lit. 1111,111 
pancreatic cancer cell lines. 2 different types ot , 111LILItIO11S WCI-C dCtCCtCd. The 
scqLICIICC ofthe codon 12 wild type GGT (,, IYCITlC: Mltl'ill IMICS) %US 111LILItCd 10 I- 
GTT (valinc: left lanes) and GAT (aspartate: right lanes). The boxes enclose tile 
codon 12 triplet. 
Figure 8.5 Sequeilces of the K-ras gene exon 2'1 e 11) codoll 58-(14 in human 
Pancreatic cancer cell lines. Mutatiolls were undetected. Tl1C SC(ILICIICC 01' thC 
codon 61 wild type CAA (glutamme) Is silown. The box ciiclo,, c.,,, tile codon 01 
triplet. 2M 
K-ras 
Ibmour Passage Exon 1 Exon 2 
codon 12 codon 61 
Capan-l* Gjr CAA 
AsPc-l* GAT CAA 
BxPc-3 GGT CAA 
Hs766T GGT CAA 
Mia PaCa-2* G3: r CAA 
Panc-l* GAT CAA 
Kpan* GAT CAA 
Table 8.1 Summary of K-ras mutations in human pancreatic cancer cell lines. The 
point mutations in exon I at codon 12 are underlined. GGT. glycine, GAII. aspartate, 
GTIP: valine, CAA: glutamine. Five of these tumour cell lines* possess a point 
mutation in codon 12 of the K-ras gene. No mutations were found at codon 61. 
8.4 Effects of sCCK-8 and nsG-17 on FAK phosphorylation 
8.4.1 Methods 
The methods are described in Chapter 3. Mia PaCa-2 and NlH3T3CCK-BR cells were 
stimulated with either sCCK-8 or nsG- 17 (section 3.1), lysed (section 3.2) and FAK 
was immunoprecipitated and positive samples electrophoresed as described in sections 
3.3-3.7, transferred to a membrane and immunoblotted with appropriate antibodies 
(section 3.8-3-10). 
8.4.2 Results 
Phosphorylation studies showed tyrosine phosphorylation of the 125 kDa focal 
adhesion kinase (pl25FAK) in the NIH3T3CCK-BR cells (Figure 8.6). The 
phosphorylation was promoted by both 100 nM sCCK-8 and 100 nM nsG-17. 
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Figure 8.6 Immunoblot of 6.5% PAGE (Yel with FAK tyi-osine phospliol-viat (),, it, 
NIH3T3CCK-BR cells induced by sCCK-8 and nsG- 17. 
NIH3T3CCK-BR FAK immunoprecip'tates: Lanes 1+5: Lintreated-, 2+6: 100 ilM.,,,, CCK- 
8-, 3+7: 100 nM nsG-17,4+8: 10% bovine calf serum, 9: FAK control cell lysatc. 
Lanes 1-8 and 9 were 111111ILinoblotted with phosphotyrosme and FAK antibodies 
respectively. 
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In unstimulated NIH3T3CCK-BR cells the level of FAK phosphorylation was 
undetectable compared to the stimulated cells. In contrast Mia PaCa-2 cells 
constitutively expressed phosphorylated FAK. There was no increase in FAK 
phosphorylation by either nsG-17 or sCCK-8 at the various concentrations in serum- 
starved Mia PaCa-2 cells (Figure 8.7 and 8.8 respectively). Figure 8.9 shows an 
elevation in the basal level of phosphorylated FAK in Mia PaCa-2 cells compared with 
phosphorylated FAK in NIH3T3CCK-BR cells. 
8.5 Effects of CCK-R antagonists on elevated basal FAK 
phosphorylation levels in Mia PaCa-Z cells 
8.5.1 Methods 
The methods are described in Chapter 3. Mia PaCa-2 cells were incubated for 48 hr in 
medium with FCS containing CCK-R antagonists, followed by a 48 hr incubation in 
serum-free medium in the presence of the antagonists as described in section 3.1. The 
cells were lysed and FAK immunoprecipitated (sections 3.2-3.5). The 
immunoprecipitated samples were electrophoresed, transferred to a membrane and 
immunoblotted with appropriate antibodies as described in sections 3.6-3.10. The level 
of FAK phosphorylation in the presence of specific CCK-BR antagonists was 
determined. The CCK-BR antagonists were chosen due to their inhibitory effect on 
sCCK-8 induced growth responses in NIH3T3CCK-BR described in chapter 7. 
8.5.2 Results 
The CCK-BR antagonists, RPR-X, L-740,093, L-365,260 and CI 988 did not reduce 
the elevated basal FAK phosphorylation levels in Mia PaCa-2 cells as shown in Figures 
8.10 and 8.11. 
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Figure 8.7 Immunoblot of 6.517c PAGE gel showing lack ofelevation of FAK tyrosine 
phosphorylation in Mia PaCa-2 cells with varyinc-, nsG- 17 conce lit rat lolls. Mia PaCa-2 
FAK illIMUnoprecipitates from lane 1: netoative control (beads only), 2: Lintreated, 3: 
500 nM nsG-17,4: 200 nM nsG-17-, 5: 50 nM nsG-17-, 6: 10 nM risG-17,7: vehicle 
control; 8: positive control (endothelial cell lysate); 9: FAK control. 
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Figure 8.8 Inimunoblot ot'6.5c/(, PAGE --el showing lack of elevation ofl'AK tvi-osine 
phosphorylation in Mia PaCa-2 cells with varying sCCK-8 coricent rat I ons. Mia PaCa- 
2 FAK immunoprecipitates from lane 1: negative control (beads only), 2: untreated: 3: 
500 nM , CCK-8,4: 200 nM sCCK-8,5: 50 nM sCCK-8 6: 10 nM sCCK-8,7: vehicle 
control-, 8: positive control (endothelial cell lysate)-, 9: FAK control. 
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Figure 8.9 Immunoblot of 6.5(/c PAGE gel showing basal FAK tyroshic phosphorylation 
in NIH3T3CCK-BR and Mia PaCa-2 cells. Lanes 1+4: Linstimulatcd N1113T3CCK- 
BR, 2+3: Mia PaCa-2 FAK 1111111LInoprecipitates', 5: FAK control. 
Lanes 1-4 and 5 were ininiunoblotted with pliosphotyrosine and FAK antibodies 
respectively. 
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Figure 8.10 IIIIIIILIIIOblOt ot'6.51'; PAGE , cl showing lack ol'ct'I'Cct oI'('('K-l3R 
ýjjjtagoiiists oil basal FAK phospliorylation in Nim PaCa-2 cells. I- 
Lane 1: FAK control, 2: untreated: 3: 0.1 nN/I RPR 102681,4: 10 nM RIT 102681-, 5: 
1 pM RPR 102681.6: untreated; 7: 0.1 nM L-740,093,8: 10 nM L-740,093; 9: 1 PM L- 
740,093. 
Lanes 2-9 and I were immunoblotted with phospliotyrosine and FAK antibodics 
respectively. 
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Figure 8.11 linnumoblot of 6.517(, PAGE ,, el showing lack of' effect of CUK-BR 
antaoonists on basal FAK phospliorylation in Mia PaCa-2 cells. 
Lane 1: FAK control, 2: untreated, 3: 0.1 nM L-365,260,4: 10 W L-365,260: 5: 1 PM 
L-365,2260,6: untreated. 7: 0.1 nM C1988-, 8: 10 nM C1998,9: 1 pM C1988. 




We found that 5 out of the 7 human pancreatic tumour cell lines possessed a point 
mutation in exon 1 at codon 12 of the K-ras gene. These results are supported by the 
work of 0' Hara et A (1986) and Sumi et aL (1994), who also showed that 2 of these 
cell lines, Panc- I and Mia PaCa-2 had point mutations in codon 12 resulting in a GGT 
(glycine) to GAT (aspartate) and GTT (valine) substitution, respectively. Mutations 
were not found in exon 2 at codon 61 in any of the cell lines investigated. This result 
was not surprising, since 90% of K-n7s mutations in human pancreatic cancer studied 
are located in exon I at codon 12 (Almoguera et aL, 1988; Smit et aL, 1988). Point 
mutation mediated-activation of the K-ras oncogene in vivo is restricted to codons 12, 
13 and 61. These produce amino acid substitutions that reduce the GTPase activity of 
the encoded proteins (Walter et aL, 1980) resulting in an activated p2lras protein. In 
this form, ras continuously transmits signals to its downstream effectors such as 
MAPK (Marshall 1994). However, as discussed in the introduction section, the 
alteration in the ras protein alone is not sufficient for full malignant transformation of 
human pancreatic cells (Lemoine et A, 1992a). 
Tyrosine phosphorylation has been implicated in the intracellular signalling of 
neuropeptides that act as potent growth factors through receptors with seven 
transmembrane helices, such as bombesin, vasopressin, endothelin and bradykinin 
(Leeb-Lundberg & Song, 1993; Zachary etal., 1992). In 1992, Zachary and co- 
workers showed that bombesin, vasopressin and endothelin stimulated the rapid 
tyrosine phosphorylation of FAK. FAK was originally found as a substrate for 
activated variants of src (family of retroviral oncogenes, Schaller et al., 1992). FAK is 
also known to be stimulated by the integrin family of cell surface receptors (Komberg 
et al., 1992; Schaller et al., 1992) which co-localises with several components of 
cellular focal adhesions, such as tensin, vinuculin and talin. Hence, it is termed focal 
adhesion kinase. FAK is a protein tyrosine kinase that displays unique features: for 
example, it does not contain SH2 or SH3 domains or acylation sites important in 
protein-protein interactions. The catalytic domain is located centrally between the non- 
catalytic amino and carboxyl termini. FAK is capable of autophosphorylation at one 
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site, tyrosine-397. It has been proposed by a number of researchers that FAK 
phosphorylation is a ras-independent mechanism (Secki et al., 1995; Chen et al., 
1996) which was demonstrated by using dominant negative inhibitors of ras in 
NIH3T3 and Swiss 3T3 cells. 
The work carried out on the CCK-BR signalling pathways has shown that several 
protein species including MAPK and FAK (Taniguchi et al., 1994; Seufferlein et al., 
1995) are activated by phosphorylation. These findings suggest that CCK-B/gastrin 
receptors may transmit mitogenic signals by cross-talking with the kinase cascades. 
Recently, Seva et al. (1996) have also shown that stimulation of the gastrin/CCK-B 
receptor, promotes MAPK activation in a ras-dependent manner. Since ras, a potential 
oncogene is known to be constitutively active in 90% of pancreatic turnours, the MAPK 
cascade could be constitutively activated in the majority of pancreatic carcinomas. This 
can lead to cellular responses such as growth and differentiation which are independent 
of CCK receptor activation. Moreover we confirmed that 5 of these pancreatic cancer 
cell lines possessed a point mutation in codon 12 of the K-ras gene (Mia PaCa-2, 
Capan-1, KPan, Panc-1 and AsPc-1), theoretically removing the need for CCK 
receptor activation. 
NIH3T3CCK-BR cells responded to sCCK-8 and nsG-17 by an elevation in FAK 
tyrosine phosphorylation. This was originally shown by Taniguchi et al. (1994) using 
CCK-8. The Mia PaCa-2 unstimulated cells already had phosphorylated FAK and there 
was no further phosphorylation by either sCCK-8 or nsG-17. The absence of further 
phosphorylation is also in favour of lack of sufficient CCK receptors in these cells as 
shown by RNP assay and radioligand binding studies. Scott & Liang (1995) have 
shown that an adherent human metastatic melanoma cell line (SKMEL28) expressed 
high levels of basal phosphorylated FAK compared with a non-adherent human 
metastatic melanoma line (SKMELI) and normal human melanocytes. Moreover, FAK 
phosphorylation was induced by 01 integrin- activating antibodies in the normal 
melanocytes but not in the metastatic melanoma cells. They found that the non-adherent 
metastatic cells had less pI integrin receptors than the normal melanocytes and adherent 
metastatic cells, thus resulting in a lack of FAK phosphorylation. The increased basal 
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level of phosphorylated FAK in Mia PaCa-2 cells was not reduced by the various CCK- 
R antagonists, indicating that this elevation is not related to activated CCK-R in these 
cancer cells, providing the receptor is not mutated and no longer recognised by the 
antagonists. 
It is not surprising that basal FAK phosphorylation is higher in the cancer cells than the 
NIH3T3CCK-BR cells, since FAK is a point of convergence in the action of integrins, 
oncogenic forms of pp6(Y"c, mitogenic neuropeptides and growth factors. In pancreatic 
cancer many growth factors, growth factor receptors and oncogenes are activated, 
which may lead to an elevated basal FAK phosphorylation status. 
It may be possible that the CCK-R is mutated resulting in a constitutively active 
receptor. This would by-pass the effects of the CCK-R antagonists. However, this 
has not been reported in relation to CCK-R and cancer growth. One would have to 
sequence the whole of the CCK-R to determine this possibility. Another possibility is a 
mutation in the G-protein a subunit that is coupled to the CCK-R resulting in a 
constitutively activated receptor. Again, this active form of the receptor would by-pass 
the effects of the antagonists. Gain of function mutations in G-protein a subunits have 
been well documented (Lyons et at., 1990; Gupta et al., 1992b) for seven 
transmembrane GPCR in thyroid turnours. Whether the elevation in basal FAK 
phosphorylation is due to constitutively active CCK-R or other growth factor signalling 
pathways remains to be answered. 
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CHAPTER 9 
CHARACTERISATION OF A HUMAN PANCREATIC CANCER IN 




Cholecystokinin receptor studies on primary human pancreatic cancer are few and far 
between. However, molecular as well as protein binding studies have been carried out 
on animal models of pancreatic cancer. The expression of CCK-R mRNA has been 
examined in pancreatic carcinomas from transgenic mice and also in several rat 
pancreatic cancer models (Zhou etal., 1993; Povoski et al., 1994). The animal models 
of pancreatic cancer cannot be compared directly with human pancreatic cancer due to 
variations in morphology and genetics. RT-PCR demonstrated the expression of both 
CCK-A and CCK-B receptors in the normal human pancreas (Zhou et al., 1994). 
However, one of the questions addressed here is whether there is a differential 
expression of the CCK-A and CCK-B receptors in primary pancreatic cancers 
compared with their matched normal specimens. 
9.2 Aims 
Attempts were made to a) xenograft, b) passage tumours c) develop a stable cell line, 
from more than one primary human pancreatic cancer but all three aims were successful 
in only one case, PTI. 
The aims of these investigations were; i) to compare the CCK-R and K-ras, status on the 
xenograft established in vivo and the cell line cultured in vitro from a primary human 
pancreatic tumour I (PTI); ii) to determine the differential expression of CCK-A and 
CCK-B receptors in 4 human pancreatic cancers with their matched 'normal' 
counterparts by RT-PCR (PTNI-PTN4). Two sets of patient pancreatic specimens 
were collected for these studies; a) pancreatic turnour tissue without matched normal 
specimens which were used for the in vivo and in vitro studies and b) pancreatic 
turnours, with matched 'normal' specimens (from the same patient) which were used for 
the CCK-R differential expression studies. 
213 
9.3 Molecular studies to determine CCK-R status in a human 
pancreatic cancer and its xenografts 
9.3.1 Methods 
9.3.1.1 CCK-R RT-PCR 
The methods are described in section 4.1.3-4.1.7. Total RNA was extracted from the 
primary turnour (PTI), xenografts of this tumour and the cell line established from this 
turnour. The RNA was reverse- transcribed into cDNA and the cDNA was amplified 
using the CCK-R specific primers by PCR. The amplified products were then 
subjected to agarose gel eIectrophoresis. 
9.3.2 Results 
Turnour PTI. was obtained from a 56 yr. old female patient who was diagnosed with 
stage IV pancreatic cancer. PTI was 1 of 5 other pancreatic turnours that grew in vivo 
as well as in vitro. A cell line was established from the xenograft of this turnour in 
passage 7. Attempts at growing the turnour in vitro from the original tumour and from 
xenografts of the first and second passage were unsuccessful. 
Pancreatic tumour Sex Age Stage of cancer 
PT1 female 56 IV, 13, NI, MI 
PT2 female 46 111, T2, N1, MO 
PT3 male 58 11, T3, NO, MO 
PT4 male 59 1, T1, NO, MO 
PT5 female 43 111, T3, NI, MO 
Table 9.1 Details of patients and tumour specimens analysed for in vivo and in 
vitro pancreatic tumour growth establishment. TI. - tumour extension; N: lymph node 
involvement; M: metastasis. 
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RT-PCR showed the expression of both CCK-A and CCK-B/gastrin receptors in the 
original pancreatic turnour (PTI), the xenografted turnours (passages 2,5 and 7) and in 
the cell line (established from turnour xenograft at passage 7 from PITI) as shown in 
Figure 9.1. The T cell lymphoma cell line was used as a positive control for both 
CCK-AR and CCK-BR (lanes 6A and 6B) and NlH3T3 mouse fibroblast cells were 
used as a negative control as indicated in lanes 7A and 7B in Figure 9.1. The results 
obtained for the CCK-A and CCK-B/gastrin receptor PCR in the NIH3T3CCK-BR 
cells are shown in Figure 9.2. Lane 2A shows a lack of expression for the CCK-AR 
whereas lane 2B shows the expression of the human CCK-BR in the NIH3T3CCK-BR 
cells. The last three lanes verify the presence of intact cDNA in the NlH3T3 and 
NIH3T3CCK-BR cells by the amplification of a 120 bp [ý-actin fragment. There was 
not enough tumour material available for CCK-R expression analysis with tumours 
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Figure 9.1 AL'arosc '-'CI clcctrophorc,, is ofUCK-AR and CUK-13R) RT 1)('[\) pr(Otict" in 
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NlH3T3 and NIH3T3CCK-BR cells. 
The size ofthe amplified fragments were 340hp and 430hp for the ('('K--,, \R and ('('K- 
BR respectively. 
Lancs IA. IB: Tcell I ine (posit we control), 2A. 213: Nil l3T3CCK-BR cell,,:.; -5 represent 
the P-actin gene expression. Lane 3: wild type N1113T3 cells, 4: NIll3T3C('K-BR 
cells-, 5: T cell line, III: molecular markers. 
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9.3.3 Methods 
9.3.3.1 Mase protection assay 
The methods are described in section 4.4. Total RNA from the primary pancreatic 
cancer and its xenografts was hybridised with the radioactively labelled CCK-AR, or 
CCK-BR probe overnight. The unhybridised RNA (single stranded) was digested with 
RNase and the remaining product electrophoresed bn a polyacrylamide gel. Kodak film 
was exposed to the gel for several days before developing. 
9.3.4 Results 
The RNP assays did not detect expression of either the CCK-A or CCK-B/gastrin 
receptors in the pancreatic cancer samples analysed from PTI and its subsequent 
xenografts and cell line as shown in Figures 9.3 and 9.4 respectively. Human gall 
bladder revealed a 340 bp protected CCK-AR mRNA and the NIH3T3CCK-BR cells 
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respectively. 
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cell line-, 4 xeno-rafts: passage 2,5: passage 5,6: passage 7; 7: N11-13T3 cells, 8: Mia t- tý I- Z- 
PaCa-2 (negative control), ni: moleCLIkIr markers. 
The protected fragnicrits were resolved on a V'c polvacrylanlide oel at 55W for 5 lirs in 
Ix TBE buffer. 
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Figure 9.4 ALItoradiography ot'6`/ý PAGF-el following the RNP assay. The CCK-13R t, I- 
mRNA was not detected III the 111.1111MI 1)ýIIICIVIIHC CW1CCI' (PTI ) 111.11 W10, l)IVSCIIt III 
NIH3T3CCK-BR cells (lane 1). 
Expression studies were carried out on the original 111.1111an pancreatic tunlour (PT I) and 
on the subsequent PTI xenografts from mice and the PTI Cell line CUltLII'Cd ill 1'1070. Z- 
NIH-')T3CCK-BR and Mia PaCa-2 cells were used as positive and neoativc controls 
respectively. 
Lane 1: NIH3T3CCK-BR (positive control)- 2: original pancreatic tllll)OLli--, 3: U111101.11- 
cell line: 4 xenografts: passage 2,5: passage 5,6: passage 7-, 7: NlH3T3 cells-, 8: Mia I -- Z- -1 
PaCa-2 (negative control)-, m: molecular markers. I 
The protected fragments were resolved on a 6(/(, polyacrylamide gel at 55W for 5 lirs in 
Ix TBE buffer. 
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9.4 The K-ras status In the human pancreatic cancer, PT1 
9.4.1 Methods 
The methods are described in section 4.6.2. K-ras exon I and 2 were amplified, 
cloned and sequenced. The sequenced products were subjected to polyacrylamide gel 
electrophoresis. Kodak film was exposed to the gel ovemight before developing. 
9.4.2 Results 
Cloning and sequencing of the K-ras PCR products showed that the original PTI 
tumour and its first passage xenograft possessed a wild type ras sequence. However, 
there was a mutation in codon 12 of exon I from the second passage onwards of PTL 
The cell line established from passage 7 of this tumour also had a point mutation in 
codon 12. The substitution was from the wild type glycine to a valine at codon 12 as 
indicated by a base point mutation from guanine (G) to a thymine M in Figure 9.5. 
There was no mutation detected in the hot spot region of codon 61 in exon 2 in the 
pancreatic cancer specimen or the xenograft passages investigated as shown in Figure 
9.6. The mutations detected are summarised in Table 9.2. 
Human pancreatic 
tumour 1 (PT1) 
-ras Exon I Exon 2 
codon 12 codon 61 
original tumour GGT CAA 
passage one GGT CAA 
passage two* Gir CAA 
passage three* G17 CAA 
passage five* G17 CAA 
passage seven* GIF CAA 
tumour cell line* G37. CAA 
Table 9.2 K-ras mutations in the xenografted human pancreatic cancer, FITI and 
its cell line (passage 7). The point mutations* in exon 1 at codon 12 are underlined. 
GGT. - glycine, GTT. valine, CAA: glutamine. No mutations were found at codon 61. 
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Figure 9.5 Sequences of' the K-ras gene exon I in codon repion 11 - 18 in a human 
pancreatic cancer (PT I) and SUbscquent xenografts and PTI cell line. MLItatIOI1 fi'0111 
wild type GGT (glycine: left lanes) to GTT (valine: right lanes) was detected In COdOn 
12. 
Lane 1: original tuniour-, lane 2: xenografts from first passage, 3: second passaoc, 4: 
third passage; 5: t'01.11111 PýISSage; 6: seventh passage; 7: cell line established t*1'0111 tLI111OL11' 
passage 7. The boxes enclose the codon 12 triplet. 
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Figure 9.6 Sequences of tile K-ras gene exon 2 in codon rcoion 58-64 111 a human 
pancreatic cancer (PT I) and subsequent xenografts and PT I cell line. Mutations were 




Table 9.3 shows that as the passage number of the xenograft increased, the time for the 
turnour to form decreased. This tumour was the only tumour that was successfully 






One 76 4.00 
Tw o 60 7.30 
Three 35 6.30 
Four 22 2.00 
Five 20 2.25 
Six 12 3.00 
Seven 10 3.00 
Table 9.3 The human pancreatic cancer PTI xenograft in nude mice: Tumour 
growth time decreases as the number of passages increase. 
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9.5 Semi-quantitative CCK. R RT. PCR in human pancreatic 
cancer with matched normal tissues 
9.5.1 Methods 
The methods are described in section 4.7. The cDNA from pancreatic tumours and 
matched normal tissue was diluted and amplified using the CCK-R specific primers by 
PCR in the presence of f3-actin. The amplified products were then subjected to agarose 
gel electrophoresis. 
9.5.2 Results 
Semi-quantitative RT-PCR was carried out on 4 human pancreatic cancers with their 
matched normal tissues (PTNI, PTN2, PTN3 and PTN4). In Figure 9.7 all 4 normal 
and tumour specimens showed the expression of both CCK-A and CCK-B receptors. 
As the cDNA was diluted down to 1: 10,000 the message for both CCK-AR and CCK- 
BR was lost in both cancers and 'normal' tissues. All the pancreatic cancer specimens 
along with their matched 'normals' show that both CCK-A and CCK-B receptors were 
expressed. These results indicate that the CCK-R were equally expressed in the 
matched 'normal' and tumour specimens, as the message for these receptors was lost at 
the same dilutions in both the cancer and normal pancreatic tissues. 
Pancreatic tumour Sex Age Stage of cancer 
with matched normal 
PTN1 male 57 1, TI, NO, MO 
PTN2 male 68 1, TI, NO, MO 
PTN3 male 65 1, TI, NO, MO 
PTN4 female 63 1, T1, NO, MO 
Table 9.4 Details of patients and tumour specimens with matched normal 
pancreatic tissue analysed for serniquantitative CCK-R RT-PCR expression studies. T: 
turnour extension; N: lymph node involvement; M: metastasis. 
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Figures 9.7A, B and D may indicate higher expression of CCK-AR than CCK-BR in 
the tumour samples although this is not reflected in Figure 93C. 
However RT-PCR is not a quantitative method in order to make this assumption when 
comparing PCR products of differing lengths (340 and 430 bp for CCK-AR and CCK- 
BR respectively). Table 9.4 shows the tumour and patient details of each specimen 
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Figui-e 9.7 Agarose gel electrophoresis showing serni-quantitative CCK-A and 
CCK-B receptor RT-PCR in four hunian pancreatic cancers with matched nornial 
tissue. A to D are pancreatic tumour specimens with matched normals. PTN I (A), 
PTN-l (B), PTN3 (C) and PTN4 (D). 
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9.6 Discussion 
The RT-PCR studies show that both CCK-A and CCK-B receptors am expressed in the 
human pancreatic cancer PTI, but the receptors were not detected utilising the RNP 
assay which had a detection limit of 10 pg for CCK receptor mRNA. As mentioned 
previously, the CCK-A and CCK-B receptors were detected by RNP in the human gall 
bladder and NIH3T3CCK-BR cells, respectively. In these two controls the receptors 
are known to have a role in either muscle contraction (gall bladder) or cell growth 
(NIH3T'3CCK-BR). Thus, these results in the primary pancreatic cancer indicate that 
the receptor message is expressed at very low levels at which they are probably unable 
to elicit a response. The cell line established from the tumour also lacked significant 
CCK-R expression as shown by RNP assays (Figures 9.3 and 9.4). 
Freshly isolated cultures from an original turnour are known as primary cultures until 
they are passaged or subcultured. They are usually heterogeneous and have a low 
growth rate but are more representative of the cell types in the tissue from which they 
were derived. Subculture allows the 
; 
xpansion of a culture (known as a cell line). 
After several subcultures a cell line will either die out (finite cell line) or 'transform' to 
become a continuous cell line. 
We have shown the gain of a K-ras mutation from tumour passage 2. The original 
tumour and the primary passaged tumour displayed a wild type K-ras gene. This 
finding is not surprising as it is well documented that upon tumour passaging whether 
in vivo or in vitro, the faster growing cells are selected, leading to the survival of the 
fittest clones (Nowell, 1976). Generally these faster growing cells gain various genetic 
mutations that confer a growth advantage such as a ras mutation, hence outcompeting 
the slower dividing cells. This also explains the reduction in time from which the 
tumour was injected to the time when it was palpable with an increase in passage 
number, as well due to the involvement of other oncogenic mutations such as p53. The 
original and primary tumour was difficult to grow in vitro. However, the xenografted 
turnour taken from passage 7 resulted in cells growing in vitro supplemented with 15% 
foetal calf serum. However, these cells could not be grown in serum-free medium. 
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The cells were weaned on medium containing varying amounts of foetal calf serum. 
The serum content was reduced from 15%, to 10,5,2.5 and 0% foetal calf serum with 
time. At 5% foetal calf serum the cells began to die. This can be due to the cells being 
partially transformed (eg. ras mutation) but not yet able to grow independent of growth 
factors such as epidermal growth factor and insulin that are provided by the serum. 
Continuous cell lines have an advantage of an increase in growth rate to higher cell 
densities, their lower serum requirement and general ease of maintenance in simple 
media. However, their disadvantages include greater chromosomal instability, 
divergence from the donor phenotype and loss of tissue specific markers. 
We were unable to establish any other fresh pancreatic cancer obtained from theatre as a 
xenograft in nude mice or as a cell line. PTI was the only carcinoma that was 
successfully passaged out of 5 human pancreatic cancers. The same procedure was 
carried out with all the 4 tumours in that they were injected into nude mice within 60 
min of receiving the fresh specimen from theatre ensuring that the tumours did not dry 
out and aseptic techniques were used whilst handling the tumours. One explanation for 
the lack of tumour growth in these mice may be the stage of the disease when the 
tumour was resected. The details of the specimens analysed are shown in Table 9.1. 
Interestingly the PTI specimen was taken at a more advanced stage of pancreatic cancer 
(stage IV). At this stage the tumour had spread to the lymph nodes as well as other 
organs indicating a more aggressive cancer than stage II and III cancers used. The 
other specimens used for this study were stage II or III tumours and this may reflect 
crucial properties of the tumour in order to establish a xenograft, in the nude mice as 
well as a cell line in vitro. 
Pancreatic turnours with matched nonnal tissues were difficult to obtain. However, all 
the turnours investigated indicate equal expression of both CCK-A and CCK-B 
receptors by RT-PCR compared with their matched normal specimens of pancreas. 
Semi-quantitative RT-PCR is a method that can be used when the source is a limiting 
factor and is sensitive enough to detect a single molecule of mRNA. Other methods 
such as RNP assays and Northern blotting can be used when the source of RNA is 
abundant. The RNP assay was not used in this study due to the lack of sufficient 
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pancreatic tissue. 'Me turnours investigated in the RT-PCR study were classified TI, 
NO, MO indicating that there was no lymph node involvement or metastasis to other 
organs. Whether there would be increase in CCK-R expression at a later stage of the 
disease remains to be determined. However it would be difficult to obtain matched 
normal pancreatic tissue at more advanced stages in order to make comparisons since 
these are rarely operated on. 
This is the first study to my knowledge on CCK-R expression in human pancreatic 
cancers with matched normal controls. Expression studies carried out in azaserine- 
induced rat pancreatic cancers have shown over-expression of the CCK-AR (Bell etal., 
1992) and novel expression of the CCK-BR (Zhou etal., 1992) mRNA. This was 
shown by CCK-8 binding and Northern blot analysis respectively. The binding of 
[1251] gastrin-I was detected only in the precursor lesions of pancreatic cancer and in the 
cancer itself (Povoski et al., 1993b). Later, Povoski et al. (1994) showed by RT-PCR 
that CCK-AR expression was similar in transgenic mouse pancreatic cancers and 
normal nontransgenic mouse pancreas as we have found in human pancreatic 
specimens. 
The data obtained from human pancreatic carcinomas cannot be compared directly to 
animal models as morphological and genetic evidence indicates that the cellular origin of 
malignant lesions differs in rats, hamsters and humans. For example, activation of the 
K-ras gene is frequent in human pancreatic cancer and in N-nitrosobis (2-oxopropyl) 
amine (BOP)-induced pancreatic cancer in the hamster, but is not found in azaserine- 
induced lesions in rats (Bos, 1989; Van Kranen, etal., 1991). Also carcinogens in rats 
induce lesions of acinar cell origin, a form of malignancy that is less common in 
humans (Longnecker, 1986; McGuiness et al., 1987) as 90% of human pancreatic 
turnours are of ductal origin (Morohoshi etal., 1983). 
However, RT-PCR is exquisitely sensitive and may be detecting a very low copy 
number of mRNA molecules. Furthermore, demonstration of receptor mRNA does not 
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always reflect the presence of functional receptors in the cell membrane. Due to the 
paucity of primary tissue it was impossible to carry out any form of receptor protein 
expression studies, such as mdioligand binding analysis, to indicate the presence of the 
receptor protein. This may be a general problem with human pancreatic cancer, 
resulting in a lack of research in this field. 
231 
CHAPTER 10 




The transplantation of human tumour cells into immunodeficient mice has provided an 
in vivo model for the study of biological behaviour and tumour progression. Although 
extrapolation from animal to man is difficult, working directly on human tumours has 
the advantage that it is possible to focus the studies on particular types of cancer. T'his 
model allows the effects of various external factors on human tumour growth to be 
studied in vivo in an environment that is more physiological compared to in vitro cell 
culture studies. 
10.2 Aims 
The aims of this study were (1) to establish pancreatic cancer cell line xenografts in 
immunodeficient, mice (2) to investigate the effect of gastrointestinal hormones, sCCK- 
8 and nsG-17 on the growth of human pancreatic cancer cell line (Mia PaCa-2) 
xenografts (3) to determine the effects of novel specific CCK-R antagonists on Mia 
PaCa-2 xenograft growth. 
10.3 Establishment of human pancreatic cancer cell line 
xenografts in nude and SCID mice 
10.3.1 Methods 
The methods are described in section 5.5.1. The various pancreatic cancer cell lines 
were cultured in vitro and the harvested cells resuspended in tissue culture medium 
devoid of serum. These cells were injected into either SCID or nude mice maintained in 
sterile conditions. 
The histopathological studies on the xenografts were carried out by Dr. S. Humphries 
using the basic haernatoxylin and eosin staining technique. 
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10.3.2 Results 
IN VITRO IN V! VO 
Pancreatic Cell culture SCID Nude n 
cancer Time sem Time sem Time sem 
cell line (days, mean) (days, mean) (days, mean) 
Mia PaCa-2 1.50 0.09 6.0 0 3.8 0.5 4 
Panc-I 2.5 0.13 18.5 1 10.5 0.5 4 
BxPc-3 2.0 0.05 11.5 0.5 6.5 0.6 4 
Hs766T 3.0 0.1 31.5 1.4 23.5 0.8 4 
Table 10.1 Time taken for the xenografted human pancreatic cancer cell lines to 
form a palpable tumour in SCID and nude mice and their doubling time in vitro. The 
tumours formed at a faster rate in the nude mice. 
The time taken for the formation of a palpable tumour in two strains of mice varied with 
each ceR line xenografted (Table 10.1). The Mia PaCa-2 cells were first to induce a 
tumour followed by BxPc-3, Panc-I and Hs766T. This is also reflected by the 
doubling time of the cells in in vitro growth studies. The histopathology data on human 
pancreatic cancer cell line xenografts, from both SCID and nude mice demonstrated 
identical histopathology. The Mia PaCa-2 (Figure 10. IA) and Panc- I (Figure 10.1B) 
xenografts were shown to be poorly differentiated epithelial turnours. The AsPc- I 
xenografts were found to be a differentiated carcinoma with glandular structures as 
shown in Figure 10.1C and the BxPc-3 xenografts showed a very well differentiated 
adenocarcinoma with mucin secreting cells (Figure IOAD). 
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Figure 10.1A Mia PaCa-2 xenograft taken from nude mice: a poorly 







Figure 10.1B Panc- I xenograft taken from nude mice: a poorly differentiated 
epithelial carcinoma with pleomorphic malignant epithelial cells (very similar in 
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Figure 10.1C AsPc-I xenograft taken from nude mice: a differentiated 
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Figure 10.1D BxPc-3 xenograft taken from nude mice: a very well 
differentiated adenocarcinorna with mucin secreting goblet cells. (H+E, 250X). 
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10.4 The effects of sCCK-8 and nsG. 17 on the growth of human 
pancreatic cancer cell line xenografts 
10.4.1 Methods 
The methods are described in section 5.5 to 5.5.4. The Mia PaCa-2 cells were 
established in nude mice and 15 days after injection and they were subsequently treated 
daily with various doses of sCCK-8, nsG-17 and antagonists (I mg/kg) for 49 days. 
The mice were sacrificed on day 64 and the turnours and spleens weighed and snap 
frozen in liquid nitrogen. All the mice were examined at post mortern for signs of 
abnormalities and tumour metastasis throughout the thorax and abdomen. DNA and 
protein content of each tumour was determined as described in 5.5.4. 
10.4.2 Results 
The results obtained in the xenograft studies using CCK-R agonist and antagonists are 
shown in Tables 10.2 and 10.3. The average tumour weights and the DNA and protein 
content of these xenografts showed no significant differences. The vehicles, NH40H 
and DMSO also had no significant effect on the growth of the Mia PaCa-2 xenografts. 
The results obtained for the xenografted tumour weights show that the data do not 
conform to a normal distribution (see Table I in appendix H, p292). If the data were 
distributed normally one would have expected 95% of the data to be encompassed by 
twice the SD value (2 x SD). However, for all treated and untreated groups the 2x SD 
values are less than zero, which is not the case in a normally distributed population. 
Table 2 in the appendix H shows that the coefficient of variation was greater than 100% 
in 15 out of the 21 groups, i. e. the SD is more than the mean value of the group, which 
further implies that the data do not conform to a normal distribution. This is also 
confirmed by the difference between the mean and median values of the tumour 
weights. For normally distributed data these would typically be very close, but this is 
not the case (see Table 2 in appendix II, p293). When data available for analysis do not 
fit the normal distribution population, one can avoid a more complicated model of 
analysis by transforming the data such that it makes the normal distribution model 
appropriate. This is done by logarithmic or square root transforination of the original 
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data. Unfortunately, logarithms of the data cannot be taken as there are a number of 
zero values and the square roots still result in a skewed distribution. Hence, parametric 
statistical analysis cannot be used to assess significance for this data. 
Treatment group DMSO PBS/NH40H 
Tumour weight (g) Turnour weight (g) 
mean sem n mean sern n 
untreated 0.48 0.17 12 0.48 0.17 12 
vehicle 0.31 0.09 12 0.05 0.03 6 
15 gg/kg sCCK-8 0.32 0.24 6 0.46 0.17 6 
30 gghkg sCCK-8 0.53 0.25 6 0.24 0.24 5 
100 gg/kg sCCK-8 0.58 0.31 6 0.52 0.23 6 
15 gg/kg nsG-17 0.55 0.28 5 0.46 0.19 6 
30 gg/kg nsG-17 0.25 0.06 6 0.31 0.07 6 
100 gglkg nsG-17 1.04 0.41 5 0.54 0.22 6 
1 mg/kg L-364,718 0.44 0.18 9 - - 
1 mg/kg L-365,260 0.57 0.30 9 - - 
1 mg/kg L-740,093 0.67 0.29 9 - - 
1 mg/kg RPR-X 0.37 0.17 8 - - 
20 mg/kg JB93182 0.13 0.10 6 - - 
JB93182 vehicle (saline) 0.31 0.12 6 - - 
Table 10.2 Human pancreatic cancer xenograft weights were unaffected by sCCK- 
8, nsG-17 and their antagonists, although the effects of sCCK-8 and nsG-17 at higher 
doses are associated with higher average tumour weights (not significantly different). 
The first statistical analysis of the data considered the solvents. A non-parametric 
Kruskal-Wallis one way analysis of variance was carried out on the following groups: 
untreated control, saline, DMSO and NH40H in order to determine whether or not 
there are differences between these groups. No one group was used as a control for the 
other groups. There were no significant differences between these control/solvent 
groups (0.2>P>0.1). 
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Treatment group Tumour DNA Tumour protein 
(mgtkg of tumour) 
mean Sem n mean sem n 
untreated 0.97 0.02 10 88.38 0.42 10 
DMSO 0.95 0.02 9 86.88 1.18 9 
PBS/NH40H 0.95 0.04 3 87.30 1.41 3 
15 gg/kg sCCK-8 0.93 0.02 9 86.11 1.27 9 
30 gg/kg sCCK-8 0.97 0.04 6 80.00 0.60 6 
100 gg/kg sCCK-8 0.94 0.04 9 87.05 1.27 9 
15 gg/kg nsG-17 0.96 0.04 9 87.05 1.27 9 
30 gg/kg nsG-17 0.93 0.03 12 86.51 0.89 12 
100 gg/kg nsG-17 0.96 0.02 12 86.20 1.08 12 
1 mg/kg L-364,718 0.99 0.03 8 87.31 0.93 8 
1 mg/kg L-365,260 0.97 0.02 7 88.20 0.34 7 
1 mg/kg L-740,093 0.96 0.01 8 87.41 1.30 8 
1 mg/kg RPR-X 0.96 0.02 7 86.89 1.73 7 
20 mg/kg JB93182 1.01 0.09 2 88.35 1.45 2 
JB93182 vehicle (saline) 1.02 0.04 6 87.61 1.29 6 
Table -10.3 Human pancreatic cancer xenograft DNA and protein concentrations 
were unaffected by sCCK- 8, nsG- 17 and their antagonists. 
The in vivo data show a block of groups involving the three variables, agonist (sCCK- 
8/nsG-17), dose of agonist and solvent (DMSO or NH40H) as shown in Table 10.4. 
Hence, there are 14 groups in this 3 factor experiment and another 7 groups including 
the antagonists which are considered separately. If there were equal numbers per group 
and had the data been normally distributed then a '3-way ANOVA-with-replication' 
would have answered whether there were any significant solvent, agonist or dose 
effects and whether there were any interactions. To date a non-parametric version of 
the 3-way ANOVA which can accommodate the unequal numbers is not available. 
Hence, the data have been analysed in separate blocks. Comparing the solvents with all 
agonists (i. e. 0.227 vs. 0.476) shows that the agonists give more than twice the effect 
of the solvents. 
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Tumour weights (g) 
DMSO PBS/N114011 
0.875 0.000 0.050 
0.059 0.000 0.000 
0.000 0.666 0.000 0.227 0.227 
0.397 0.130 0.000 (n=18) 
0.493 0.328 0.070 
0.137 0.676 0.199 
0.313 0.054 
sCCK-8 0.294 0.144 0.997 0.193 
15 pg/kg 1.497 0.000 0.135 0.021 0.389 
0.000 0.000 0.512 0.869 
0.323 0.455 
30 pgfkg 0.044 0.576 1.186 0.000 
1.350 0.000 0.031 0.000 0.399 0.446 
1.206 0.000 0.000 (n=35) 
0.529 0.241 
100 pgAkg 0.464 0.236 0.000 1.180 
2.098 0.231 0.000 0.878 0.547 
0.220 0.224 1.029 0.000 
0.579 0.515 
0.477 (n=18) 0.414 (n--17) 
nsG-17 0.000 0.018 
15 pg/kg 0.338 1.456 
0.930 
0.548 








0.163 0.203 0.278 0.506 
0.165 0.511 (n--34) 
100 pg/kg 0.901 2.263 0.385 0.255 
0.135 0.213 0.277 0.292 0.764 
1.671 0.375 1.640 
1.037 0.537 
0.588 (n=16) 0.434 (n--18) 
0.473 0.370 0.424 
(n=34) (n--35) (n--87) 
0.476 
(n=69) 
Table 10.4 The weights of the xenografts from agonist treated and untreated groups 
in the two vehicles arranged for statistical analysis. 
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Analysis of the individual data shows that there are no values greater than 1.0 in the 
solvent groups (out of 18) but 12 out of 69 are greater than 1.0 in the agonist groups. 
To determine whether this is simply by chance or not, the data was analysed statistically 
using Chi-square tests. The Chi-square techniques involve analysis of the data in the 
form of frequencies and are often arranged as `2 x2 contingency tables". 
Tumour weights were classified as <I. Og or >1.0g. Hence, for solvents there were 18 
and 0 cases respectively while for agonists there were 57 and 12 cases respectively. 
'Me Chi square value was 0.2<P>O. 1. Re-analysing the data using those values greater 
or less than twice the "global average" of 0.424g (i. e. lower or greater than 0.848g) 
gave 17 and I cases for solvents respectively, while for agonists there were 51 and 18 
cases respectively. The Chi-square value was P 0.05<P>0.02. One further analysis 
using results lower and greater than the "global average" gave 14 and 4 cases for 
solvents respectively and for agonists gave 44 and 25 cases respectively. The Chi- 
square value was 0.5<P>0.3. It is important to note here that data "snooping" by 
selection procedures can give an answer that one is looking for. One is more likely to 
find a difference when the dividing lines are extreme (high or low). The results here 
indicate that globally there may be a real difference between solvents and agonists. In 
order to confirm this, the experiment needs to be repeated several times to increase the 
numbers. In general, one rule of thumb for statistical analysis states that the greater the 
departure of the population distribution from normal, the larger the sample must be. 
Some statisticians require a sample size of 30 or more. 
An inspection of the effects of the agonists (i. e. averages of 0.446 and 0.506 both vs. 
0.227) suggests that there is no difference between sCCK-8 and nsG-17. This was 
confirmed by carrying out Chi square "3 x 2" contingency table7' tests. The solvents 
were compared with gastrin and CCK. The same block groups as above were 
analysed. Tumour weights that were either < 1.0g or > I. Og for solvents were 18 and 0 
cases respectively, for sCCK-8 were 28 and 7 respectively and for nsG-17 were 29 and 
5 cases respectively. The Chi square value was 0.2<P>O. 1. Re-analysing the data 
using those values greater or less than twice the "global average" of 0.424g for solvents 
were 17 and I cases respectively, for sCCK-8 were 25 and 10 respectively and for 
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nsG- 17 were 26 and 8 cases respectively. The Chi square value was 0.2<P>O. 1. The 
final analysis using results lower and greater than the "global average" gave 14 and 4 
cases for solvents respectively, 22 and 13 cases for sCCK-8 respectively and 22 and 12 
cases for nsG- 17, respectively and the Chi square value was 0.7<P>0.5. These results 
indicate that there was no significant differences in the turnour weights between the 
solvent (vehicle), sCCK-8 or nsG-17 treated groups. 
A sub inspection seems to rule out the evidence of a dose-related effect of the agonists 
(assuming there was an effect primarily) as judged by the marginal averages for each 
dose level. Nonetheless, it is interesting to note that the higher doses of the agonists 
are associated with higher averages. Statistical analysis is not feasible on these groups 
consisting of n=6 or less as the distribution is not normal. 
Looking at the difference for the two solvents overall shows a small ratio (i. e. 0.473 
vs. 0.370, n=34 and 35 respectively). Also for the marginal averages across the two 
agonists (0.477 vs. 0.414 for sCCK-8 and 0.588 vs. 0.434 for nsG-17) -there does not 
appear to be a marked influence. This is important because it is in keeping with the 
conclusion below that there was no statistically significant effect of PBSINH40H 
vehicle. Chi-square analysis by "2 x2 contingency tables" for sCCK-8 and nsG-17 
dissolved in the two vehicles were carried out for tumours of weights lower and greater 
than the global average of 0.424g. Hence, for sCCK-8 there were 12 and 6 cases in 
DMSO, respectively and 10 and 7 cases in PBS/NH40H, respectively. The Chi square 
value was 0.95<P>0.9. With nsG-17 there were 9 and 6 cases in DMSO, respectively 
and 12 and 6 cases in PBS/NH40H respectively and a value of PA. 0 was obtained. 
'ne effects of the vehicle PBS/NH40H were compared with the untreated group using 
the Mann-Whitney test. The nonparametric Mann-Whitney test based on the ranks of 
the numbers rather than their absolute magnitudes yielded a value of 0.1<P>0.05 
between the untreated and PBS/NH40H groups. It is also interesting to note that 3 
mice from the 6 treated with PBS/NH40H showed regression of the tumour at the end 
of the study. 
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The effects of the antagonists L-365,260, L-740,093, devazepide and RPR-X were 
compared with the DMSO solvent control utilising the Kruskal-Wallis analysis. This 
test yielded aP value of >1.0 indicating no significant differences between the various 
groups. It is interesting to note the JB93182 compound yielded 2 tumour weights of 
0.117 and 0.610 and 4 mice had no turnours. Whether this response is due to the effect 
of the antagonist cannot be concluded since the numbers in the group are too low. 
However, compared to the vehicle control (saline) the data suggest that this compound 
may have had an inhibitory effect on the tumour growth at the high concentration of 20 
mg/kg. 
The DNA and protein content of the tumours were unaffected by either agonist or 
antagonist treatment (see Tables 3 and 4 in appendix II, p294-295). Interestingly the 
DNA and protein data fit a normally distributed population. Thus the data were 
analysed by using the unpaired Student's t test. The spleen weights from the treated 
and untreated mice also fitted a normal distribution, hence the Student's unpaired t test 
was used for spleen data analysis. The presence or absence (cases where the tumour 
regressed) of the tumour in the various treated and untreated groups was not 
significantly related to the weight of the spleens (see Table 5 in appendix 11, p296). 
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10.5 Discussion 
The xenograft of the Mia PaCa-2 cell line induced a palpable tumour at a faster rate than 
the other turnour cell line xenografts. Ibis is not surprising since the Mia PaCa-2 cell 
line has a faster doubling rate than the other three cell lines investigated in vitro and in 
vivo. Published literature on the growth of these cell lines also indicate that Mia PaCa- 
2 (Yunis etal., 1977) is the fastest growing cell line, followed by BxPc-3 (Tan etal., 
1986), Panc-I (Lieber etal., 1975) and the slowest growing of the four is Hs766T 
(Owens et al., 1976) consistent with our results. 
The histopathology results also confirm that the xenografts have the same phenotype as 
the cell lines from which they were derived as one would expect (Yunis et al., 1977; 
Tan etal., 1986; Lieber etal., 1975; Owens etal., 1976). Xenografts in SCID and 
nude mice are known to retain the morphological characteristics of the tumour/tumour 
cell line xenografted (Taghian & Huang, 1995). 
The finding that the nude mice developed turnours before the SCID mice may reflect the 
greater residual immune activity in SCID mice. Nude mice have been demonstrated to 
have some residual T cells (Taghian et al., 1993) and SCID mice have been shown to 
possess natural IdIler cells, macrophages and other haernapoietic cell lineages which are 
not affected by the autosomal recessive SCID mutation (Dorshkind etal., 1985). 
The results from our experiments indicate that sCCK-8 and nsG-17 had no effect on 
pancreatic tumour growth in vivo. The lack of effect of sCCK-8 on the human 
pancreatic cancer xenograft growth has been shown by a number of research groups 
using pancreatic cancer xenografts from various human cell lines. For example no 
effect 6n growth was shown by Hudd etal. (1989) with 50 gg/kg sCCK-8 on Mia 
PaCa-2 and Panc-I xenograft growth, Maani et al. (1988), with caerulein (CCK 
analogue) and Nio et al. (1993) with 25 gg/kg of CCK-8 showed an inhibitory effect 
on one human pancreatic cancer xenograft and no effect on another in nude mice using 
cell lines PC-YY and PC-T1 respectively. Stimulatory effects have also been reported 
on either the same or different human cell line xenografts. For example Smith et al. 
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(1990a, 1991) showed stimulation with 15 pg/kg of CCK-9, of the SW-1990 xenograft 
and Upp et A (1987) demonstrated the stimulation of growth of a CCK receptor 
positive human pancreatic cancer cell line xenograft with caerulein but no effect on the 
CCK receptor negative xenograft. 
The literature indicates the importance of establishing the CCK receptor status of the 
human pancreatic cancer to be investigated. We found a low level of CCK-BR in the 
Mia PaCa-2 cell line in vitro compared to the NIH3T3CCK-BR cells. This could be 
one reason for the lack of effect of the agonists on tumour growth. 
Smith et A (1990a, 1991) demonstrated that the Mia PaCa-2 and SW-1990 cells 
respond to CCK-8 in vitro as well as in vivo. They showed using ligand binding that 
these cell lines demonstrated the presence of CCK-BR and absence of CCK-AR assays 
(1994). 
Recently, Smith et al. (1995) have shown the involvement of the CCK-BR using the 
human Panc-1 cell line xenograft where I mg/kg of pentagastrin stimulated growth 
which was inhibited by the CCK-BR specific antagonist, L-365,260. They showed 
that pentagastrin increased tumour weight and DNA but not protein content of the Panc- 
1 xenografts. Our results show no significant effect on DNA or protein levels in the 
xenografts as would be expected since there was no significant increase in the tumour 
weights. Moreover, histopathology studies showed no increase in cell size within the 
tumour. 
These differences in results in our laboratory to the work of other researchers can be 
explained by i) alteration of CCK-R in Mia PaCa-2 cells not related to growth, ii) low 
doses of sCCK-8 and nsG-17, iii) method and site of injection, iv) frequency of drug 
administration to accommodate for the variation in half lives of these agonists compared 
to the agonists used by other research groups, and v) duration of the study. The dose 
used for the various agonists varies from one research group to another. Smith etal. 
(1990a, 1991) used a final concentration of 15 gg/kg of CCK-9 dissolved in 0.15 M 
sodium chloride while further dilutions were carried out in 1% bovine serum albumin. 
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The CCK-9 was administered twice daily subcutaneously in 2% gelatin in order to 
prolong the absorption. The mice were treated for 20 days following the formation of a 
turnour from the xenografted cell line. Hudd et al. (1989) also used sodium chloride 
vehicles for the administration of 50 gglkg of sCCK-8 and the treatment was continued 
for 15 days. Their drug injection site was different, being carried out intraperitoneally 
and twice daily, but no effect was observed in the turnour weights or DNA and protein 
content. The work done by Smith etal. (1995) on the Panc-1 xenograft with I mg/kg 
pentagastrin was carried out for a period of 24 days following the development of the 
turnour The pentagastrin was dissolved in 0.05 M NH40H and further diluted in 
saline. The injections were administered twice daily in gelatin. It has been reported 
that a considerably higher dose of pentagastrin is required to obtain the same 
physiological effects as gastrin-17 or CCK (Majumdar & Goltermann, 1979). 
Pentagastrin is 10 times less potent than gastrin-17 in displacing radiolabelled gastrin 
from rat gastric mucosa gastrin receptors (Takeuchi et aL, 1980), explaining the high 
dose of pentagastrin used by Smith etal. (1995). The differing results for the in vivo 
studies compared with the work of Smith et al. (1995) can be due to the above 
mentioned reasons and also due to the use of a different cell line. 
Effects of CCK-R antagonists on xenografts of human pancreatic cancer 
Our studies also indicate that the various antagonists investigated had no effect on Mia 
PaCa-2 xenograft growth. This is further confirmed by the absence of any effects on 
the DNA and protein levels in the treated and untreated tumours. Other research 
workers have shown the effects of CCK-AR antagonists on xenografts of human 
pancreatic cancers (see next paragraph) and recently Smith et al. (1995) reported the 
inhibitory effect of a CCK-BR antagonist L-365,260, on the growth of Panc-1 
xenografts. 
Morimoto et A (1993) showed inhibitory effects of the CCK receptor antagonist 
loxiglumide on the growth of a human pancreatic cancer cell line xenograft, PC-HN. 
This cell line was also shown to possess CCK receptors using 1251-CCK-39. They 
suggested that loxiglumide inhibits human tumour growth by other mechanisms since 
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the antagonist also inhibited the growth of human pancreatic cancer cell lines that lacked 
CCK receptors. Later, Nio et al. (1993) also showed that loxiglumide had an 
inhibitory effect on the growth of these human pancreatic cancer xenografts and this 
inhibition was reversed by a trypsin inhibitor FOY-305. They suggested that the 
inhibitory action of loxiglumide on pancreatic turnour growth may be due to its effects 
on proteolytic enzymes found in the lysosomes of the pancreatic cells rather than an 
inhibitory effect on CCK receptors. Furthermore, the CCK-AR antagonist L-364,718 
was shown to have no effect on the growth of PC-HN xenograft in vivo (Morimoto et 
al., 1993). 
Maani et al. (1988) showed that L-364,718 inhibits the the growth of a human 
pancreatic cancer xenograft, PGER, and that this inhibition was reversed by caerulein 
administration. The subcutaneously -implanted tumour was shown to be CCK-R 
positive. They suggested this effect was due to the involvement of endogenous CCK 
as CCK alone had no effect on the tumour growth. Smith etal. (1990b) reported that 
L-364,718 decreased tumour weight, DNA and protein content of human pancreatic 
cancer cell line (SW1990) xenografts. Later the same group (Smith et al., 1995) 
showed that L-365,260 inhibited Panc- I xenograft growth, also resulting in a decrease 
in tumour weight, DNA and protein content. 
'Me apparent lack of effect of the CCK-R specific antagonists in our laboratory may be 
due to several reasons i) CCK-R not related to pancreatic tumour growth, ii) the lack 
sufficient CCK receptors in the xenografted cell line and Singh etaL (1991) have 
shown the loss of CCK receptor binding sites with increasing passage number of the 
pancreatic cancers, iii)The variation in the dose regime (as mentioned previously with 
agonists). Smith et al. administered the CCK-AR antagonist (L-364,718) twice daily at 
2 mg/kg and the CCK-BR antagonist (L-365,260) twice daily at a final dose of I 
mg/kg. It is also important to note that the lack of effect of L-364,718 both in our 
laboratory and in the work done by Morimoto etal. (1993) may indicate the lack of a 
role of CCK-AR in the growth of human pancreatic cancers. 'Me effects of L-364,718 
(devazepide) have been studied in 18 patients with advanced pancreatic carcinoma 
(Abbruzzese et al., 1992). The subjects received 5 mg of L-364,718 orally, twice daily 
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for four weeks. Some of the patients received treatment for an additional 4 or 8 weeks 
at a dose of 10 mg twice daily. The study failed to demonstrate any impact of L- 
364,718 on tumour progression, the level of pain experienced or nutritional parameters. 
Several of the patients experienced toxic reactions even at the lower dose, although this 
was only about 1/25 of the dose used by Smith et al. (1990b) in mice. One of the 
patients did not complete the study because of abdominal cramps, one required dose 
reduction because of nausea, vomiting, abdominal cramps and two others required 
treatment for abdominal cramps. The dose of L-364,718 used by Smith and co- 
workers in mice is very high compared to the human studies, exceeding the dose used 
in humans by 25 fold. The inhibitory effects of L-364,718 on SW1990 xenografts 
(Smith etal., 1990b) may be explained by toxic effects of this antagonist at such high 
doses. This compound has now been withdrawn from the clinic due to its toxicity even 
at low doses. 
Since some of the CCK-BR antagonists used in these studies are novel there is a lack of 
information about the properties of these compounds. In these experiments the doses 
of the antagonists were chosen by extrapolation from published literature by Smith et 
d. (1990b), Abbruzzese etal. (1992) and Maani etal. (1993) in mice and humans. 
This does raise a number of questions such as the phan-nacokinetics of the compound in 
mice. It may be that the half life of the antagonist in vivo is short, thus requiring either 
a higher dose or more frequent injections of the drug in order to maintain the 
concentration. Statistically the vehicle does not have any effects on the action of these 
antagonists as suggested by the results. Moreover, this is confirmed by the in vitro 
data obtained with these antagonists in the NIH3T3CCK-BR cells. Maani et al. (1988) 
Nio etal. (1993) and Smith etal. (1995) used the same NH40H vehicle (10% higher 
concentration) and did not report any significant differences between the control and the 
vehicle treated groups. 
On inspection there seems to be an interesting finding in the NH40H and JB93182 
group (Table 10.2), but with a larger sample number the data in these groups may look 
like the rest of the data. Scanning the other groups in Table 10.4 one notices that the 
mid dose of sCCK-8 with the PBS/NH40H solvent, that 4 out of 5 results are zero or 
250 
near to zero and there is one large figure and likewise with the lowest dose of sCCK-8 
using DMSO as solvent. In such a case one is in danger of being a victim of a type II 
error. This occurs when we conclude that no significant differences exist when they do 
and the only way that this can be substantiated is by increasing the n number. However 
as already mentioned it is unlikely that this is the case since the pancreatic cancer cell 
line used in this study has a low number of CCK receptors and thus not responsive to 
either CCK agonists or antagonists. 
Spontaneous tumour regression observed in our in vivo studies has not been reported 
by any of these workers in the control groups of nude mice bearing pancreatic 
carcinoma xenografts. However, tumour regression has been reported to occur in both 
SCID and nude mice. Several reports have demonstrated residual immune reactivity by 
the nude mouse against the xenografts (Rofstad, 1989; Zietman et al., 1988; Taghian 
et al., 1993). Thus the observation of spontaneous tumour regression in our laboratory 
can be explained by this residual immune reactivity. The in vivo studies carried out by 
Smith et al. (1990,1995) were 35 days long whereas our studies were 64 days long. 
Recently Taghian and Huang (1995) have reported that by the time a xenograft has 
grown to a specific size at which it can be treated, it may well have produced a host 
reaction which although not strong enough to cause tumour regression will nevertheless 
influence regrowth after the tumour has undergone cytoreduction. Thus the endpoint of 
an in vivo study is highly critical. Future suggestions would include i) reducing the 
length of the study (in order to minimise the activation of the residual immune 
reactivity) and ii) whole body irradiation of the mice in order to depress the residual 
immunity. 
In conclusion it is difficult to decipher a role for CCK-R in the growth of human 




IDENTIFICATION OF KINASES INVOLVED IN PANCREATIC 
CANCER DEVELOPMENT 
252 
CIIA P TER 11 
11.1 Background 
Since the discovery of tyrosine-specific phosphorylation by pp60v-src, members of the 
protein tyrosine kinase family have been increasingly identified over the last decade 
(Hunter, 1987; Hanks etal., 1988). This large class of enzymes can be divided into 
two major subgroups: the receptor and the non-receptor families. Most tyrosine 
kinases mediate the response of eukaryotic cells to external stimuli and hence are a 
crucial component in the regulatory system that co-ordinates cell proliferation and 
differentiation (Cantley etal, 1991). Some terminally differentiated cells also express 
significant levels of tyrosine kinases, suggesting that these enzymes are important for 
the functioning of differentiated as well as growing cells. Receptor tyrosine kinases 
transmit the signal of natural ligands such as growth factors, hormones or 
differentiation factors. These kinases exhibit a similar molecular topology including a 
large glycosylated, extracellular domain, a single hydrophobic transmembrane region 
and a cytoplasmic catalytic domain (Ullrich & Schlessinger, 1990). 
in principle every tyrosine kinase receptor bears transforming potential, since 
constitutive expression of its signalling function may override cellular control 
mechanisms. Oncogenic receptor versions are either characterised by structural 
deviations from normal counterparts or result from receptor overexpression through 
autocrine stimulation (Ullrich & Schlessinger, 1990). Qualitative alterations of receptor 
molecules range from gross deletions or recombinations affecting the extracellular 
region to single point mutations within the extracellular, transmembrane or cytoplasmic 
domain. 
The non-receptor class of tyrosine kinases represent a collection of cellular enzymes 
that are grouped together because of their lack of extracellular sequences. A number of 
the non-receptor tyrosine kinases have been found to be associated with other cell 
surface proteins (which generally lack endogenous enzyme activity such as Janus 
kinases, JAKs) and are shown to be capable of facilitating cell surface initiated signal 
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transduction much like the receptor class of tyrosine protein kinases. Currently there 
are at least 24 individual non-receptor tyrosine protein kinases comprised of eight 
different groups. They range in size from 50 kDa for the C-src kinase (Csk) family to 
approximately 150 kDa for the Abl kinase family. 
Serum Anisomysin Arsenite 
















Figure 11.1 Flow diagram summarising the various signal transduction processes of 
intraceHular signafling. 
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Receptor stimulation involves activation of several cytoplasmic signal transduction 
pathways including sequential protein kinase reactions using serine/threonine protein 
kinases. Mitogen activated protein kinase (MAPK, also known as ERK, extracellular 
regulated kinase) is a seri ne/threo nine kinase that is stimulated by receptor tyrosine 
kinases and GPCR (Kahan etal., 1992). Upon activation, ERK translocates into the 
nucleus to mediate changes in gene expression. ERK is activated by phosphorylation 
of both tyrosine and threonine. This reaction is catalysed by a specific 
threonine/tyrosine directed kinase called MAPK kinase (MEK/ERK kinase) (Crews et 
al., 1992). In turn MEK is phosphorylated and activated by the serine/threonine 
protein kinase Raf (MEKK; Lange Carter et al., 1993; Kyriakis et al., 1992). Two 
additional parallel kinase cascades composed of enzymes functionally related to either 
Raf, MEK or ERK were discovered in mammalian cells (Cano & Mahadevan, 1995). 
These cascades are only poorly activated by mitogens but are strongly stimulated by 
cellular stress inducers. One of these recently identified cascades is preferentially 
trigerred by anisomycin, UV radiation and some alkylating agents and the other is 
activated by lipopolysaccharide, osmotic stress and heat shock leading to the activation 
of Jun-N-terminal kinaselstress activated protein kinase (JNK/SAPK) (Cano et al., 
1994; Kyriakis etal., 1994) and p38RK (Rouse etal., 1994) respectively (see Figure 
11.1). All three kinases (ERK, SAPK and p38RK) are found in the nucleus after 
activation (Cavigelli et al., 1995, Raingeaud et al., 1995). Direct activators of 
JNK/SAPK and p38RK are either the dual specificity kinase SEKI/MKK4 
(SAPK/ERK kinase 1) which activates both JNK/SAPK and p38RK when 
overexpressed or MKK3 which specifically activates p38RK. 
Originally identified as MEKI/2 kinase, MEKKI does not trigger the activation of 
MEK and ERK but stimulates the SAPK activator (SEKI) and thus acts parallel to raf. 
These activated kinases (ERK, JNK/SAPK and p38) are also known to have specific 
substrates in the cytoplasm. ERK is known to activate p90RSK MAPKAP-K1 (MAPK 
protein kinase-1) and p38RK activates MAPKAP-K2 (MAPK protein kinase-2; Stokoe 
et al., 1992; Rouse et al., 1994). A newly identified kinase 3pK has been 
demonstrated to be activated by both stress inducers and mitogens (Ludwig et al., 
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1996). Little is known about the substrates of MAPK-KI (ribosomal S6 kinase), 
MAPKAP-K2 and 3pK and the physiological effects resulting from their activation. 
RSK (ribosomal S6 kinase) was originally named for its ability to phosphorylate the C- 
terminus of the ribosomal S6 protein. In vivo RSK, a serine/threonine kinase has been 
demonstrated to phosphorylate the serum response factor, which contributes to the 
regulation of serum-response factor dependent transcription (Chen et al., 1993b). 
MAPKAP-K2 substrates include heat shock protein Hsp25 and its human counterpart 
Hsp 27 (Stokoe et al., 1992). 
The cell cycle is also controlled by serine/threonine kinases known as cyclin dependent 
kinases (CDKs; Hartwell & Weinert, 1989). The cell cycle is a collection of highly 
ordered processes that result in the duplication of a cell. As cells progress through the 
cell cycle, they undergo several discrete transitions. A cell cycle transition is a 
unidirectional change of state in which a cell that was performing one set of processes 
shifts its activity to perform a different set of processes. These transitions are 
monitored by cell cycle checkpoints. The checkpoints are a pause in the cycle that 
allow any damaged DNA to repair. Inhibition of CDKs is a mechanism by which some 
checkpoint pathways cause cell cycle arrest, e. g. by the tumour suppressor p2l. which 
is a CDK inhibitor (El-Deiry et al., 1993). Hence the loss of these checkpoints would 
result in genomic instability and has been implicated in the evolution of normal cells 
into cancer cells. 
The diversity of the kinase signalling pathway(s) is complex and knowledge about the 
mechanisms is constantly expanding. Since kinases play an important role in cell 
growth and differentiation, they are an important and an attractive target for cancer 
therapy. 
11.2 Aims 




11.3.1 R T-PCR 
The methods are described in Chapter 6. PCR was carried out using degenerate 
oligonucleodde primers targeting two invariant amino acid motifs within the catalytic 
domain of protein kinases in two human pancreatic cancers (PTI and PT3). Each PCR 
product was cloned and several colonies (31 from PTI and 15 from PT3) selected and 
sequenced. 
11.4 Results 
Figure 11.2 shows the amplification product of 220 bp using the degenerate primers 
targeting the catalytic domain of protein kinases. Table 11.1 shows the various protein 
kinases that were isolated from the two human pancreatic cancers investigated. Insulin 
like growth factor I receptor (IGF-IR) was isolated more frequently in comparison to 
the other kinases in both turnours. 
Kinase Pancreatic Pancreatic 
Tumour 1 Ibmour 3 
(PTi) (PT3) 
IGF-IR 16 6 
PDGFOR 1 2 
Eph 3 1 
c- MET I 
UFO 1 
JAK1 6 3 
JAK2 1 1 
c-Abl 1 1 
Novel 1 1 
Table 11.1 Kinases isolated from two human pancreatic cancers, PTI and PT3. 
The predicted amino acid sequence obtained from the 220 bp DNA sequence for the 
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DNA used in dot blots. 
Protein kinases were loaded as follows: Lane 1: Eph-, 2: IIDGF[iR-, 3: LIFO, 4: c- 
abl; 5: c-met; 6: JAKI, 7: JAK2; 8: IGFR-1; 9,10: novel kinase; ill: molecular 
markers. 
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A novel kinase was isolated from both PTI and PT3. This novel kinase is a scrine 
threonine kinase as demonstrated by the conserved amino acid sequences in the catalytic 
domain (Table 11.2). Ile alignment was made by eye and the gapping introduced into 
the sequences in order to optimise the position of the similarities between the kinases 
isolated. This alignment clearly demonstrates the overall similarity among the catalytic 
domains. The catalytic domains are not conserved uniformly but rather consist of 
alternating regions of high and low conservation. 
11.5 Methods 
11.5.1 DNA dot-blots 
The methods are described in 6.11. PCR was carried out using the degenerate 
oligonucleotide primers from cDNA synthesised from 4 human pancreatic cancers 
(PTI-PT4), 3 normal human pancreatic specimens (histologically diagnosed as normal, 
PN1-PN3) and four human pancreatic cancer cell lines (Mia PaCa-2, BxPc-3, Capan-I 
and Hs766T. The 220 bp amplified product was cleaned and used as a template for the 
synthesis of a radioactively labelled probe. The labelled probe was hybridised 
overnight with the kinase dot blots prepared using the DNA obtained from each isolated 
kinase from PTI and PT3. The dot blots were washed the following day and Kodak 
film was exposed to the blots overnight before development. 
11.6 Results 
DNA dot blots of the kinases isolated were used to assess the levels of specific kinase 
expression. All normal and malignant pancreas and human pancreatic cancer cell lines 
showed the novel kinase and IGF-IR to be highly expressed relative to the other 7 
kinases in each specimen. Equal loading of the protein kinase DNA blotted was 
confirmed by agarose gel electrophoresis as shown in Figure 11.3. The P-actin 
negative control did not hybridise to the probes synthesised, showing that the 
hybridisation was kinase specific. Furthermore when comparing the 220 bp kinase 
sequence from each kinase used, there was only 56% similarity at the nucleic acid 
sequence level when the primer sequence was removed, with no long range sequence 
similarity. Thus under the hybridisation conditions used one would not expect any 
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PTI expresses all the 9 kinases but to varying levels as shown in Figure 11.4.7 
different kinases were isolated from PT3 and the dot blots indicate the detectable 
expression of 5 different kinases indicating that the kinases are expressed at different 
levels. The kinases PDGFOR, c-MET and JAK2 showed a low level or no expression 
in the 4 cancers investigated as shown in Figure 11.4 (see Table 9.1 for details of the 
pancreatic turnours investigated). 
The pancreatic cancer cell lines show a differential pattern of expression shown in 
Figure 11.5. The Mia PaCa-2 cell line expressed similar levels of PDGFPR, UFO, 
IGF-IR and the novel kinase. The pancreatic cancer cell lines Capan-1 and Hs766T 
show a similar pattern of expression of the kinases with PDGFPR, IGF-IR and the 
novel kinase being overexpressed in comparison to the other kinases. The BxPc-3 cells 
show an overexpression of IGF-IR and the novel kinase with PDGFPR and c-Abl, 
expressed more than the other kinases in this cell line. In summary all the pancreatic 
cancer cell lines investigated showed an overexpression of the novel and IGF-IR 
kinases; compared to the other 7 kinases in these cell fines. 
The normal pancreatic specimens also show expression of IGF-IR as well as the novel 
kinase with 2 of the normals (PN2 and PN3, see Table 11.3 for details of tissues used) 
also showing a higher expression of PDGFPR in comparison to the other kinases 
within each tissue shown in Figure 11.6. 
Pancreatic Sex Age Diagnosis 
tissue 
PN1 male 64 Cholangiocarcinoma 
PN2 male 43 Cholangiocarcinoma 
PN3 female 36 Cholangiocarcinoma. 
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Figure 11.4 Dot blots showing the relative abundance ofeach protem kinase in ZI 
four hunian pancreatic cancers. 
TLIIIIOLII* 1: PT 1, TuIlIOUr 2: PT2. TLlmour 3: PT3 and Tumour 4: PT4. 
Key is shown below. 
Epli PDGFýR LTO 
c-Abl c-MET JAKI 












Figure 11.5 Dot blots showing the relative abundance ofeach protein kinase ill 
fOL11- hunian pancreatic cancer cell lHics: VIM PaCa-2, Capan- I, BxlIc-3 and 1 ls700T. 
Key is shown below. 
Eph PDGFýR LTO 
c-Abl c-MET JAKI 









Figure 11.6 Dot blots showing the relative abundance ofeach protein kinase ill 
three normal IlUman pancreases. 
'Normal' 1: PNI, 'Normal'2: PN2-, 'Normal'3: PN3. 
Key is shown below. 
Eph PDGFýR LTO 
c-Abl c-MET JAKI 
JAK2 IGFR- I Novel 
Novel O-actin 
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Low levels of other kinases such as Eph, UFO, c-Abl and JAK I were also detected in 
2 of the normal specimens (PNI and PN2). However, the data cannot be compared 
between the normal and malignant specimens as parameters such as exposure time and 
specific activity of the probe have to be taken into consideration. I did not have enough 
RNA for this comparison which would require Northern blotting. 
It is important to note that this method is a semi-quantitative method and is a good 
indicator of expression levels but is by no means absolute. 
265 
11.7 Discussion 
Table 11.2 shows highly conserved individual amino acids within the catalytic domains 
of each kinase which play an important role in catalysis. Subdomain VIII contains the 
consensus sequence APE, a conserved feature often mentioned as a key protein kinase 
catalytic domain indicator (Hunter & Cooper, 1986). Mutagenesis studies have shown 
that each residue in the APE consensus is required for activity of v-Src. The novel 
kinase has been demonstrated to possess the APE sequence. Sites of 
autophosphorylation have also been found to lie near to this site (Shoji, 198 1) but their 
role is not entirely clear. Subdomains VI and VIII are conserved in either protein 
tyrosine kinases or serine/threonine kinases. It has been suggested that these domains 
may play an important role in recognition of the correct amino acid either serine, 
threonine or tyrosine (Hanks etal., 1988). The sequence DLKPEN in subdomain VI is 
known to be a strong indicator of a serine/threo nine kinase. In the novel kinase the 
sequence is DLKPTN while the sequence DLAARN/DLRAAN is indicative of a protein 
tyrosine kinase. Another highly conserved sequence among the protein tyrosine 
kinases with a more limited conservation among the protein serine/threonine kinases is 
PI/VK/RWT/MAPE in subdomain VIII. In the serinelthreonine protein kinases the 
consensus is GT/SXXY/FXAPE. The amino acid sequence of the novel kinase also 
possesses this consensus site. 
insulin like growth factor-I (IGF-I) is a polypeptide that exhibits structural homology to 
proinsulin and exerts growth-promoting and metabolic effects (Froesch et aL, 1985). 
Its actions are dependent on the presence of specific cell surface receptors, the IGF-I 
receptor (IGF-IR). IGF-IR is a tyrosine kinase receptor with 70% structural homology 
to the insulin receptor (Ullrich etal., 1986). IGF-IR has a high affinity for IGF-I and a 
low affinity for insulin and IGF-II (Werner etal., 1991). The IGF-IR is composed of 
of a heterotetrameric a2Nsubunit structure and has a ligand-stimulated tyrosine kinase 
activity. Unlike other tyrosine kinase receptors such as platelet derived growth factor 
receptor (PDGFR) and epidermal growth factor receptor (EGFR), the insulin receptor 
does not have direct associations with SH2 proteins. In contrast the activated insulin 
receptor phosphorylates insulin receptor substrate-1 (IRS-1) on multiple tyrosine 
266 
residues and She, which in turn recognise and bind to various signal transduction 
proteins such as PI-3- kinase, ras, and MAPK. Cells treated with insulin rapidly 
increase glucose uptake and lipid and glycogen synthesis but only increase DNA 
synthesis after a prolonged stimulation. IGF-I however, appears to be a more potent 
stimulator of DNA synthesis and cell growth (Randszzo etal., 1990). IGF-I functions 
as an autocrine and a paracrine growth factor in a variety of mesenchymal and epithelial 
tumours (Macaulay, 1992; Daughaday, 1990) and is essential for entry into the S phase 
of the cell cycle (DNA synthesis, Baserga, 1995). 
The dot-blots indicated that IGFR-I was highly expressed compared to the other 
kinases isolated in all the pancreatic specimens investigated. Pancreatic tumours have 
been shown to overexpress mRNA for both IGF-I and IGF-IR by Northern blot 
analysis confirming our findings. It has been suggested that IGF-I may play a role in 
the aberrant autocrine and paracrine activation of IGF-IR in pancreatic cancer as the 
IGF-IR was found to be overexpressed in those pancreatic cancers that had a high 
expression of IGF-I mRNA (Bergmann et al., 1995). 
The c-MET proto-oncogene encodes a transmembrane tyrosine kinase receptor (MET) 
that has the capacity to modulate cell proliferation and differentiation (Cooper et aL, 
1984). It is activated by the hepatocyte growth factor (HGF). HGF is a 105 kDa 
protein that is mitogenic to hepatocytes, endothelial and epithelial cells (Montesano et 
al., 199 1; Zarnegar et aL, 1990). Ile HGF action is dependent on its binding to MET, 
the HGF receptor. As with most receptor tyrosine kinases, MET is triggered by HGF 
dependent homodimerisation and cross phosphorylation on specific tyrosine residues in 
the intracellular carboxy terminus of the receptor. Activation of MET leads to 
stimulation of various intracellular signalling cascades, including PLC^j, ras, 
phosphotyrosine phosphatase, pp6osrc, MAPK and PI-3-kinase. 
Our results indicate a low level of MET expression compared to the other kinases such 
as IGF-IR and PDGFOR. However, c-MET has been shown to be overexpressed in 
pancreatic cancer (Di Renzo el aL, 1995) and the overexpression is associated with 
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increased levels of HGF mRNA (Ebert et al., 1994). The importance of this 
upregulation is not yet determined but it may be involved in motility or invasiveness of 
pancreafic tumour cells (Oikawa et d, 1995). 
PDGF was identified over 20 years ago as a growth promoting activity in human 
platelets for fibroblasts, smooth muscle cells and glial cells. There are three PDGF 
isoforms, PDGF-AA, -AB and -BB. Two receptors for PDGF, denoted the PDGF(x 
and PDGFp receptor binds the PDGF isoforms with differing affinities. The PDGFOR 
only binds the B-chain containing PDGF isoforms. Binding of PDGF activates the 
receptor by dimerisation, accompanied by tyrosine phosphorylation of the receptor. 
The phosphorylated tyrosines bind various intracellular messengers such as, 
cytoplasmic kinases, Src, Fyn and Yes, Shc, PLCy, PI-3 kinase, ras and MAPK 
leading to cell proliferation, cell migration, angiogenesis or membrane 
ruffling/cytoskeletal rearrangement depending upon cell type. 
PDGF and PDGFPR have been shown to be involved in an autocrine manner in tumour 
growth (Nister et al., 1991). Glioblastoma cell lines express both PDGFaR and 
PDGFPR types as well as PDGF in different ways: PDGFaR is mainly expressed in 
the turnour cells whereas the PDGFPR is expressed in the stroma (Hermanson et al., 
1988,1992). The PDGFPR has been shown to be important in tumour development by 
providing the tumour with nourishment (Forsberg etal., 1993). To date there has been 
no work carried out on PDGF receptors in pancreatic cancer. 
The JAK-STAT (Janus kinase-signal transducers and activators of transcription) 
pathway is a newly discovered intracellular signal transduction pathway that is used by 
a growing number of extracellular signalling proteins resulting in either cell growth, or 
differentiation (Darnell et al., 1994). It is now recognised that JAK-STAT pathways 
are activated by most cytokines (Sadowski et al.., 1993), growth factors that bind to 
receptor tyrosine kinases (Shuai et al., 1993) and by the ligand induced activation of 
certain GPCR (eg. angiotensin II, Marrero et al., 1995). 
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Ligand binding results in the dimerisation (or multimerisation) of the receptor subunits 
and consequent activation of one or more JAKs. JAKs are cytoplasmic non- 
transmembrane tYrosine kinases with a molecular weight between 125 kDa and 135 
kDa. Reports vary as to whether the JAKs are constitutively associated with the 
receptor or associate with the receptor following ligand binding. Moreover, it is not 
known whether the association of JAKs with the receptor is direct. Nevertheless, JAK 
activation requires the integrity of a proline-rich sequence within a membrane-proximal 
region of the receptor subunits cytoplasmic domains. 
Activated JAKs generally phosphorylate tyrosine residues on one of the receptor 
subunits, thereby providing sites for binding by the SH2 domains of specific STATs. 
The bound STAR are then phosphorylated on a single tyrosine, presumably by the 
receptor associated JAKs, dimerise by a high affinity reciprocal SH2-phosphotyrosine 
interactions and are translocated to the nucleus. Stat proteins translocate to the nucleus, 
bind specific DNA sequences and promote transcription. The JAK family is presently 
comprised of four mammalian enzymes, JAKI, 2,3 and IYU and six mammalian 
STAT genes have been isolated (Ihle, 1996). Different ligands specifically activate 
different members of the JAK and STAT families. 
JAKI was detected in both 'normal' and cancer pancreatic tissues and pancreatic cancer 
cell lines. However, JAK2 was only found to be expressed in 2 human pancreatic 
turnours and not in the 'normal' pancreatic specimens. Whether this is indicative of 
overexpression of JAK2 in human pancreatic cancer remains to be elucidated. With the 
exception of JAK3 all JAKs are expressed in most tissues. The expression of JAK3 
seems to be restricted to cells of the immune system (Kawamura et al., 1994) but as yet 
no work has been done in the expression and role of JAKs in cancer. 
Eph belongs to the largest family of receptor tyrosine kinases. Eph was the first 
receptor to be discovered, isolated from human hepatocellular carcinoma cell line cDNA 
library (Hirai etal., 1987). This receptor has been found to be overexpressed in lung, 
liver, breast and colon carcinoma (Maru et al., 1990). However, no ligand for eph has 
yet been reported, thus restricting the studies on eph function. 
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The c-AbI tyrosine protein kinase appears to be a multifunctional tyrosine kinase 
localised to the nucleus and cytoplasm (Van Etten et al., 1989). Biochemical studies 
suggest a role in cell cycle progression or transcriptional regulation (Kipreos & Wang, 
1990). Recently c-AbI has been reported to act as a negative regulator of cell growth 
(Sawyers et al., 1994) and cells deficient in this kinase fail to activate stress activated 
protein kinase (SAPK) after treatment with DNA damaging agents (Kharbanda et al., 
1995). An additional role of c-AbI in signal transduction is provided by the finding that 
the c-AbI SH3 domain associates with a protein QBPI) through a proline-rich motif 
and that the 3BPI protein possesses additional sequences that are related to other 
proteins with GTPase activating activity toward members of the Rho/Rac family of 
small G proteins (Cicchetti et al., 1992, Ren et al., 1993). Rho and Rac proteins have 
a role in membrane ruffling and in the formation of actin stress fibers as well as focal 
contacts suggesting that c-AbI may have an important role in regulation of the cell 
cytoskeleton. 
c-Abl was detected in all specimens examined except in the cell line, Capan-1. This 
probably reflects the multifunctional role of the kinase in this tissue. However, to-date 
no expression studies or functional studies of c-Abl have been carried out in cancer. 
UFO (unidentified function of protein)/Axl (from Greek word anexelekto meaning 
uncontrolled) was originally isolated from three patients with chronic myeloid 
leukaemia (Janssen etal., 1991; O'Bryan etal., 1991). This kinase has transforming 
characteristics which results from overexpression of Axl mRNA rather than from 
structural mutation (0" Bryan et al., 1991). Northern-blot studies show the kinase to be 
expressed in human bladder and cervical cell lines and in a number of organs in the 
mouse such as bone marrow, ovary and spleen. Two distinct variants of the UFO/Axl 
receptor have been identified (Janssen et al., 199 1; O'Bryan et al., 199 1) but the 
significance of this is not yet known. The functional role of this kinase has not been 
elucidated and literature on this kinase is sparse. To date UFO/Axl expression studies 
in cancer have not been carried out. 
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The novel 220 bp DNA sequence depicts a serine/threonine kinase. The 
overexpression of the novel serine/threonine kinase compared to its expression in the 
normal human pancreatic samples makes this kinase a potential target for pancreatic 
cancer therapy. This finding is very interesting and needs further investigation (see 
future studies section 12.3 p275). This kinase may be involved in the control of cell 
cycle regulation as are other serinelthreonine kinases and furthermore it may be specific 
to the pancreas. 
Very little work has been reported on the regulation/disregulation of kinases in 
pancreatic cancer. This would be a very important field to pursue, since kinases are 
known to lead to cell proliferation and/or differentiation. Findings such as 
overexpression/novel expression or even variation in activity levels of these kinases 
may provide new diagnostic markers for pancreatic cancer. Moreover, these kinases 
may prove to be important in the development of this disease and a potential target for 
the treatment of pancreatic cancer. 
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CHAPTER 12 




The aim of this project was to determine the role of CCK-A and CCK-B receptors in 
the growth of human pancreatic cancer cells using in vitro, in vivo and molecular 
studies. 
The in vitro and in vivo studies suggest that both the CCK-A and CCK-B receptor 
types do not have an important role in the growth of human pancreatic cancer. 
Moreover, molecular expression studies indicate a low level of expression of CCK 
receptors in human pancreatic cancer and their established cell lines. 
The in vitro cell culture studies show both sCCK-8 and nsG-17 to be ineffective in the 
growth of human pancreatic tumour cell lines and cancers used. Similarly, the 
preliminary in vivo data does not show a role for either sCCK-8 and nsG-17 in the 
growth of human pancreatic cancer. 
One of the many findings in the recent explosion in CCK-R research is the involvement 
of ras in CCK-R signalling. This questions the role of CCK-R antagonists in the 
treatment of human pancreatic cancer. The antagonists were shown to have an 
inhibitory effect on sCCK-8 stimulated growth in NIH3T3CCK-BR cells which 
possess a wild type ras protein, but the mutated ras protein (found in 90% of human 
pancreatic cancers) may by-pass the requirement for CCK-R activation in human 
pancreatic tumour growth. Whether the CCK-R feed through ras-independent 
pathways leading to cell proliferation/differentiation remain to be determined. 
The kinase study showed the expression of a novel serine/threonine ýinase which is 
overexpressed in all human normal and malignant pancreas as well as pancreatic cancer 
cell lines investigated. The over/novel expression or even variation in activity levels of 
kinases may provide new diagnostic markers/therapeutic targets for pancreatic cancer 
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This thesis covers a wide area examining the role of CCK-R in pancreatic cancer 
ranging from molecular to in vivo studies. A lack of sufficient human pancreatic cancer 
specimens with controls was a problem for all aspects of the project. During the 3 
years only 5 human pancreatic cancers with matched normal specimens and a further 4 
pancreatic cancers without normal specimens were obtained from the hospitals in the 
South-East. More importantly as mentioned in the discussion (section 9.6), those 
tumours with matched normal controls were from patients with cancer at a less 
advanced stage and the disease may display different growth characteristics at a later 
stage. To overcome these problems, it would be better to work with fresh tumour 
tissue from theatre, having established a library of pancreatic turnours, and to focus on 
receptor-expression studies before pursuing growth studies in vitro or in vivo. 
In order to overcome the problem of tissue shortage, cell lines were initially used as 
they are readily available. This thesis has highlighted the flaw in using established cell 
lines for research purposes mainly in growth dependent studies. The constant 
adaptation to the environment by the cells results in cells that are not representative of 
the original tumour. 
12.2 Conclusion 
We have not identified a role for cholecystokinin receptors in pancreatic cancer growth 
in vitro. However, their role in vivo, if any, remains to be elucidated but seems 
unlikely. The identification of a novel serinelthreonine kinase which is over-expressed 
in human pancreatic cancer may provide a new clue to the development of this disease. 
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1.2.3 Future studies 
A pancreatic cancer tissue library needs to be built up at the outset of any project using 
human pancreatic tissue, as one does not exist. 
In order to determine the role of CCK-R in human pancreatic cancer growth 
transfection studies using the mouse fibroblast NIH373 cell line should be carried out. 
Transfection of NIH3T3 cells with mutant ras with either the CCK-A or CCK-B 
receptor would prove to be a valuable study saving time and pancreatic tissue. These 
experiments would involve the elucidation of ras depen den L/i n dependent CCK-R 
stimulated pathways leading to cell proliferation and/or differentiation. If ras- 
independent CCK-R stimulated growth pathways are involved then molecular, in vitro 
and in vivo studies can be pursued using primary human pancreatic cancers only. 
Initially the receptor status of the tumour should be determined using both molecular 
(RT-PCR and RNP assay) and radioligand binding studies. Once the receptors are 
detected using the binding studies then in vitro and in vivo experiments can be set up 
with constant monitoring of the CCK-R receptor status during the studies. 
The finding of the novel serine/threonine kinase provides a very interesting area as a 
potential target for pancreatic cancer therapy. This kinase may prove to be overactive in 
cancers compared with normally associated tissues even though it was shown to be 
over-expressed in the 'normal' pancreatic tissues. Thus, future work would include 
sequencing of the the full length kinase, then transfection of the kinase into a fibroblast 
cell line such as NlH3T3 cells in order to elucidate the function and properties of this 





Solutions that were autoclaved were sterilised at 12 1 *C for 20 min. 
CELL CULTURE 
DMEM (low sodium bicarbonate) 
13.5 g DMEM powder with 0.6 g of glutamine and 2.0 g sodium bicarbonate dissolved 
in IL of ddH20, medium was filter sterilised with a Millipore sterilising filter unit. 
Foetal calf serum, horse serum and bovine calf serum 
AU serum was thawed overnight at 4*C from frozen then heat-inactivated at 56*C for 30 
min before use. Foetal calf serum was purchased from JRH /biosciences and bovine 
calf and horse serum were purchased from Sigma. 
Phosphate buffered saline 
48 g of phosphate powder (Gibco BRL) was dissolved in 5L of ddH20 and autoclaved 
to give a phosphate buffered saline solution of 0.2 g/I potassium chloride, 0.2 g/I 
KH2PO49 0.05 9/1 MgC129 8.0 g/I NaCl and 1.15 g/l Na2HP04- 
0 Trypsin 
10 ml of sterile phosphate buffered saline was added to each vial of bacto trypsin 
powder (Difco) and filter sterilised using 0.45 gM filters. The sterilised solution was 
diluted 1: 20 in PBS prior to use. 
Cell lines 
7 human pancreatic cancer cell lines, Mia PaCa-2, Panc-1, Capan-2, BxPc-3, Capan-1, 
Capan-2, AsPc-1 and Hs766T were purchased from the American Type Tissue Culture 
(ATCC, USA). One human pancreatic cancer cell line, KPan and aT cell lymphoma 
cell line, Jurkatts J6 were a kind gift from Dr. Darling (Department of Molecular 
Medicine, King's College School of Medicine and Dentistry, UK). The mouse 
fibroblast NlH3T3 cell lines, wild type NlH3T3 and NIH3T3CCK-BR were a 
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generous gift from Dr. Matsui (Kobe University, Japan). 
Cell culture media 
The cell culture media, DMEM and RPMI 1640 were purchased from Sigma and stored 
in a refrigerator. 
Antibiotics 
The antibiotics penicillin and streptomycin were purchased from Sigma at 1000 U/ml 
and stored at -20*C. 
Epidermal growth factor 
0.25 mg of epidermal growth factor (Sigma) was dissolved in 10 ml of sterile 
phosphate buffered saline and filter sterilised with a 0.45 IiM filter (ICN). The solution 
was stored at -20*C. 
Insulin 
100 mg of insulin (Sigma) was dissolved in 20 ml of 0.1% acetic acid (BDH) and filter 
sterilised with a 0.45 gM filter (ICN). 'I'lie solution was stored at -20*C. 
1.4 mM Hydrocortisone 
86 mg of hydrocortisone (Sigma) was dissolved in 19.15 ml of sterile ddH20 and filter 
sterilised with a 0.45 gM filter (ICN). The solution was stored at -20*C. . 
5 mM Isobutylmethylxanthine (IBMX) 
21 mg of IBMX (Sigma) was dissolved in sterile 0.5 mM sodium hydroxide and filter 
sterilised with a 0.45 gM filter (ICN). The solution was stored at -20*C. 
250 mM Glutamine 
3.65 g of glutamine (Sigma) was dissolved in sterile ddH20 and filter sterilised with a 
0.45 gM filter (ICN). The solution was stored at -20*C. 
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Peptide agonists 
I mg of the octapeptide sulphated cholecystokinin (sCCK-8) and non-sulphated gastrin 
I (nsG-17) were dissolved in sterile 0.01M ammonium hydroxide solution. Further 
dilutions were made in sterile phosphate buffered saline. The agonists were stored at - 
20*C. These peptide agonists were purchased from Cambridge Research Biochemicals. 
Antagonists 
I mg of all the antagonists except L-740,093 were dissolved in 100% DMSO (Sigma). 
1 mg of L-740,093 was dissolved in sterile phosphate buffered saline. The antagonists 
were stored at -20*C. Further dilutions of the antagonists (except L-740,093) were 
carried out in a solution consisting of 40% DMSO and 60% phosphate buffered saline. 
The antagonists L-364,718, L-365,260 and L-740,093 were a generous gift from 
Merck Sharpe and Dohme. RPR-X, was a gift from Rhone Poulenc Rorer and the 
antagonists C1988 and CR 1409 were a gift from Parke-Davis and Rotta, laboratories 
respectively. 
Plastic ware 
All the disposable plastic materials used such as 24 well plates, falcon tubes, cryovials 
were purchased from Greiner (UK) unless stated otherwise. 
FAK PHOSPHORYLATION STUDIES 
Bradford solution 
100 mg of coomassie blue (Sigma) was dissolved in 50 ml of ethanol (BDH) followed 
by the addition of 100 ml orthophosphoric acid. The volume was made upto 1 litre by 
adding 850 ml of distilled water. The solution was stored away from light at 4*C. 
Coomassie blue stain 
50% methanol (v/v) (BDH), 0.05% (v/v) coomassie brilliant blue R-250 (Sigma), 10% 
(v/v) acetic acid (BDH), 40% distilled water. 
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Destaining solution 
5% methanol, 7% acetic acid (methanol), 88% distilled water. 
DMEM (low sodium bicarbonate) 
13.5 g DMEM powder with 0.6 g of glutamine and 2.0 g sodium bicarbonate dissolved 
in IL of ddH20, medium was filter sterilised with a Millipore sterilising filter unit. 
Enhanced Chernilurninescence Kit 
The ECL kit was purchased from Amersham and stored at 4*C in darkness. 
Immunoprecipitation buffer (2x) 
2% Triton -X-100 (BDH), 300 mM sodium chloride (BDH), 20 mM Tris pH 7.4,2 
mM EDTA (BDH), 2 mM EGTA (BDH), 0.4 mM sodium vanadate (Sigma), 0.4 mM 
PMSF (Sigma, dissolved in 100% ethanol), 1.0% NP-40 (BDH), 20 mM sodium 
fluoride (Sigma). 
Phosphate buffered saline 
48 g of phosphate powder (Gibco-BRL) was dissolved in 5L of ddH20 and 
autoclaved. 
Running Buffer (10x) 
15.5 g Tris (BDH), 72 g glycine (BDH), 5g SDS (BDH) dissolved in 1L of distilled 
water. 
Sample buffer for SDS protein gel electrophoresis 
1.1 ml of sample buffer was prepared by adding 200 gI 10% SDS, 240 gI 40% 
glycerol (Sigma), 80 gI IM Tris-CI (pH 6.8), 10 gl 0.2% bromophenol blue (Sigma) 
460 jil of sterile distilled water. This was stored at -20*C. 100 PI of IM DIT (BDH) 
was added fresh on day of use to 1.1 ml of sample buffer. 
Separating gel (6.5%) 
6.5 ml 40% acrylamide (BDH), 3.3 ml 2% bis-acrylamide (BDH), 15 ml 1.5 M Tris 
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pH 8.8,200 gl 20% SDS, 11.6 ml distilled water, 200 gl 20% ammonium persulphate 
(BDH), 40 gI TEMED (BDH). 
Stacking gel (3.5%) 
1.5 ml 40% acrylamide, 0.8 ml 2% bis-acrylamide, 1.9 ml 1.5 M Tris pH 6.6,75 gl 
20% SDS, 10.6 ml distilled water, 75 gl 20% ammonium persulphate, 30 gl TEMED. 
TBSTWeen (0.1%) 
1.0 ml of Tween 20 (BDH) dissolved in IL of TBS. 
nansfer Buffer (10x) 
30.3 g Tris and 144.14 g glycine dissolved in IL of distilled water. 
Transfer Buffer (lx) 
200 ml methanol, 100 ml IN transfer buffer (7.1.12) and Ig SDS made upto aIL 
with distilled water. 
nis-buffered saline (TBS) 
10 mM Tris pH 7.4 (5 ml IM Tris pH 7.4), 100 mM NaCI (10 ml 5M NaC1). 
MOLECULAR STUDIES 
Agarose gel (1 %) 
1.0 g of agarose in 100 ml of Ix TBE was boiled in a microwave for 30 sec. Once the 
agarose dissolved it was cooled to 45*C and 3 gl of 10 mg/ml ethidium bromide was 
added. The gel was then poured into the casting tray, comb placed in position and 
allowed to set for at least 30 min. The comb was removed from the gel and the gel 




Dissolved 2.5 g ampicillin into 50 ml of sterile distilled water, followed by filter 
sterilisation using 0.45 gM filter (ICN). The antibiotic was stored at -20*C. 
DEPC water 
Added DEPC at a final concentration of 0.01% to ddH20 and left overnight at room 
temperature. FoHowing the overnight incubation the DEPC water was autoclaved. 
DNA Loading buffer (6x) 
50 ml of 50% glycerol, 20 ml of 1 mM EDTA pH8.0,0.25% bromophenol blue, 
0.25% xylene cyanol made up to 100 ml with ddH20- 
DNA primers 
The O-actin primers were purchased from GIBCO-BRL, the CCK-R primers were 
synthesised in the department of molecular medicine (King's College School of 
Medicine and Dentistry) and the K-ras primers were purchased from Oswell Company 
(Southampton). 
13-actin forward primer (5'CCTrCCTGGGCATGGAGTCCTG Y) 
B-actin reverse primer (5'GAGCAATGATCMATCTrC T) 
CCK-A forward primer (5CCTACGACACCGCCTCCGC T) 
CCK-A reverse primer (5TCCG-I-I'CI'I'I'CTTCTCTGCCTCCT Y) 
CCK-B forward primer (5'ACCCCAACGACAGGAAAAGGT T) 
CCK-B reverse primer (5'MGGGAAGGAAGGAGAGGGC Y) 
K-ras exon 1 forward primer (5' -GAGAATTCATGACTGAATATAAACMT -3') 
K-ras exon 1 reverse primer (5-TCGAATTCCTCTATFGTrGGATCATATTCG -T) 
K-ras exon 2 forward primer (5' -GCAAGTAGTAAITGATGGAG -Y) 
K-ras exon 2 reverse primer (5' -AGAAAGCCCTCCCCAGTCCT -Y) 
Enzyme digestion buffers 
These buffers were purchased with the respective enzymes from Promega: 
Buffer B (10 mM Tris-HCI, pH 7.4,50 mM NaCl, 0.1 mM EDTA, 1 mM DTr, 0.5 
mg/mI BSA, 50% glycerol) and Buffer E (10 mM Tris-HCI, pH 7.4,300 mM KCI, 
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0.1 mM EDTA, 1 mM DIT, 0.5 mg/ml BSA, 50% glycerol) 
Ethanol (70%) 
70 ml of ethanol was added to 30 ml of sterile water and stored at -20*C. 
Glycerol- polyacrylamide gel 
5%: 5 ml lOx TBE, 15 ml 40% acrylamide solution (BDH), 5 ml glycerol (BDH), 12.5 
ml. 2% Bis-acrylamide (BDH), 62.5 ml sterile water, 60 gl TEMED (Sigma) and 60 gl 
25% Ammonium persulphate (BDH). 0.5x TBE as running buffer at 3 Watts 
overnight. 
10%: 10 ml 10x TBE, 15 ml. 40% polyacrylamide solution, 10 ml glycerol, 12.5 ml 2% 
Bis, 52.5 ml sterile water, 60 gI TEMED and 60 gl of 25% Ammonium persulphate. 
lx TBE as running buffer at 5 Watts overnight. 
Hepes-NaOH buffer 
130 mM NaCl, 4.7 mM KCI, 5 MM MgC12,10 mM HEPES, 1 mM EDTA and 0.125 
g/l bacitracin (Sigma). 
LB Agar 
To 1.0 L of LB broth added 20 g of agar (Difco) and autoclaved. The broth was stored 
at 40C. 
LB Agar with X-gal and ampicillin 
To 1L LB agar at 55*C added 400 pl 100 mg/ml X-gal (Promega) and 100 pl 50 mg/ml 
ampicflHn. 
LB Broth 
10 g sodium chloride, 10 g tryptone, 5g yeast extract and distilled water. Adjust pH to 
7 with 5M sodium hydroxide and autoclaved. 
Loading buffer (SSCP) 
0.3% bromophenol blue, 0.3% xylene cyanol, 10 mM EDTA and 95% formamide. 
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Lysis buffer 
1%SDS in 0.2 M sodium hydroxide 
MOPS (lox) 
0.4 M MOPS, 0.1 M sodium acetate, 10 mM EDTA, pH solution to 7.2 with 5M 
sodium hydroxide. The solution was autoclaved and stored at 4*C in darkness. 
NZY broth 
5g of sodium chloride, 2g of magnesium sulphate (7H20). 5g of yeast extract, 10 g 
of NZ Amine (Casamino acids), dissolved in 1.0 L of ddH20 having adjusted to pH 
7.5 with 5M sodium hydroxide. The broth was autoclaved and stored at 4*C. 
NZY Agar 
5g of Sodium chloride, 2g of magnesium sulphate (7H20), 5g of yeast extract, 10 g 
of NZ Amine (Casamino acids), 15 g of agar dissolved in 1.0 L of ddH20 and 
autoclaved, stored at 4*C. 
One phor all buffer (10x) 
100 mM Tris-acetate (pH7.5), 100 mM magnesium acetate and 500 mM potassium 
acetate. 
Polyacrylamide gel (6%) 
40 ml of sequagel 6 and 10 ml of sequagel buffer (National Diagnostics), 400 gl 10% 
ammonium persulphate were mixed and rapidly poured into the gel plates. 
3M potassium acetate (pH 4.8) 
To prepare 100 ml, mixed 60 ml of 5M potassium acetate, 11.5 ml of glacial acetic acid 
and 28.5 ml of distiRed water. 
RNA Formaldehyde gel 
A 1% formaldehyde agarose gel (100 ml) was prepared by boiling Ig of agarose in 85 
ml of sterile water. Once the agarose dissolved it was cooled to 45*C and 10 ml Of lOx 
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MOPS buffer, 5 ml of 40% formaldehyde and 3 gI of ethidiurn bromide (10 mg/ml) 
added in a fume cupboard. The solution was mixed thoroughly, poured into a casting 
tray and allowed to set (30 min). Once set, the comb was removed and the gel placed 
in the tank with sufficient Ix MOPS running buffer to cover to a depth of 2 mm. 
Stripping buffer (10x) 
50 mM Tris-HCI pH 8,2 mM EDTA, 0.5% sodium pyrophosphate, 0.02% polyvinyl- 
pyrrolidone, 0.02% bovine serum albumin and 0.02% f icoll. 
Taq buffer (10x) 
This buffer was purchased with Taq polymerase (Promega) 500 mM KCI, 100 mM 
Tris-HCL pH 9.0,1% Triton X-100 and 15 MM MgC12. 
TE buffer 
1 mM EDTA, 10 mM Tris pH 7.5 
Trichloroacetic acid (10%) 
5g of trichloroacetic acid powder (BDH) was dissolved in 50 ml of distilled water. 
The 10% solution was stored at 4*C in the dark. 
Tris-borate EDTA (TBE, 10x) 
121 g Tris base, 55 g boric acid and 7.45 g EDTA adjusted to LOL with d ddH20 and 
autoclaved. 
TNE (10x) 
100 mM sodium chloride, 10 mM Tris pH 8.0 and 1 mM EDTA 
Kits 
Superscript reverse transcriptase 
This kit was purchased from Gibco BRL and stored at -200C. The kit comprised of the 
following: 
First strand buffer (5x: 250 mM Tris/HCI, pH 8.3,375 mM potassium chloride, 15 
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mM magnesium chloride), 0.1 M DTT, mixed dNTP stock and superscript reverse 
transcriptase. 
Qiaex 11 
This kit was purchased from Qiagen and consisted of the following: 
Buffer QX1 QM sodium iodide, 4M NaC104,, 10 mM Tris/HCI, pH 7.0,10 mM 
sodium thiosulphate), Buffer QX2 (8M NaCIO4,10 mM Tris/HCI, pH 7.0), Buffer 
QX3 (70% ethanol, 100 mM sodium chloride, 10 mM Tris/HCI, pH 7.0) and Qiaex 
beads. 
TA cloning kit 
This kit was purchased from In vitrogen and consisted of the following: 
Ligation buffer (IOx: 0.5 M Tris-Cl pH7.5,50 mM MgC12,50 mM DTT and 0.5 
mg/mI BSA), pCRTM vector, I u/gl T4 DNA ligase, Competent E. Coli cells, 0.5 M 0- 
mercaptoethanol, SOC medium (2% bacto-tryptone, 0.5% bacto-yeast extract, 10 mM 
sodium chloride, 2.5 mM potassium chloride, 10 mM magnesium chloride, 10 mM 
magnesium sulphate and 20 mM glucose). 
T7Sequencing kit 
This kit was purchased from Pharmacia Biotech and consisted of the following: 
Labelling mix A (1.375 gM each dCTP, dGTP and dTIP in 333.5 mM NaCl), 
Annealing buffer (lM Tris-HCI (pH7.6), 100 MM MgC12 and 160 mM dithiothreitol), 
Short mixes 
W (840 [tM each dCTP, dGTP, and dTTP; 93.5 gM dATP; 14 gM ddATP; 40mM 
Tris-HCI (pH 7.6) and 50 mM NaCI) 
'C' (840 gM each dATP, dGTP, and dTTP; 93.5 gM dCTP; 17 gM ddCTP; 40 mM 
Tris-HCI (pH 7.6) and 50 mM NaCI) 
IG' (840 gM each dATP, dCTP, and dTrP; 93.5 gM dGTP; 14 gM ddGTP; 40 mM 
Tris-HCI (pH 7.6) and 50 mM NaCI) 
'T' (840 gM each dATP, dCTP, and dGTP; 93.5 gM dTTP; 14 gM ddTTP; 40 mM 
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Tris-HCI (pH 7.6) and 50 mM NaCl) 
Stop buffer (0.3% bromophenol blue and xylene cyanol, 10 mM EDTA pH 7.5, and 
97.5% deionised formamide), Universal primer (5'-d[GTAAAACGACGGCCAGTI-3' 
in aqueous solution, 0.86 A260 units/ml (5 pmol/pl)), Enzyme dilution buffer (20 mM 
Tris-HCI (pH 7.5), 5 mM DTT, 100 gg BSA/ml and 5% glycerol), T7 DNA 
polymerase (8 u/gl in buffered glycerol solution). 
Maxi-script and RPA 11 kit 
These kits were purchased from AMS-biotechnology and consisted of the following: 
Nuclease free water, Transcription buffer (10x), 2.5 mM of each NTP, rRNasin 
ribonuclease inhibitor (20 u1W), SP6 polymerase and T7 polymerase (20 u/gl), RNase- 
free DNase 1 (2 u/gl), gel loading buffer (95% formamide, 0.025% xylene cyanol, 
0.025% bromophenol blue, 0.5 mM EDTA, and 0.025% SDS), Probe elution buffer 
(0.5 M ammonium acetate, 1 mM EDTA and 0.2% SDS), RNase solution (250 units/ml 
RNase A (approximately 0.5 mg/ml RNase A) and 10,000 units/ml RNase Tl), 
Hybridisatiori buffer (80% deionised formamide, 100 mM sodium citrate pH 6.4,300 
mM sodium acetate pH 6.4,1 mM EDTA), Solution Dx (patent pending), and yeast 
RNA (5 gg/ul). 
IN VIVO STUDIES 
TNE (10x) 
100 mM sodium chloride, 10 mM Tris (pH 8) and 1 mM EDTA. 
Sample buffer (protein extraction) 
1.1 ml of sample buffer was prepared by adding 200 gl. 10% SDS, 240 gI 40% 
glycerol, 80 gI 1M Tris-Cl (pH 6.8), 10 gl 0.2% bromophenol blue 100gl of 1M 
DTIP and 460 gI of sterile water. 
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Denaturation buffer 
1.5 M NaCl and 0.5 M NaOH 
Denhardt solution (50x) 
5g ficoll 400 [2% (w/v)], 5g polyvinyl-pyrrolidone and 5g BSA made upto 500 ml 
with ddH20. Filter sterilised and stored at -20*C. 
Hybridisation buffer 
4 ml formamide, 0.8 ml 50x Denhardts, 200 gl 20% SDS, 2.4 ml 20% SSC, 80 gl 
boiled 10 mg/ml salmon sperm DNA and 333 gl sterile ddH20. 
Neutralisation buffer 
1.5 M NaCl and 0.5 M Tris pH8.0 
NZY Agar -kanamycin 
1L of NZY agar autoclaved, cooled to 55*C with 50 mg of filter-sterilised kanamycin 
added. The fresh agar is poured into petri-dishes prior to use. 
Oligo-labelling buffer (OLB) 
OLB is made up by mixing the solutions ARC in a ratio of 10: 25: 15. 
Solution A: 1.25 M Tris-HCI (pH 8), 0.125 M MgCl (pH 8), 10 mM 13- 
mercaptoethanol, 0.5 mM dATP, 0.5 mM dGTP and 0.5 mM dTTP. 
Solution B: 2M Hepes (pH 6.6) 
Solution C: Oligo dTMs. Dissolve 50 optical density units of powder in 0.55 ml T. E. 
Phage Buffer 
5.8 g sodium chloride, 2.0 g magnesium sulphate, 50 ml IM Tris-HCI (pH 7.5), 0.1 g 
gelatin made upto 1L with ddH20. 
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PTK Primers 
These primers were purchased from King's College School of Medicine and Dentistry: 
sense 17MER: 5'-CGGATCCAC(A/C)G(A/C/G[DGA(CM(CIDT-3' 
antisense 23MER: 5'-GGAATMCA(A/T)AGGACCA(G/C)AC(A/G)TC-3' 
Salmon sperm DNA 
Salmon sperm was dissolved in ddH20 at a concentration of 10 mg/mI and autoclaved 
for 10 min at 121T. Sodium chloride was added to a final concentration of 0.1 M and 
the DNA extracted with an equal volume of phenol/chloroform (1: 1), followed by 
chloroform extraction prior to alcohol precipitation (2.5 volumes). DNA was then 
resuspended in TE to a final concentration of 10 mg/ml and stored at -200C. 
Sephadex G50 
100 g of sephadex beads were added to 100 ml of ddH20, after vigorous mixing the 
solution was topped up with more ddH20 to a final volume of 200 ml and autoclaved. 
The sephadex solution was stored at room temperature. 
SSC (20x) 
175.3 g of sodium chloride and 88.2 g of sodium citrate dissolved in 1L ddH20 and 
adjusted to pH 7.0. with sodium hydroxide. 
Stripping buffer (10x) 
50 mM Tris-HCI pH 8,2 mM EDTA, 0.5% sodium pyrophosphate, 0.02% polyvinyl- 
pyrrolidone, 0.02% bovine serum albumin and 0.02% ficoll. 
Top agar 
0.7% (w/v) agarose was added to IL of NZY agar and autoclaved. 
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Kits 
Zap expressTM predigested vector kit 
This kit was purchased from Stratagene and consisted of the following: 
vector phage an-ns (I gg/gl), Ligase buffer (IOx: 300 mM Tris-HCI, pH 7.5,100 mM 




Tumour weight (g) 
Control DMSO NH4011 Saline 
0.04 0.875 0.05 0.151 
0.044 0.059 0 0.196 
1.426 0 0 0.061 
0 0.397 0 0.887 
0.815 0.493 0.07 0.32 







mean 0.48 0.313 0.054 0.305 
L-365 L-364 L-740 RPR-X JB93182 
260 718 093 
0.27 0.311 0.851 0.098 0.117 
2.86 0.632 0.977 0.258 0 
0.771 0.553 0.311 1.503 0 
0 0.137 0.607 0.516 0.610 
0.365 1.724 2.81 0 0 
0.270 0 0.139 0.218 0 
0.212 0.44 0.138 0.277 
0 0.114 0 0.094 
0.418 0.016 0.197 
mean 0.574 0.436 0.670 0.371 0.125 
sCCK-8 (gg/kg) 
in DMSO in NU4011 
is 30 100 is 30 100 
0.294 0.044 0.464 0.997 1.186 0 
1.497 1.35 2.098 0.135 0.031 0 
0 1.206 0.22 0.512 0 1.029 
0.144 0.576 0.236 0.193 0 1.18 
0 0 0.231 0.021 0 0.878 
0 0 0.224 0.869 0 
mean 0.323 0.529 0.579 0.455 0.241 0.515 
nsG. 17 (gg/kg) 
in DMSO in NH40fI 
is 30 100 is 30 100 
0 0.144 0.901 0.961 0.248 0.385 
0.338 0.293 0.135 0.523 0.163 0.277 
0.93 0.178 1.671 1.042 0.165 0.375 
0.018 0.103 2.263 0 0.565 0.255 
1.456 0.506 0.213 0.117 0.203 0.292 
0.255 0.09 0.511 1.6 
mean 0.548 0.247 1.037 0.456 0.309 0.537 
Table I Showing individual weights of the treated and untreated xenografted 
turnours. 
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Tumour weight (g) 
Control DMSO N1140H Saline 
average 0.48 0.313 0.054 0.305 
median 0.27 0.23 0.025 0.21 
SD 0.603 0.307 0.076 0.297 
sem 0.174 0.089 0.032 0.121 
CV 125.3% 97.9% 145.8% 97.5% 
L-365 L-364 L-740 RPR-X JB93182 
260 718 093 
average 0.574 0.436 0.67 0.371 0.125 
median 0.27 0.311 0.311 0.238 0 
SD 0.888 0.534 0.872 0.483 0.244 
Sent 0.296 0.178 0.291 0.171 0.1 
cv 155% 123% 130% 130% 201% 
sCCK-8 (gg/kg) 
in DMSO in NI 14011 
is 30 100 is 30 100 
average 0.323 0.529 0.579 0.455 0.241 0.515 
median 0.072 0.31 0.23 0.35 0 0.44 
SD 0.587 0.621 0.75 OA07 0.527 0.572 
sem 0.24 0.254 0.306 0.166 0.236 0.233 
cv 182% 117% 129.6% 89.5% 217% 111% 
nsG-17 (gg/kg) 
in DMSO in N1140H 
% is 30 100 15 30 100 
average 0.548 0.247 1.037 0.456 0.309 0.537 
median 0.338 0.22 0.901 0.32 0.23 0.33 
SD 0.632 0.145 0.924 0.46 0.181 0.547 
sem 0.282 0.059 0.413 0.188 0.074 0.222 
cv 115% 58.9% 89.2% 101% 58.5% 101% 
Table 2 Showing the calculated averages, medians, standard deviations (SD), 
standard error of the mean (sem) and coefficient of variation (CV) of the treated and 
untreated xenografted tumour weights. 
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DNA concentration (mg/kg of tumour) 
Control DMSO N114011 Saline 
1.0 0.91 0.95 0.99 
0.9 1.02 0.89 1.07 
0.98 0.88 1.01 1.18 
0.99 1.01 0.97 
0.95 0.95 0.99 





mean 0.97 0.95 0.95 1.02 
L-365 L-364 L-740 RPR-X JB93182 
260 718 093 
0.96 0.97 0.93 1.02 0.92 
0.94 0.94 1.02 0.85 1.10 
1.04 0.94 0.93 0.99 
0.98 0.95 0.94 0.95 
1.00 1.04 0.98 1.0 
0.94 0.91 0.93 0.94 
0.91 0.96 0.94 0.96 
1.2 1.00 
mean 0.97 0.99 0.96 0.96 1.01 
sCCK-8 (gg/kg) nsG. 17 (gg/kg) 
is 30 100 is 30 100 
0.99 1.12 0.86 1.23 1.04 0.99 
0.97 0.89 1.00 1.01 0.86 1.00 
1.0 0.96 0.91 0.98 1.02 1.00 
0.98 0.99 0.85 0.99 1.06 0.99 
0.95 0.95 0.91 0.89 1.01 0.98 
0.85 0.89 0.98 0.85 1.02 0.96 
0.87 1.23 0.86 0.82 0.85 
0.88 0.89 0.88 0.90 0.93 




mean 0.93 0.97 0.94 0.96 0.93 0.96 
Table 3 Showing individual DNA concentration of the treated and untreated 
xenografted turnours. 
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Protein concentration (mg/kg of tumour) 
mean 
mean 
Control DMSO N114011 Saline 
89.25 88.00 90.10 87.40 
89.70 84.80 85.60 87.80 
87.70 78.34 86.20 88.50 
86.30 87.22 84.60 
86.90 87.60 84.36 





88.38 86.88 87.30 87.61 
L-365 L-364 L-740 RPR-X JB93182 
260 718 093 
89.00 86.80 91.70 87.80 89.80 
87.40 87.00 80.14 77.50 86.90 
86.90 81.30 86.80 87.80 
87.60 89.10 84.10 89.00 
88.90 88.70 89.00 91.50 
89.10 88.60 89.20 89.50 
88.50 89.50 89.00 85.10 
87.50 89.30 




is 30 100 is 30 100 
85.00 89.01 87.50 90.30 87.50 85.50 
84.80 86.40 85.80 87.20 82.00 88.90 
90.00 86.70 86.40 87.50 85.40 87.43 
83.33 87.30 79.20 87.30 87.50 88.40 
89.62 88.40 86.50 86.50 89.25 84.00 
90.68 90.20 89.80 88.00 86.30 95.00 
80.52 92.62 88.00 90.20 82.00 
82.00 90.30 86.30 85.00 82.50 




86.11 80.00 87.05 87.89 86.51 86.20 
Table 4 Showing individual protein concentration of the treated and untreated 
xenografted tumours. 
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Spleen weight (g) 
Control Control DMSO N114011 Saline 
no tumour tumour 
0.117 0.117 0.136 0.125 0.120 
0.152 0.111 0.140 0.110 0.107 
0.123 0.185 0.123 0.122 0.098 
0.113 0.130 0.216 0.113 0.114 
0.146 0.110 0.084 0.112 0.125 







mean 0.128 0.139 0.120 0.116 0.108 
L-365 L-364 L-740 RPR-X JB93182 
260 718 093 
0.130 0.130 0.142 0.106 0.080 
0.265 0.088 0.119 0.102 0.120 
0.214 0.121 0.163 0.103 0.085 
0.091 0.091 0.128 0.127 0.161 
0.098 0.090 0.208 0.129 0.180 
0.173 0.098 0.102 0.257 0.130 
0.144 0.075 0.093 0.186 
0.120 0.166 0.112 0.103 
0.138 0.09 0.083 
mean 0.153 0.105 0.128 0.139 0.126 
sCCK-8 (gg/kg) 
in DMSO in N114011 
is 30 100 is 30 100 
0.140 0.134 0.139 0.152 0.123 0.107 
0.140 0.109 0.217 0.081 0.165 0.122 
0.120 0.157 0.119 0.165 0.100 0.144 
0.136 0.120 0.113 0.191 0.105 0.120 
0.097 0.110 0.100 0.067 0.132 0.170 
0.130 0.103 0.100 0.064 0.100 
mean 0.127 0.122 0.131 0.120 0.125 0.127 
nsG. 17 (ggfkg) 
in DMSO in N114011 
15 30 100 15 30 100 
0.103 0.140 0.197 0.100 0.100 0.103 
0.106 0.140 0.177 0.103 0.101 0.099 
0.193 0.164 0.139 0.100 0.134 0.130 
0.200 0.121 0.192 0.150 0.114 0.139 
0.170 0.155 0.084 0.133 0.133 0.102 
0.119 0.132 0.102 0.143 
mean 0.154 0.140 0.158 0.120 0.114 0.119 
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